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Abstract 
 
Chloracne is a hyperkeratotic acneform skin disease caused by exposure to 2,3,7,8-
tetrachlorodibenzo–p-dioxin (TCDD), a potent agonist of the aryl-hydrocarbon 
receptor (AhR). Despite the known role of TCDD exposure in the pathogenesis of 
chloracne, the molecular mechanisms mediating the disease remain poorly defined.  
 
Using a previously optimised in vitro primary human keratinocyte epidermal 
equivalent model, we demonstrated the temporal regulation and development of a 
significantly reduced viable cell layer and compacted stratum corneum over 7 days 
with 10nM TCDD. These morphological changes were paralleled by cumulative AhR 
protein degradation and increased mRNA levels of CYP1A1. One of the key findings 
was a significant increase in the expression of the apoptotic marker, caspase-3 whilst 
there was no significant effect on Ki67 staining. Furthermore, TCDD treatment 
caused de-regulated epidermal differentiation as evidenced by increased mRNA 
expression but decreased protein expression of late differentiation markers. 
Treatment with TCDD also resulted in an induction of LC3 lipidation and endogenous 
LC3 protein expression as well as decreased P62 protein expression, well-
established markers of autophagy induction. Interestingly, co-treatment of epidermal 
equivalents with TCDD and the lysosomal inhibitor, bafilomycin or cathepsin D 
inhibition (by pepstatin A or shRNA knockdown) resulted in restoration of the viable 
cell layer and reduction in TCDD-induced caspase-3 expression. Similar results were 
also seen after blockade of the autophagy pathway by ATG7 knockdown. Results 
also demonstrated lysosomal function and autophagy are required for TCDD-induced 
AhR degradation, indicating a potential role for chaperone-mediated autophagy. 
Collectively these data suggest exposure to TCDD results in deregulated epidermal 
differentiation, induction of autophagy, reduction of a viable cell layer and caspase-3 
dependent cell death, likely mediated via lysosomal processing. Results provide an 
insight into the pathophysiology of chloracne, and demonstrate novel findings 
including TCDD-induced autophagy and potential role of lysosomal function in 
TCDD-induced death and AhR degradation.     
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1.1. Structure and function of skin 
 
The skin consists of two layers, the epidermis and the dermis and provides protection 
against external agents such as chemical injury and physical stress. Made up of 
dermal fibroblasts and extracellular matrix proteins, the principal function of the 
dermis is to support the epidermis by providing both a blood supply and growth factor 
mediated regulatory signals (Loertscher et al., 2001a). Conversely, the upper layer or 
epidermis is a stratified squamous epithelium, mainly comprised of keratinocyte cells 
and organised into viable cell layers (VCL). These layers or strata are known as the 
basal, spinous and granular layer and at the top, a final cornified layer. Each layer 
has a distinct functional characteristic (Loertscher et al., 2001a). In addition to 
keratinocytes, melanocytes, Merkel cells and langerhan cells are also present in the 
epidermis. Briefly, melanocytes are involved in pigmentation of the skin and produce 
melanosomes which contain melanin (Wickett and Visscher, 2006). Langerhans cells 
are dendritic cells found in the basal and suprabasal layers within the epidermis and 
are involved in antigen presentation and adaptive immune system (Cumberbatch et 
al., 2003, Wickett and Visscher, 2006). Merkel cells serve as mechanoreceptors and 
as such are concentrated in areas which give the greatest tactile response e.g. the 
fingertips (Svensson, 2009). However, the work in this project focused on monolayer 
and epidermal skin equivalent models derived from primary human keratinocytes 
alone.  
 
1.1.1. Epidermal differentiation 
 
Keratinocytes undergo a continuous differentiation process to maintain epidermal 
structure (as shown in Fig 1.1) and regeneration of skin. 
Undifferentiated stem cells, located in the basal membrane, have a distinct 
intracellular cytoskeleton composed of an extensive network of keratin 5 and keratin 
14 filaments (Nelson and Sun, 1983, Fuchs, 1990). Proliferating keratinocytes in the 
basal layer are able to generate new cells that lose their proliferative ability and 
subsequently begin to differentiate (Eckert et al., 2005, Eckhart et al., 2013). These 
post-mitotic but metabolically active cells move up into the suprabasal layers of the 
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epidermis, firstly into the spinous layer. Within the basal and spinous layers are 
desmosomes, intercellular junctions required for hyper-adhesion between cells, 
forming a lattice shape and maintaining epidermal structure (Fuchs, 1990, Franke et 
al., 1987, Thomason et al., 2010). These differentiating keratinocytes then start to 
express keratin 1 and keratin 10, replacing keratin 5 and 14 and start to produce 
envelope proteins such as involucrin, deposited on the inner surface of the plasma 
membrane (Rice and Green, 1979, Fuchs, 1990).  
Cells then move into the granular layer, characterised by keratohyalin granules 
which contain pro-filaggrin as well as lipid filled lamellar bodies (Sutter et al., 2011). 
Although at this stage pro-filaggrin is not able to bind to keratins, it is later de-
phosphorylated and proteolysed to produce filaggrin monomers (Sandilands et al., 
2009). It is in the granular layer cells are transformed into corneocytes. In this 
cornification process, organelles are destroyed, DNA is degraded and the plasma 
membrane is replaced with a cornified envelope, made of cross-linked proteins and 
lipids. Proteins expressed in the granular layer include transglutaminase 1 (TGM-1), 
TGM3 and TGM-5, involucrin as well as keratin 1 and keratin 10.  
The cornified layer consists of dead flattened, enucleated cells and terminally 
differentiated corneocytes which are eventually sloughed from the surface and 
removed from the epidermis (Proksch et al., 2008). These corneocytes are held 
together by tight and adheran junctions, keratin filaments and cornified envelope 
proteins (Baroni et al., 2012).  
Intracellular structural proteins are extremely important in the formation of the 
epidermal barrier and provide cellular strength (Sutter et al., 2011). Within the 
cornified layer, filaggrin aggregates to keratin filaments, helping to form flattened 
corneocytes and provides a uniform scaffold for cornified envelope assembly (Candi 
et al., 2005, Proksch et al., 2008). The cornified layer is also reinforced by other 
structural proteins, including loricrin, involucrin and trichohyalin crosslinked by 
transglutaminase enzymes (TGM1 and TGM3) to ceramides and small proline rich 
proteins (Furue et al., 2014). 
Many structural proteins have been located on the epidermal differentiation complex 
(EDC) locus on the 1q21 human chromosome and loss of function mutations in these 
proteins can be the underlying cause of skin diseases (Sutter et al., 2011, Kypriotou 
et al., 2012). 
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Figure 1.1 Schematic of the epidermis.  
The epidermis consists of viable cell layers and stratum corneum, with each layer expressing distinct 
differentiation protein markers. Adapted from, Wickett and Visscher (2006)  
 
1.1.2. Metabolism within the skin 
 
As previously described (section 1.1) the skin is constantly exposed to the 
environment and provides protection from mechanical and chemical threats. 
Therefore, it is no surprise that drug metabolising activity has been found in the skin 
and it is capable of biotransformation of drugs or chemicals that penetrate through 
the stratum corneum (Svensson, 2009, Pannatier et al., 1978). The expression and 
localisation of xenobiotic metabolising enzymes within the skin has been extensively 
reviewed (Svensson, 2009, Oesch et al., 2007, Oesch et al., 2014).  
One of the most important groups of Phase I metabolising enzymes are cytochrome 
P450 enzymes, heme-containing membrane proteins capable of xenobiotic 
metabolism via oxidation reactions. Substrates for CYP450 enzymes range from 
ingredients in cosmetics to allergens and carcinogens present in the atmosphere. 
Numerous CYP450 enzymes have been detected in the skin at both mRNA and 
protein level, including CYP1A1, CYP2B6, CYP2E1 and CYP3A5 (Baron et al., 2001, 
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Saeki et al., 2002, Vyas et al., 2006). Although activity in the skin may be less 
compared to the liver, other Phase I metabolising enzymes, have been detected in 
the skin. This includes flavin-dependent monooxygenases, alcohol dehydrogenases, 
and epoxide hydrolases.  
After Phase I metabolism, in which the substrate is modified by introducing a reactive 
or polar group, Phase II metabolism begins. Phase II enzymes conjugate the active 
metabolite with a charged group such as glutathione to allow for easier transportation 
across membranes. Numerous Phase II enzymes have been identified in skin 
including glutathione-S-transferase, UDP-glucuronosyltransferase, sulfotransferase 
and N-acetyltransferase (Oesch et al., 2007). 
 
1.2. Aryl hydrocarbon receptor 
 
The aryl hydrocarbon receptor (AhR) is an intracellular mediator of the xenobiotic 
signalling pathway. It belongs to the bHLH–PAS (basic Helix-Loop-Helix- 
Per/ARNT/Sim) family of proteins and is a ligand activated transcription factor 
expressed in various mammalian tissues including the skin (Song et al., 2002, Abel 
and Haarmann-Stemmann, 2010). The AhR has a uniform molecular structure, 
comprised of three functional domains and unlike other members of the bHLH-PAS 
family, can bind to endogenous xenobiotics (Hao et al., 2013).  
 
1.2.1 AhR pathway activation 
 
In the absence of ligand binding the AhR resides in the cytoplasm in an inactive 
complex with the chaperone protein p23 (prostaglandin E synthase 3) a dimer of 
hsp90 (heat shock protein 90) and AIP (AhR interacting protein) also known as XAP-
2 (HBV X-associated protein 2) (Sorg, 2014) (Fig 1.2). 
AhR is activated by a variety of lipophilic compounds able to diffuse through the 
plasma membrane. Upon ligand binding AhR dissociates from its chaperone proteins 
and the AhR-ligand complex binds to ARNT (AhR nuclear translocator) (Sorg, 2014). 
The AhR-ligand-ARNT complex translocates into the nucleus and then binds to its 
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cognate DNA sequence (TNGCGTG) in the promoter regions of AhR target genes, 
known as xenobiotic response elements (XRE) (Hao et al., 2013, Denison et al., 
1988, Ma, 2011). Binding to XRE causes altered transcription of target genes e.g. 
glutathione-s-transferase and UDP-glucoronosyltransferases as well as CYP genes, 
particularly CYP1A1 all of which are involved in xenobiotic metabolism.  
The location of a transcription factor such as AhR, can affect gene regulation. 
Localisation of nuclear proteins is often determined by a nuclear localisation signal 
(NLS), which causes the protein to be transported into the nucleus, or alternatively a 
nuclear export signal (NES) (Ikuta et al., 2009). The AhR possesses both NLS and 
NES sequences and as such, is continuously shuttled between the cytoplasm and 
nucleus (Ikuta et al., 1998, Ikuta et al., 2009, Hao et al., 2013). It is thought that 
phosphorylation or de-phosphorylation of an amino acid near the NLS or NES can 
impact the balance between nuclear import or export and subsequent localisation of 
the protein in the cell (Zhang et al., 2001, Ikuta et al., 2009). As well as exposure to 
exogenous ligands, AhR localisation and activity can be affected by cellular 
confluency (Ikuta et al., 2009).  
 
1.2.2. Degradation and regulation of AhR with the AhR substrate TCDD 
 
AhR degradation is thought to occur within the cytoplasm of the cell after a nuclear 
export signal (NES) initiates nuclear translocation. Research suggests levels of AhR 
are tightly regulated and the ubiquitin-proteasome pathway is responsible for 
degradation. Initial studies demonstrated when cells were treated with TCDD in the 
presence of MG-132 a 26S proteasome inhibitor AhR degradation was blocked in a 
dose-dependent manner (Davarinos and Pollenz, 1999). MG-132 is thought to also 
have off-target effects and inhibit lysosomal proteases and calpains, however, when 
cells were treated with a more specific calpain inhibitor (ALLM) inhibition of AhR 
degradation did not occur (Davarinos and Pollenz., 1999). Later studies also 
revealed AhR is ubiquitylated and inhibition of the 26S proteasome caused TCDD-
induced CYP1A1 expression to increase (Ma and Baldwin, 2000). Additionally, 
results showed ligand activated AhR had a reduced half-life (around 3 hours) 
compared to stable cytoplasmic AhR (around 28 hours) and this reduction in half-life 
was blocked by the 26S proteasome inhibitor (Ma and Baldwin, 2000).  
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As well as AhR targeting xenobiotic metabolism genes, the AhR/ARNT complex also 
targets the aryl hydrocarbon receptor repressor (AhRR) an integral part of AhR 
signalling (Mimura et al., 1999). The AhRR acts as a negative feedback loop, 
however, the mechanisms by which AhRR represses AhR signalling is not fully 
understood (Hao et al., 2013). It has been suggested AhRR is able to form 
heterodimers with ARNT, blocking AhR-ARNT binding to xenobiotic response 
elements (XREs) and subsequent upregulation of target genes (Mimura et al., 1999).  
This ability to reduce the over-expression of enzymes such as CYP1A1 is particularly 
useful as such metabolic reactions can produce reactive oxygen species (ROS) 
which if accumulated can induce oxidative stress, leading to DNA damage amongst 
other consequences (Tigges et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic of AhR signalling within the cell.  
Upon ligand binding, AhR is translocated into the nucleus of the cell, where it dissociates from 
chaperone proteins and forms a dimer with ARNT. AhR-ARNT then binds to XREs on target genes, 
causing up-regulation of transcription.  
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1.2.3. AhR ligands 
 
The AhR is well known for its involvement in the toxic effects of dioxins and synthetic 
ligands such as poly-cyclic aromatic hydrocarbons (PAHs) (Tian et al., 2015). Indeed, 
the majority of high affinity AhR ligands identified are synthetic, with the more stable 
halogenated aromatic hydrocarbon (HAH) molecules (e.g. TCDD and TCDF) being 
most potent compared to PAH molecules (e.g. benzo(a)pyrene) which have a lower 
affinity (Denison and Nagy, 2003, Murray et al., 2014).  
However, more recently, ligands with alternative non-halogenated structures have 
been identified including several drugs which have off-target effects such as 
omeprazole (a treatment gastroesophageal reflux disease) and tranilast (an anti-
allergy drug) (Jin et al., 2014, Murray et al., 2014). Furthermore, endogenous and 
plant based ligands have also been identified and thought to play a role in the 
physiological function of AhR under normal or healthy conditions. In fact, it has been 
suggested that a variety of naturally occurring chemicals from the diet, can activate 
or inhibit the AhR pathway (Denison and Nagy, 2003). For example, phytochemicals 
such as flavonoids have been found exert both agonistic (e.g. galagin) and 
antagonistic (e.g. luteolin) effects when interacting with the AhR, although results 
have been cell line-dependent (Zhang et al., 2003, Murray et al., 2014). UV 
irradiation of tryptophan can also generate compounds with a high affinity for the 
AhR, the most active derivative being 6-formylindolo[3,2-b]carbazole (FICZ), thought 
to be a physiological AhR agonist (Nguyen and Bradfield, 2008). Indeed, FICZ 
(10nM) was found to rapidly induce CYP1A1 mRNA expression in HaCat cells, with 
maximal induction after just 3 hours (Wei et al., 1998).   
 
1.2.4. TCDD  
 
The AhR is known as an intracellular mediator for the xenobiotic signalling pathway 
and as such, it is responsible for the majority of all toxicological responses to the 
dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as shown in Fig 1.2. 
TCDD is a halogenated hydrocarbon and a potent toxin which has a high affinity for 
the AhR. It is highly lipophilic with a long elimination half-life, staying in the body for 
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up to 11 years (Sorg et al., 2009). Indeed, dioxin-like compounds cause sustained 
induction of target enzymes such as CYP1A1, compared to the transient induction by 
other AhR agonists (Wincent et al., 2009). Very low levels of dioxin are present in the 
environment, often released as waste products from industrial processes such as 
herbicide and pesticide manufacturing. However, it can be released from natural 
phenomena such as volcanic eruptions or forest fires. Due to its long half-life, TCDD 
can accumulate in animal fat and plant tissue; as such human populations are 
primarily exposed through the food chain (Pelclova et al., 2006). The maximum 
accepted daily dose for humans is 4pg/kg (Saurat et al., 2012).  
 
 
 
 
 
Figure 1.3 Molecular structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). 
TCDD has a planar structure with four chlorine atoms, hence the term “chloracne”.  
 
1.3. Chloracne  
 
TCDD is classified as a known human carcinogen, shown in laboratory animals to 
promote the formation of neoplastic lesions in areas such as the liver and skin (Knerr 
et al., 2006; Ray and Swanson, 2009). However, after abnormally high TCDD 
exposure, one of the most consistent outcomes of systemic poisoning is the 
development of a form of acne, “chloracne” and as such development of chloracne is 
used as a specific marker of dioxin toxicity (Saurat et al., 2012, Ju et al., 2012).  First 
described in 1887, chloracne was originally thought to be the result of chlorine 
exposure, although now many chloracnegenic agents have been identified, with the 
most potent being dioxins (Ju et al., 2009). One of the most notable cases of TCDD 
poisoning was that of Viktor Yuschenko, a Ukrainian presidential candidate, who 
received a dose 50,000 fold greater than normal exposure in 2004 (Sorg et al., 
2009). Another infamous case occurred in 1976, when exposure to more than 2kg of 
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TCDD released into the atmosphere, after an explosion at a chemical plant, resulted 
in 135 cases of chloracne developing in Seveso, Italy (Ju et al., 2009, Baccarelli et 
al., 2005).  
After exposure through inhalation, ingestion or direct contact, acne vulgaris like 
lesions, primarily non-inflammatory comedones and cysts, develop often within a few 
weeks (Ju et al., 2012). Distribution is initially on the face and neck but can then 
extend to the trunk and other extremities (Ju et al., 2009) and in contrast to acne 
vulgaris, sebum excretion is generally reduced (Gawkrodger et al., 2009). 
Hyperkeratosis or abnormalities in keratinocyte differentiation within the follicle is also 
often detected, causing keratotic plugs to form (Pastor et al., 2002) as well as 
thinning of the follicular wall (Ju et al., 2012).  
The cellular and molecular pathogenesis of chloracne remains incompletely 
understood, although most effects seem to be mediated via the AhR (Ju et al., 2012). 
As such, there is no known treatment or therapy for chloracne, other than avoiding 
further exposure to chloracnegens.  Some patients have seen improvements after 
retinoid or corticosteroid treatment and dermabrasion, but in general chloracne is 
resistant to most tested treatments (Ju et al., 2009).  
 
 
 
Figure 1.4 Viktor Yushenko pre and post poisoning with TCDD.  
Images of Viktor Yushenko pre poisoning with TCDD (A) then 5 months (B) 3 years (C) and 11 years 
(D) post poisoning with TCDD. Image adapted from (Sorg et al., 2009).  
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1.3.1. Mice models of chloracne 
 
The degree and range of TCDD-induced effects vary significantly between animal 
species and although AhR knockout animals have helped in understanding the 
endogenous role of AhR in other organs e.g. liver (Lahvis et al., 2000, Loertscher et 
al, 2002) chloracne affects both hair follicles and the interfollicular epidermis and as 
such suitable animal models are difficult to derive.  Nevertheless, mouse models with 
differing AhR alleles are available which have provided some mechanistic insight.  
Mice with a responsive AhR allele (Ahb) able to bind ligands with a high affinity and 
mice with an unresponsive allele (Ahd) able to bind ligands with a low affinity, have 
been developed (Thomas et al., 1972, Loertscher et al., 2002). Mice with the Ahb 
allele did develop an array of pathologies; however, as with most strains of mice, 
TCDD treatment failed to induce chloracne. Studies have also been carried out using 
mice with a hairless mutation (Knutson and Poland, 1982, Puhvel et al., 1982). 
Although TCDD induced a “chloracne-like” phenotype, including epidermal 
hyperkeratosis, hyperplasia and loss of sebaceous glands, results between strains of 
hairless mice varied. In addition, the mice are genetically sensitised and as such 
results should be viewed with caution. Due to the lack of data in both adult haired 
mice and developing mouse skin, Loertscher et al (2002) pursued an alternative 
method of in utero TCDD exposure. TCDD was delivered to the mother by oral 
gavage, and interestingly, results revealed alterations in terminal differentiation in 
foetal mouse skin, with TCDD inducing filaggrin protein expression (Loertscher et al., 
2002).  
However, as discussed by Murray et al (2014) there are several structural differences 
between mouse and human AhR which may affect function and explain the 
differences in TCDD toxicities. Firstly, the interaction with hsp90 is much more stable 
in mouse AhR than human. In addition, differences in binding affinity to ligands is 
evident, of importance, mouse AhR binds TCDD with tenfold higher affinity than 
human AhR (Ramadoss and Pardew, 2004, Murray et al., 2014). There is also low 
amino acid sequence homology between human and mouse AhR, particularly in the 
caboxy-terminal region of the protein which contains the transactivation domain 
(Murray et al., 2014).   
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1.3.2. Human models of chloracne 
 
Due to the drawbacks of using animal models and differences in AhR activity 
between species, human keratinocyte cell lines such as the HaCaT cell line and 
primary cells obtained from human tissue biopsies are often used. Normal human 
epidermal keratinocytes (NHEKs) are particularly useful as they retain cellular 
structures and regulatory components involved in normal differentiation, even though 
they are a submerged culture (Sutter et al., 2011).  Although monolayer cultures can 
be used to study biochemical and molecular mechanisms, organotypic models or 
epidermal equivalents more accurately reproduce the morphology and differentiation 
of human epidermal tissue (Loertscher et al., 2001a, b). 
This project will incorporate both monolayer cultures and epidermal equivalents. The 
epidermal equivalent models were developed and used in previous research projects 
within the Reynolds lab (Forrester thesis). Briefly, primary human keratinocytes are 
seeded at high confluence onto a polycarbonate membrane and the following day 
raised to the air liquid interface. After culturing for 12 days a fully formed, fully 
stratified epidermis will develop and can be treated accordingly. Cultured 3D models 
like this have previously been found to accurately mimic native skin, including barrier 
protein expression (De Breij et al., 2012, El Ghalbzouri et al., 2008, Thakoersing et 
al., 2011) 
Other forms of organotypic models are available and have been used by other 
groups to explore chloracne; for example, Loertscher et al. (2001b) used a full 
thickness system consisting of dermis and epidermis with primary human fibroblasts 
and near-diploid immortalised human keratinocytes (NIKs). 
However, although skin equivalents, both epidermal and full thickness, represent 
useful models to investigate the effects of TCDD on human skin, these models lack 
appendages.  Thus, tissues from chloracne lesions would obviously be gold standard 
when investigating the histopathology behind the phenotype (Saurat et al., 2012). 
However, cases of abnormally high TCDD exposure are rare and therefore studies 
on these lesions and biopsies are limited and few papers have been published. 
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1.4. AhR and role in the skin 
 
Research over the years has revealed involvement of the AhR in numerous 
physiological processes and cross-talk between pathways, from the immune 
response (Quintana, 2013) to a role in cancer (Feng et al., 2013). However, recently 
the role of AhR in epidermal homeostasis and disease has become a popular area of 
research and revealed interesting findings as detailed below.  
As previously described (section 1.1.3) skin is the first pass organ for dermal 
exposure and therefore as expected it is more than capable of metabolising 
xenobiotics (Tigges et al., 2013). One example of this is the presence of AhR which, 
when activated by ligands such as polycyclic aromatic hydrocarbons (PAHs), induces 
Phase I and Phase II enzymes capable of metabolising such ligands (Tigges et al., 
2013).  
Although the molecular mechanisms involved in the toxicity of TCDD and the 
chloracne phenotype are not fully understood, research has delineated the ability of 
TCDD to alter epithelial morphology and homeostasis (Loertscher et al., 2002). 
TCDD and the effect it has on keratinocyte differentiation has been well studied in 
vitro. In organotypic skin models dosed with TCDD, keratinocyte differentiation was 
altered, with a fully differentiated cornified layer developing quicker than in vehicle 
treated control models (Loertscher et al., 2001b). Interestingly, there was also no 
reported change in apoptosis induction or proliferation (Loertscher et al., 2001b). In 
monolayer, TCDD has been reported to increase protein expression of involucrin and 
filaggrin (Sutter et al., 2009). In addition, TCDD induces expression of genes in the 
human epidermal differentiation complex found on chromosome 1q21 (Kennedy et 
al., 2013).  
However, the mechanism by which TCDD regulates these differentiation genes is not 
entirely known. Geng et al. (2006) found when ARNT null human keratinocytes were 
exposed to TCDD, filaggrin mRNA was not increased and therefore ARNT may be 
involved in this regulation. In contrast, Sutter et al. (2011) found using NHEKs that 
TCDD-activated AhR bound a small fragment of DNA upstream of the transcriptional 
start sites of the filaggrin gene. These start sites contained one of two candidate 
xenobiotic response elements and when the XRE sites were mutated the increased 
transcription of filaggrin disappeared (Sutter et al., 2011). Sutter et al (2009) also 
 14 
 
suggest a role for epidermal growth factor receptor (EGFR) signalling, in dioxin 
induced keratinocyte differentiation and indeed, as a regulator or AhR. They reported 
dioxin induced filaggrin and CYP1A1 mRNA expression was repressed by epidermal 
growth factor (EGF) and propose EGF inhibits recruitment of the transcriptional co-
activator protein p300 to the CYP1A1 gene (Sutter et al., 2009, Hankinson, 2009).  
Research has also indicated that AhR may have a function in wound healing. Ikuta et 
al. (2009) carried out full thickness skin wounding on AhR -/-, AhR wildtype and AhR 
+/- mice and found that during the early phase of wound healing, AhR deficiency 
increased wound closure (Ikuta et al., 2009). In addition, Carvajal-Gonzalez et al. 
(2009) found in wild type and AhR knockout mice that loss of AhR expression 
increased migration of keratinocytes and increased skin re-epithelialisation whilst not 
effecting cell proliferation. Similarly, Moirangthem et al. (2013) found wound healing 
to be disrupted and poor when wild type mouse models of cutaneous wound healing 
were exposed to TCDD. 
As discussed, it is well established that AhR activation by exogenous ligands such as 
TCDD induces terminal differentiation. However, Van den Bogaard et al (2015) 
recently explored the physiological role of AhR in keratinocyte differentiation, without 
exogenous ligand activation, using both murine and human models (Van den 
Bogaard et al., 2015). Results demonstrated AhR -/- primary keratinocytes had a 
significant reduction in differentiation gene and protein expression including 
involucrin and loricrin, which was in accordance with AhR +/+ primary keratinocytes 
treated with AhR antagonists (Van den Bogaard et al., 2015). Treatment of epidermal 
skin equivalent models with AhR antagonists also led to defects in stratification and 
reduced stratum corneum thickness. Finally, levels of nuclear AhR were also 
increased in differentiated primary mouse keratinocytes grown in monolayer. 
Psoriasis is a chronic autoimmune skin disease which results in scaly, itchy and often 
painful patches of skin. In a study using both patient skin psoriasis biopsies and a 
psoriasis mouse model, Di Meglio et al (2014) suggests AhR signalling plays a role in 
preventing excessive skin inflammation. Interestingly, in the immiquimod-induced 
inflammatory mouse model, the endogenous AhR ligand FICZ was found to reduce 
inflammation and in AhR-deficient mice psoriasis was exacerbated compared to AhR 
control mice. In addition, the study found expression of a subset of psoriatic genes 
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decreased in the presence of the AhR agonist FICZ whilst the AhR antagonist 
CH223191 induced expression (Di Meglio et al., 2014, Colonna, 2014).  
In corroboration with these findings, AhR was also recently suggested to have a role 
in coal tar treatment of atopic dermatitis (AD) (Van den Bogaard et al., 2013). AD is 
an inflammatory skin disease thought to be triggered by both environmental factors 
for instance allergens and genetic factors such as impaired skin barrier function. 
Mutations of the gene filaggrin are now known to represent an important cause of 
atopic eczema with ~50% of moderate to severe cases harbouring a mutated 
filaggrin allele. Within the European population, the 5 most commonly mutated alleles 
lead to severe truncation of filaggrin mRNA and reduced (hetereozygote) or absent 
(homozygote) filaggrin protein. Topical application of coal tar has been used to help 
treat AD for over 2000 years and is made up of over 10,000 organic compounds 
including many polycyclic aromatic hydrocarbons (Van den Bogaard et al., 2013). 
CYP450 enzymes help detoxify and metabolise such compounds and are found to be 
induced in coal tar treated patients. Using primary keratinocytes from both healthy 
patients and those with filaggrin-mutated AD, Van de Bogaard et al. (2013) used 
monolayer and organotypic models to investigate the effect of coal tar. The group 
observed that within 4 hours of coal tar treatment, AhR translocated from the 
cytoplasm into the nucleus, indicating coal tar was bound to AhR. Coal tar also 
induced levels of CYP1A1 and CYP1B1 and increased differentiation proteins such 
as filaggrin, loricrin and hornerin. In skin equivalents, terminal differentiation markers 
were also expressed earlier after coal tar treatment. In all, results indicate coal tar 
activates AhR and results in increased epidermal differentiation.  
Together, these data underscore the physiological role of AhR in skin, its potential 
utility as a pharmacological target and the fact that CYP1A1 induction is not 
synonymous with toxicity and chloracne induction.  
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1.5. Autophagy  
 
Autophagy is a catabolic lysosomal degradation pathway for cytoplasmic material. 
Unlike the ubiquitin proteasome system, autophagy is able to degrade long lived 
proteins and damaged organelles. There are three types of autophagy which only 
differ in the way material is delivered into the lysosome (Eskelinen, 2005).  The term 
autophagy in general refers to macroautophagy, which describes the formation of a 
double membrane around a targeted region of the cell cytoplasm. The resultant 
vesicle then fuses with a lysosome for degradation. In microautophagy lysosomes 
engulf cytosolic components through direct invagination of the lysosomal membrane. 
In contrast, chaperone mediated autophagy (CMA) is characterised by its selectivity 
of substrates it degrades (Cuervo et al., 1996, Eskelinen, 2005). In this case, 
cytosolic proteins containing a KFERQ-like pentapeptide sequence are unfolded by 
chaperone proteins and translocated across the lysosomal membrane via a LAMP2A 
receptor (Kaur and Debnath, 2015). This is in contrast to macro or micro autophagy 
when substrates are engulfed or sequestered in bulk. 
 
1.5.1. Process of autophagy 
 
Autophagy is essential for normal cellular homeostasis and is generally a survival 
pathway activated in times of nutrient deprivation or stress to maintain cellular energy 
(Shpilka et al., 2012). It also has important roles in other processes such as cell 
development and defence mechanisms (Shpilka et al., 2012). Initially when 
autophagy is induced, a small isolation membrane or phagophore is formed and 
elongates to engulf part of the cytoplasm, as illustrated in Figure 1.5. This results in a 
double membrane autophagosome which then fuses with a lysosome, creating an 
autolysosome. The inner membrane of the autophagosome and the cytoplasmic 
material are then degraded and recycled (Shpilka et al., 2012). The proteases 
cathepsin D and B are translocated from the golgi body and are the main lysosomal 
proteases involved with the autophagy process (Aymard et al., 2011). 
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1.5.2. Autophagy genes and autophagy regulation 
 
Research into genes associated with autophagy originally began in yeast mutants; 
however, homologs for many of these genes have been found in higher eukaryotes, 
suggesting the process of autophagy has been conserved from yeast to man 
(Eskelinen, 2005). Over 30 autophagy related genes (given the nomenclature ”ATG”) 
have been discovered and the process of autophagy is divided into distinct stages 
controlled by ATG related proteins.  
Mammalian target of rapamycin (mTOR) is a member of the phosphatidylinositol 3-
kinase-related kinase protein family and acts as a central regulator. In normal 
conditions, mTOR is activated causing inhibition of autophagy. However, when 
autophagy is induced in response to nutrient deprivation or stress, mTOR is 
phosphorylated and activates the ULK1/2 protein kinase complex (Mizushima et al., 
2010). Members of the ULK (UNC51-like kinase) complex then assemble at the 
phagophore assembly site, or isolation membrane (Kaur and Debnath, 2015).  
Of note, although nucleation is thought to occur from the endoplasmic reticulum, 
studies have recently suggested other sources of membrane may contribute to 
autophagosome formation, including mitochondria, plasma membrane and 
endosomes (Kaur and Debnath, 2015, Axe et al., 2008, Hailey et al., 2010, 
Ravikumar et al., 2010). 
The activated ULK complex then targets a class III PI3 kinase complex, which 
mediates the nucleation phase and consists of BECLIN-1, VPS34 (vacuolar protein 
sorting 34), the serine/threonine kinase p150 and ATG14 (Mizushima et al., 2010, 
Kaur and Debnath, 2015, He and Klionsky, 2009). This subsequently leads to the 
development of a pre-autophagosomal structure from the membrane. Interestingly, 
binding of anti-apoptotic BCL-2 (discussed in section 1.6.1) to BECLIN-1 can block 
autophagy and dissociation of BECLIN-1 from BCL-2 is required for autophagy 
induction (He and Klionsky, 2009).  
Elongation of this membrane around cytoplasmic material and completion of the 
double membraned autophagosome is mediated by recruitment of two conjugation 
systems. ATG12 is conjugated after activation by ATG7 (an E1 activating enzyme) 
this is then transferred to ATG10 (an E2 conjugating enzyme) and covalently 
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attached to ATG5 (He and Klionsky, 2009). The ATG12-ATG5 conjugate then 
interacts with ATG16 and attaches to the phagophore.  The second conjugation 
system involves lipidation of protein 1 light chain 3 (LC3) to 
phosphatidylethanolamine (PE) resulting in the conformational change to LC3II, this 
LC3 I/II flux is often used as an autophagic marker for example through western 
blotting, immunofluorescence or dual tagged mCherry-GFP-LC3 live cell imaging 
(Mizushima et al., 2011, Eskelinen, 2005, Kaur and Debnath, 2015).  The scaffold 
protein P62, which shuttles ubiquitylated proteins into the autophagosome, is also 
required. This is later broken down when the completed autophagosome fuses with a 
lysosome to form an autolysosome and again often used as an autophagic marker.  
Although genes involved in formation of autophagosomes are well documented, the 
process of lysosome and autophagsosome fusion is still being delineated (Shen and 
Mizushima, 2014). However, studies have suggested a role for soluble N-
ethylmaleimide sensitive factor attachment protein receptor (SNARES), a family of 
proteins involved in membrane mediated transport events (Jahn et al., 2006).  Indeed 
it has been suggested that autophagosome lysosome fusion is mediated by SNARE 
proteins: syntaxin 17, SNAP-29 and VAMP8 or VAMP7 (Shen and Mizushima, 2014, 
Itakura and Mizushima, 2013, Mizushima, 2014). 
 
1.5.3. Autophagy in the skin 
 
Recent studies have suggested a role for autophagy in skin homeostasis. Results 
demonstrate autophagy is involved in keratinocyte differentiation and may be used as 
a signal initiating keratinocyte commitment to differentiation in vitro (Aymard et al., 
2011). However, mice studies performed by Rossiter et al (2013) found autophagy 
was most likely to be involved in the later stages of differentiation and although 
autophagy was present in the epidermis and mutant mice had increased 
corneocytes, it was not essential for barrier function. Autophagy may also have a role 
in determining skin colour. Differences in skin colour are due to the presence of 
melanin in the epidermis and the amount of melanosomes produced in melanocytes, 
which are then transferred into keratinocytes (Murase et al., 2013). Using 
keratinocytes derived from both Caucasian and African American skin, Murase et al 
(2013) found autophagy to be responsible for the degradation and subsequent 
 20 
 
reduction of melanosomes in different skin types. Therefore, the level autophagy and 
level of reduction determining the skin colour, for example in Caucasian skin 
autophagic activity was higher.  
Interestingly, a recent study in monolayer primary human keratinocytes, explants and 
mouse tissue has explored autophagy marker expression in developing epidermis 
and again found autophagy plays an integral role in epidermal differentiation. 
Autophagy was found to be constitutively active in the granular layer and likely 
mediated by epidermal MTORC1 (Akinduro et al., 2016). Of note, in human psoriatic 
skin biopsies LC3 marker expression was found to be reduced, suggesting 
autophagy was impaired and could potentially be targeted therapeutically to restore 
epidermal barrier function (Akinduro et al., 2016). 
 
1.5.4. Cell death and autophagy 
 
Caspases are cysteine proteases and have long been associated with cell death, 
particularly apoptosis. There are 12-13 distinct caspases coded for in the human 
genome with at least seven contributing to cell death, and others being involved in 
processes such as inflammation (Kroemer and Martin, 2005). In terms of apoptosis, 
these seven caspases can be split into initiators or effectors, all of which begin as 
pro-enzymes and require activation (Kroemer and Martin, 2005). 
In some cases, as hypothesised in the preceding PhD project, (Forrester thesis) 
caspase-independent cell death can occur. An example of this is autophagy, 
although primarily thought of as a cell survival mechanism; it can be associated with 
cell death. This was demonstrated in work on mouse embryonic fibroblasts, lacking 
pro-apoptotic BAX and BAK (Wei et al., 2001). Even though the cells were resistant 
to apoptosis, when dosed with apoptosis inducing agents cell death still occurred. 
The cells had increased autophagic vacuoles as well as increased levels of ATG 
proteins and therefore autophagic cell death was thought to be involved (Wei et al., 
2001). Autophagic vacuoles are also linked with degenerating neurons in Alzheimer’s 
and Parkinson’s disease and it is hypothesised that autophagy is involved with cell 
death during neurodegeneration (Anglade et al., 1997). 
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Autophagic cell death still remains relatively controversial and indeed cells often 
display both apoptotic and autophagic markers. Many researchers believe that 
although large scale autophagy can occur, it is unlikely the cell dies through 
excessive autophagy alone and cross talk with apoptosis has been well documented 
(Kroemer and Levine, 2008). However, the Cell Death Committee defines autophagic 
cell death as death, which can be rescued by the inhibition of autophagy, by 
knockdown of two or more autophagy genes. Even if autophagy markers such as 
LC3 upregulation or P62 degradation are present, if the cell death is not blocked by 
autophagy inhibition, it is not autophagic cell death (Galluzzi et al., 2012).  
 
1.6. Apoptosis 
 
The term “apoptosis” was first used in 1972 by Kerr, Wyllie and Currie to describe a 
form of cell death with distinct morphological features (Elmore, 2007, Kerr, Wyllie and 
Currie, 1972). Since then, apoptosis has been recognised as a specific form of 
programmed cell death (PCD), resulting in the elimination of cells. Apoptosis is 
required for a variety of biological systems including homeostasis, particularly in 
developing tissues and organs in which the balance between cell division and PCD is 
crucial to maintain appropriate cell numbers and tissue turnover (Fuchs and Steller, 
2015). However, apoptosis can also act as a protective mechanism or “quality 
control” in which infected or damaged cells are eliminated if they have irreparable 
DNA damage or disrupted cell cycle for example. Inappropriate apoptosis i.e. too little 
or too much has also been implicated in diseases such as Parkinsons disease 
(Venderova and Park, 2012) Alzheimers disease (Shimohama, 2000) as well as 
many cancers (Wong, 2011). Apoptosis is characterised by specific morphological 
changes to the cell, identified by light and electron microscopy, including cell 
shrinkage, nuclear condensation/fragmentation and membrane blebbing (Ouyang et 
al., 2012, Hacker, 2000). Pyknosis, or chromatin condensation is the most 
distinguishing feature of apoptosis (Elmore, 2007). Key biochemical changes also 
occur, namely degradation of DNA by endogenous DNases producing double-
stranded DNA fragments but also protein cleavage and cross-linking (Saraste, 2000). 
Another key feature of apoptosis, distinguishing it from other forms of cell death such 
as necrosis, is that apoptotic cells are quickly phagocytosed and degraded within 
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phagolysosomes. Therefore, apoptotic cells do not release their cellular contents into 
the surrounding tissue and there is no inflammatory response (Savill and Fadok, 
2000). Although sometimes difficult to distinguish between, unlike necrosis, apoptosis 
is a controlled form of PCD, is energy-dependent and does not affect large fields of 
cells (Elmore, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Regulation of apoptosis.  
Schematic depicting the intrinsic (mitochondrial) pathway of apoptosis involving the formation of 
apotosomes and activation of pro-caspase 9. Schematic also depicts the extrinsic pathway of 
apoptosis, in this example involving TRADD (TNF receptor associated death domain) and activation of 
pro-caspase 8 or 10. Eventually both pathways converge and activate pro-caspase 3,6 or 7 which is 
then activated and induces apoptosis.  
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1.6.1. Regulation of apoptosis 
 
Activation and completion of apoptotic cell death requires a complex cascade of 
molecular events involving a variety of cysteinyl aspartate proteases, or caspases.  
There are two main apoptotic pathways, the intrinsic (mitochondrial) pathway or 
extrinsic (death receptor) pathway, eventually however, both pathways result in the 
cleavage of caspase-3 and subsequent initiation of an execution pathway (Elmore, 
2007) (Fig 1.6). This induces the previously defined morphological and biochemical 
changes to the target cell and subsequent phagocytosis.  
The extrinsic pathway involves transmembrane receptor-mediated interactions, 
initiated when ligands bind to death receptors present on the cell surface. These 
death receptors are often members of the tumour necrosis factor (TNF) receptor 
gene superfamily (Elmore, 2007, Locksley et al., 2001) and have a cysteine rich 
extracellular domain and a cytoplasmic “death domain” allowing transmission of a 
death signal from the cell surface (Ashkenazi and Dixit, 1998). One of the more well-
known death receptors is TNFR1 (TNF receptor 1) and corresponding ligand, TNF-α 
(Wong, 2011). Briefly, upon ligand binding, intracellular adaptor proteins are recruited 
for example, in the case of TNFR, the adaptor protein TRADD (TNF receptor-
associated death domain) FADD (Fas-associated death domain protein) and RIP1 
(receptor-interacting protein 1) are recruited. The ligand-receptor-adaptor protein 
complex is known as the death inducing signalling complex (DISC) which can then 
activate pro-caspase-8 (Wong, 2011, Kischkel et al., 1995). Activated caspase-8 then 
initiates the execution phase of apoptosis by cleaving other downstream caspases 
(Wong, 2011). 
The intrinsic or mitochondrial pathway, involves a variety of non-receptor mediated 
stimuli, such as irreversible genetic damage, growth-factor deprivation or hypoxia, 
which produce intracellular signals that can act on targets within the cell (Elmore, 
2007). This results in the opening of the mitochondrial permeability transition pore 
(MPT) as well as loss of mitochondrial potential. This increased permeability of 
mitochondria allows pro-apoptotic molecules to be released into the cytosol and 
subsequent activation of caspases (Saelens et al., 2004). Pro-apoptotic molecules 
are divided into two groups. The first group includes cytochrome c which activates 
the caspase-dependent mitochondrial pathway by binding and activating Apaf-1 
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(apoptosis protein-activating factor-1) and pro-caspase-9, which in turn activates 
caspase-9 in an ATP dependent manner (Chinnaiyan, 1999, Elmore, 2007). The 
second group contains pro-apoptotic markers which are released much later from the 
mitochondria, when the cell is already committed to die. This group includes AIF 
(apoptosis inducing factor) Endonuclease G and CAD (Caspase activated DNase) 
(Elmore, 2007).  
Apoptotic mitochondrial events can also be controlled or regulated by members of 
the Bcl-2 (B cell lymphoma-2) family. These can be pro-apoptotic, e.g. BAX and BAK 
which induce permeabilisation of the mitochondria, allowing release of pro-apoptotic 
molecules such as cytochrome c (Youle and Strasser, 2008). This release of pro-
apoptotic proteins sequestered between the outer and inner mitochondrial 
membranes is known as MOMP (mitochondrial outer membrane permeabilisation) 
(Chipuk and Green, 2008). Anti-apoptotic members e.g. BCL-W generally have four 
domains similar in sequence (BH1 to BH4) and are thought to inhibit BAX and BAK 
(Cory and Adams, 2002, Youle and Strasser, 2008).  There is also a third class of 
BH3-only proteins e.g. BAD and BIK which have a conserved BH3 domain and are 
able to bind and regulate the anti-apoptotic Bcl-2 proteins to promote apoptosis 
(Youle and Strasser, 2008.)  
However, regardless of which pathway is activated, both the extrinsic and intrinsic 
pathway activates the execution phase of apoptosis. In this phase, a series of 
effector caspases including caspase-3, caspase-6 and caspase-7 are activated and 
subsequently cause the morphological and biochemical changes described in section 
1.6, by cleaving proteins involved in nuclear membrane and cytoskeletal structure, 
DNA repair, and replication systems (Slee et al., 2001, Elmore, 2007, Raj et al., 
2006). Caspase-3 is considered to be the most important, as any initiator caspase 
can activate it including caspase-8 (extrinsic pathway) caspase-9 (intrinsic pathway) 
or caspase-10. 
 
1.6.2. Apoptosis in skin 
 
Apoptosis is essential for organ development and tissue turnover and as such, plays 
a role in skin, maintaining epidermal thickness and eliminating pre-malignant cells 
 25 
 
(Raj et al., 2006). As described in section 1.1.2 epidermal keratinocytes undergo 
cornification, a unique form of terminal differentiation and programmed cell death, 
resulting in the formation of the outermost skin barrier (Eckhart et al., 2013). In 
contrast to normal homeostasis, in keratinocyte cornification, dead cells are not 
removed and instead play a vital role and function. There are similarities between 
apoptosis and cornification at both the molecular and cellular level such as loss of an 
intact nucleus, changes to the cytoskeleton and involvement of mitochondrial events 
(Lippens et al., 2005). In addition, proteins such as cathepsins are implicated in both 
apoptosis and epidermal differentiation. However, Lippens et al (2005) propose 
cornification does not involve apoptosis and although caspases are expressed in the 
epidermis, there is a lack of evidence to show pro-apoptotic caspases are required 
for normal skin formation (Lippens et al., 2000). In contrast, Allombert-Blaise et al 
(2003) suggest epidermal differentiation involves apoptotic cell death machinery. The 
study reported mitochondrial membrane potential decreased in calcium differentiated 
normal human keratinocytes and HaCaT cells, as seen in apoptosis. In addition, 
although it did not coincide with immediate apoptosis, cytochrome c was also 
released during epidermal maturation and interestingly; treatment with the general 
caspase inhibitor zVADfmk prevented the formation of a normal stratum corneum in an 
in vivo skin equivalent model (Allombert-Blaise et al., 2003). 
A variety of agents have been shown to induce apoptosis in the skin, one of most 
well researched being UV irradiation. The most well studied is UVB (wavelength of 
290-320nm) due to its physiological relevance and ability to induce DNA damage and 
mutations which could lead to malignancy (Ananthaswamy and Pierceall, 1990). 
Numerous studies have shown UVB irradiation induces release of cytochrome c, 
activation of caspases and mitochondrial depolarisation in keratinocytes, leading to 
the induction of apoptosis (Raj et al., 2006). Indeed, apoptosis induction by UV 
irradiation is thought to be a cellular repair mechanism to eliminate cells with 
irreparable DNA damage and as such research to gain further understanding is 
desirable (Takasawa et al., 2005).  Interestingly, a study in HaCaT cells 
demonstrated the differences between apoptotic pathways induced by UVB and UVC 
irradiation. Whilst apoptotic cells appeared after only 8 hours after UVB irradiation, in 
UVC irradiated cells, apoptosis did not occur until much later. Furthermore, caspase-
8 activation only occurred in UVB irradiated cells whilst UVC irradiated cells induced 
much greater release of pro-apoptotic markers cytochrome c and Smac/DIABLO as 
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well as activation of caspase-9 (Takasawa et al., 2005). Consequently, Takasawa et 
al (2005) suggests UVB irradiation induces both the intrinsic and extrinsic apoptotic 
pathways whilst UVC induced apoptosis only via the intrinsic pathway. 
 
1.7. Cathepsins 
 
Cathepsins can be divided into two categories: aspartic proteases such as cathepsin 
D and E and cysteine cathepsins of which there are 11 known in human. Of these, 
cathepsins B, C, H and L are ubiquitously expressed but others show more regulated 
expression (Repnik et al., 2012).  Most cathepsins are endo-peptidases, initiating 
digestion at non-terminal peptide bonds, although cathepsins X and C are exo-
peptidases, initiating digestion at terminal peptide bonds of the molecule, whilst 
cathepsin B and H use both actions (Repnik et al., 2012). Cathepsins have broad 
specificity, are generally stable and function well at acidic pH (Repnik et al., 2012). 
Although cathepsins have been implicated in a variety of pathologies and 
physiological functions, this project focuses primarily on their role in autophagy 
(section 1.5) skin homeostasis (sections 1.7.2) and apoptosis after lysosomal 
membrane permeabilisation (section 1.8).  
 
1.7.1. Cathepsin D 
 
Cathepsin D, a focus of this project, is normally found within lysosomes and 
synthesised as a pro-enzyme, pro-cathepsin D (52kDa) which matures after 
proteolytic cleavage into an intermediate active enzyme (48kDa). This then forms a 
mature active form, consisting of heavy (34kDa) and light (14kDa) chains linked by 
non-covalent bonds (Benes et al., 2008). Cathepsin D has a GC rich motif in the 
promoter region to which Sp1, a basal transcription factor, can bind (Wang et al., 
1999). It also has a core sequence of a XRE to which the AhR/ARNT complex binds 
and both Sp1 and AhR are needed for maximal basal activity (Wang et al., 1999). 
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1.7.2. Cathepsins in skin 
 
Cathepsins have also been implicated in epidermal differentiation and skin. For 
example, studies in rat keratinocytes, demonstrated expression of cathepsins B, H 
and L increased when keratinocytes were calcium differentiated (Tanabe et al., 
1991). Similarly, cathepsin L activity has also been found to increase after 1-2 days 
then decrease again as differentiation progresses. Through studies with cathepsin L 
knockout mice, cathepsin L has also been implicated as an important regulator of 
keratinocyte and melanocyte differentiation during hair follicle morphogenesis (Tobin 
et al., 2002). Indeed, knockout mice had several abnormalities including, defective 
terminal differentiation of keratinocytes during the formation of the hair canal, 
abnormal hair cycling and disrupted exiting of hair shafts to the skin surface (Tobin et 
al., 2002). Furthermore, cathepsin K, known for its role in degrading collagen, is 
expressed in scarred skin and keloids, but not normal skin (Runger et al., 2007). In 
contrast, work with cultured fibroblasts found cathepsin K to be highly expressed and 
co-localisation studies with LAMP1, found cathepsin K to be associated with 
lysosomes in which exogenous collagen I and collagen IV was internalised 
(Quintanillla-Dieck et al., 2009). Finally, in a clinical trial evaluating the efficacy and 
safety of the cathepsin K inhibitor balicatib for osteoporosis, one patient developed 
scleroderma with morphea lesions developing 9 months after beginning the trial 
(Peroni et al., 2008) again suggesting cathepsin activity can influence epidermal 
differentiation and regulation.  
However, of interest to this project, cathepsin D has also been found to have a role in 
regulation and activation of transglutaminase 1 (TGM-1) (Egberts et al., 2004). 
Treatment with cathepsin D increased activity of TGM-1, an important cellular 
component involved in crosslinking of proteins in the cornified envelope. When 
pepstatin A was used to inhibit cathepsin D, TGM-1 activity decreased (Egberts et 
al., 2004). In addition, cathepsin D knockout mice have been found to have reduced 
TGM-1 and cornified envelope proteins such as filaggrin and involucrin as well as a 
skin phenotype similar to that of the disease lamellar ichthyosis (Egberts et al., 
2004). 
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1.8. Lysosomes and LMP 
 
Lysosomes are single membraned, digestive organelles present in the cytoplasm of 
almost all eukaryotic cells (Shen and Mizushima, 2014). Within the lysosome are 
more than 50 acid hydrolases, including lipases, nucleases and phosphotases 
specific for degradation of a range of macromolecule targets (Mindell, 2012, 
Eskelinen, 2006). These targets may be extracellular material captured by 
phagocytosis or endocytosis, or derived from the cell itself through autophagy 
(Gomez-Sintes et al., 2016). A key feature of a lysosome, therefore, is its acidic 
environment (pH 4.5-5.0) to maintain optimum enzymatic activity (Shen and 
Mizushima, 2014). 
The lysosomal membrane, a single phospholipid bilayer, mediates a variety of 
functions including fusion with other organelles and controlling the passage of 
material into the lysosomal lumen (Saftig et al., 2010). 
The membrane contains over 20 lysosomal membrane glycoproteins. One of the 
most important being the vacuolar type H(+)-ATPases (V-ATPases) which uses ATP 
to pump protons into the lumen of the lysosome and help create an acidic 
environment (Mindell, 2012). In addition, LAMP1 and LAMP2 (lysosome associated 
membrane protein 1 and 2) make up approximately 50% of all lysosomal membrane 
proteins (Saftig et al., 2010). In vivo studies suggest both proteins have a similar 
function as mice are viable after LAMP1 or LAMP2 knockout, but double knockout is 
embryonic lethal (Eskelinen, 2006). However, LAMP1 and LAMP2 only have 37% 
amino acid homology, and studies have found the phenotype in LAMP2 deficient 
mice is far more severe than LAMP1 knockout alone. LAMP2 also undergoes 
alternative splicing, forming LAMP2 A, B and C isoforms, which show specific tissue 
expression and function (Lichter-Konecki et al., 1999, Eskelinen, 2006).  
Interestingly, lysosomes are now considered a significant component of cell death 
machinery.  Lysosomal membrane permeabilisation (LMP) in which the contents of 
the lysosome, including cathepsins, are leaked into the cytosol initiating degradation 
of cellular components, can induce cell death. The extent of LMP determines the 
morphological features of cell death (Aits and Jaattela 2013). Complete disruption of 
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the lysosome provokes uncontrolled death by necrosis, which cannot be attenuated 
by treatment with inhibitors of lysosomal hydrolases.  
In contrast, partial or selective LMP induces the intrinsic pathway of apoptosis (Boya 
and Kroemer, 2008, Kagedal et al., 2001). This apoptotic cell death is activated 
through MOMP (as described in section 1.6.1) and can be attenuated using 
cathepsin inhibitors, primarily against cathepsin B and D. Therefore, cathepsins are 
thought to be the main executors (Gomez-Sintes et al., 2016). Destabilisation of 
lysosomes and subsequent pore formation allowing for cathepsin release, can be 
induced by a range of stimuli including lysomotropic agents such as 
hydroxychloroquine and antibiotics (Boya et al., 2003) DNA damage (Emert-Sedlak 
et al., 2005) and reactive oxygen species (ROS) (Castino et al., 2007).  
Interestingly, LMP has been shown to be regulated by proteins of the Bcl-2 family, 
also involved in apoptosis regulation. In particular, studies have demonstrated the 
pro-apoptotic BAX translocates to the lysosomal membrane after treatment rather 
than mitochondrial membrane, inducing LMP and cathepsin dependent cell death 
(Bove et al., 2014, Gomez-Sintes et al., 2016). Furthermore, cathepsins have been 
shown to induce cleavage of pro-apoptotic BID, which promotes translocation of Bax 
and Bak to the mitochondria inducing MMP and caspase-dependent cell death a 
(Droga-Mazovec et al., 2008, Gomez-Sintes et al., 2016). Together these 
demonstrate the complex crosstalk and overlap between cell deaths pathways.  
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1.9. Aims 
 
The overall theme of this project was to increase understanding of the mechanism 
behind the TCDD-induced chloracne phenotype, whilst also further delineating the 
physiological role of AhR in the skin.  
Preliminary work with the chloracne phenotype model (Forrester Thesis) revealed 
TCDD induced a significant reduction in viable cell layer thickness and compacted 
stratum corneum. Results also suggested TCDD treatment altered differentiation 
marker expression and induced autophagic activity. In addition, Ingenuity Pathway 
Analysis (IPA) revealed a link between cathepsin D and AhR (as described in section 
1.7.1) and subsequent studies revealed cathepsin D expression was increased by 
AhR activity.  
Therefore, the main focus of this research was to explore the mechanisms underlying 
TCDD induced morphological changes in an optimised epidermal equivalent model. 
Specific aims were to:  
1. Reproduce a robust and reliable chloracne phenotype model using epidermal 
skin equivalents and consider the effect of TCDD treatment over time. 
2. Explore the possible induction of apoptosis or caspase-dependent cell death 
after TCDD treatment  
3. Investigate the hypothesis of TCDD-induced autophagy activity and autophagy 
regulated effects on epidermal differentiation, AhR expression and apoptosis. 
4. Investigate the role of lysosomal function, specifically cathepsin D in epidermal 
differentiation, AhR expression and apoptosis.  
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2.1. Laboratory work and reagents 
 
All laboratory work was carried out in accordance with Newcastle University health 
and safety regulations and when necessary, in containment level two hoods under 
sterile conditions. Unless otherwise stated, reagents were purchased from Sigma 
Aldrich, UK and prepared according to manufacturer’s instruction. 
 
2.2. Tissue samples 
 
Healthy adult foreskin tissue samples were obtained after informed consent from 
patients undergoing surgery and used to culture keratinocytes (Todd and Reynolds, 
1998). Immediately after removal, skin samples were placed in keratinocyte growth 
media (MCDB 153) supplemented with 2% penicillin streptomycin amphotericin B 
(PSA) (Lonza biologics, UK) and stored at 4°C until collection.  Ethical approval for 
this has been granted by Newcastle and North Tyneside research ethics committee 
(Ref 08/H0906/95+5_Lovat). This PhD project was funded by both BBSRC and 
AstraZeneca.  
 
2.2.1. Primary cell culture 
 
Upon arrival, foreskin samples were logged and washed in a Corning 10cm sterile 
petri dish (SLS, UK) with phosphate buffered saline (PBS) to remove any residual 
blood. Excess subcutaneous tissue, fat and blood vessels were then removed with 
sterile forceps and scissors. Using a scalpel, a grid pattern was cut into the epidermis 
to allow penetration of dispase II (Roche Diagnostics Ltd, UK) before the sample was 
placed in dispase II in PBS (0.2%) and 10% PSA solution and stored at 4°C 
overnight. The following day, the epidermis was removed from the dermis and placed 
into a universal tube containing 0.05% trypsin/EDTA (Lonza, UK) and incubated in 
the water bath at 37°C for 5 minutes. The trypsin was then neutralised with 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, UK) media supplemented with 
10% Fetal Bovine Serum (FBS) (DMEM/FBS) and centrifuged at 3000G for 5 
minutes. The supernatant was removed, and the pellet re-suspended in 18-20ml of 
 33 
 
MCDB 153 medium or Epilife (Life Technologies, UK) both of which were 
supplemented with 1% PSA and 1% human keratinocyte growth supplements 
(HKGS) (Life Technologies, UK) and placed into a T175 tissue culture flask. After 24 
hours, any excess epidermis was removed and the media replaced with fresh. Cells 
were incubated at 37°C in a humidified atmosphere of 5% carbon dioxide in air and 
the media replaced with fresh media every 2-3 days. 
Whilst the majority of experiments were carried out in MCDB 153 media, epidermal 
equivalents were cultured in Epilife, however, both mediums provided a complete 
culture environment for primary keratinocytes and equally as effective. 
 
2.2.2. Cell passaging of primary keratinocytes  
 
At 70% confluence primary keratinocytes were passaged, to prevent epidermal 
differentiation. Old media was removed and the cells washed with PBS before adding 
5ml trypsin/EDTA (Lonza, UK) and incubation at 37°C for 5 minutes to allow the cells 
to detach and neutralisation of the trypsin/EDTA by addition of 10mls of DMEM/FBS. 
Cells were then pelleted by centrifugation for 5 minutes 3000g, the supernatant 
removed and the cell pellet re-suspended in complete Epilife or MCDB 153. Primary 
keratinocytes were then subsequently reseeded at a 1/3 of the original cell number, 
approximately 1 million cells per T175 in 20mls of media and cultured up to a 
maximum of 4 passages. Alternatively, cells were counted using a haemocytometer 
and seeded for monolayer experiments. Monolayer experiments were generally 
either conducted in 6 well plates in which 100,000 cells/well were seeded in 2ml of 
media, or 48 well plates in which 10,000 cells/well were seeded in 500µl of media, 
and treated for 5 days unless otherwise stated. Primary human keratinocytes were 
also seeded in to epidermal skin equivalent models (see section 2.4) 
 
2.2.3. Cell passaging of HEK293T cells 
 
The transformed human embryonic kidney (HEK) 293 cell line originates from 1973 
(Graham et al., 1977) and is widely used in cell biology. The HEK293T cell line is a 
derivative of the HEK293 cell line and often used for viral packaging due the addition 
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of a temperature sensitive allele of SV40 T antigen. This allows amplification of 
vectors carrying the SV40 region of replication and subsequently increases 
expression when transiently transfected (Lin et al., 2014). Cells were cultured in 
DMEM media supplemented with 10% FBS (DMEM/FBS) and 1% PSA and 
incubated at 37°C in a humidified atmosphere of 5% carbon dioxide in air. Media was 
replaced with fresh every 2-3 days and at 80% confluence cells were passaged as 
described above (section 2.2.2). Cells were subsequently re-seeded into T175 flasks 
at 1/3 of the original density in 20ml of media. Alternatively, cells were seeded into 
sterile 10cm petri dishes in which 250,000 cells were seeded into 10ml of media.  
HEK293T cells were cultured up to 20 passages and frozen stocks were stored in 
liquid nitrogen in 10% DMSO (Fisher Scientific, UK) and 90% FBS.  
 
2.3. Treatments with chemical agents 
 
In experiments with monolayer primary keratinocytes, cells were seeded 
appropriately (see section 2.2.2) into 6 well plates or 48 well plates and allowed to 
attach overnight prior to treatment. Epidermal skin equivalents were seeded and 
cultured for a minimum of 12 days before treatment (see section 2.4). In all 
experiments, treatment was every 48 hours for up to 7 days in either complete MCDB 
153 or Epilife media.  
The dioxin 2,3,7,8-Tetrachlorodibanzo-p-dioxin (TCDD) (Supelco, Sigma Aldrich, UK) 
was diluted in dimethylsulfoxide (DMSO) to a concentration of 10µM in the fume 
hood and kept at room temperature in the poisons cupboard. The final concentration 
in all experiments was 10nM TCDD unless otherwise stated. Control monolayer cells 
or epidermal skin equivalents were all treated with the same dilution of DMSO, 
1:1000.  
The autophagy and lysosomal inhibitor bafilomycin A1 was dissolved in DMSO to a 
stock solution of 10µM and stored at -20°C in aliquots. The final concentration in all 
experiments was 5nM and treatment was throughout the time course.   
Cathepsin D inhibitor pepstatin A was dissolved in DMSO to a stock solution of 
10mg/ml and stored at -20°C in aliquots. The final concentration used in all 
experiments was 10µg/ml and treatment was throughout the time course.  
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In differentiated monolayer primary keratinocyte experiments, cells were seeded into 
6 well plates (100,000cells/well) in complete MCDB 153 and allowed to attach 
overnight.  The following day, media was replaced with high calcium MCDB 153 to 
induce differentiation. For this, complete MDCB 153 media was supplemented with 
1mol/L calcium chloride (CaCl2) (BDH laboratory supplies, UK), 70µl of CaCl2 was 
added to 50ml of complete MCDB 153 media to give a final concentration of 1.3mM 
calcium. Cells were differentiated for 5 days whilst being treated appropriately.  
 
2.4. Epidermal Equivalents 
 
To produce epidermal equivalents, primary keratinocytes were initially seeded (0.5-1 
x106 cells/insert) onto 12mm diameter; 0.4uM Millicell inserts (Millipore, Ireland) in a 
6 well plate and cultured overnight in 2ml Epilife containing 1.5mM CaCl2 (high 
calcium Epilife). Subsequently, epidermal equivalents were raised to the air/liquid 
interface by removing media from inside the insert and replacing the media on the 
outside with high calcium Epilife supplemented with vitamin C (5µg/ml). Epidermal 
equivalents were then incubated at 37°C for 12 days and media outside the insert 
replaced every other day with fresh high calcium Epilife supplemented with vitamin C. 
At day 12 post seeding, the epidermal equivalents, then completely differentiated, 
were subjected to treatment with chemical agents as described within each 
experiment every 48 hours for up to 7 days, with control epidermal equivalents 
treated with vehicle (DMSO) at a concentration of 1:1000. 
At the end of each treatment period, epidermal equivalents were harvested by 
removal of the media in each supporting well, washing twice with PBS and cutting 
around the insert using a sterile scalpel before washing the epidermal equivalent 
again in PBS. Each epidermal equivalent was then cut into 4 sections.  
For immunohistology and haemotoxylin and eosin (H&E) staining, sections were 
placed into 4% paraformaldehyde (100µl of 37-40% paraformaldehyde in 900µl PBS) 
and left overnight at 4°C to become formalin fixed. The following day, samples were 
washed in PBS and placed into histology cassettes then processed and embedded in 
paraffin  by Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne. H&E 
was then performed (as described in section 2.4.2). 
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For immunofluorescent staining (as described in section 2.6) sections were mounted 
in OCT (Thermo Scientific) over liquid nitrogen onto cork discs (VWR, UK) and stored 
at -80°C until required.  
Epidermal equivalents sections were also snap frozen in Eppendorf tubes in liquid 
nitrogen and used for RNA extraction for subsequent qPCR experiments (as 
described in section 2.8) or protein extraction for subsequent immunoblotting (as 
described in section 2.5) 
 
2.4.1. H&E staining of Epidermal Skin Equivalents 
 
After fixation (as described in section 2.4) the formalin fixed paraffin embedded 
(FFPE) samples were sectioned (4µm) using a microtome and baked onto 
SuperFrost Plus slides (VWR, UK) overnight at 60°C. Sections were then stained 
with H&E (both stains purchased from Pioneer Research Chemicals Limited, UK). 
Briefly, excess paraffin was removed by immersion of sections in histoclear (AGTC 
Bioproducts, UK) for 20 minutes at room temperature. Sections were then 
dehydrated in ethanol and submerged in haemotoxylin (5 seconds), and rinsed well 
in tap water (10 minutes) then submerged into eosin for 5 seconds and rinsed in tap 
water. Sections were then de-hydrated in ethanol and cleaned in histoclear before 
being mounted with a glass coverslip using DPX hard mount (Thermo Scientific, UK). 
Images of the sections were captured at 20x magnification using a Zeiss Axioimager 
microscope (Carl Zeiss Ltd, UK) and with measurements of the viable cell layer 
obtained using Image J Software (National Institutes of Health, USA). For each 
experiment 6 measurements were taken, spread evenly throughout each 20x H&E 
image of an epidermal equivalent, and data expressed as the mean viable cell layer 
thickness, relative to vehicle (DMSO) control ±SEM.  
 
2.5. Immunoblotting 
 
Following 48 hours after the final treatment of monolayer primary keratinocytes 
seeded in 6 well plates, cells were lysed for protein. Whilst on ice, media was 
removed; each well washed with 2ml ice-cold PBS and then 120µl/well of RIPA lysis 
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buffer was added. RIPA lysis buffer was supplemented with 10µl of 100x 
phosphatase inhibitor cocktail, 10µl 100xprotease inhibitor cocktail, and 10µl of EDTA 
was added per ml. Using a cell scraper cells were collected into Eppendorf tubes and 
vortexed for 5 seconds then sonicated using a probe sonnicator (Soniprep 150, MSE) 
for 3 x 5 seconds. Samples were then centrifuged at 4°C at 16000g for 5 minutes. 
Conversely, epidermal equivalents were lysed in urea lysis buffer to solubilise the 
cytoskeleton. Per epidermal skin equivalent section, 120µl of urea lysis buffer was 
added (8M urea, 50mM Tris-HCL pH 8.0, 1mM NaF, 1mM Na3VO4, 1mM PMSF, 
0.25% SDS and 1x complete EDTA containing protease inhibitor cocktail) prior to 
vortexing to remove the polycarbonate membrane and sonication for 3x5 seconds 
(as described above) then centrifugation for 5 minutes at 4
°
C at 16000g.  
Both monolayer and epidermal equivalent protein concentrations were determined 
using a BCA protein assay kit (Pierce, UK) according to manufacturer’s instructions 
before proteins were separated through a NuPage gel electrophoresis system (Life 
Technologies, UK). Protein samples (60µg where possible) were combined with LDS 
sample buffer (4X) containing lithium dodecyl sulfate at a pH of 8.4 to help denature 
the protein, as well as reducing agent (10X) containing 500 mM dithiothreitol (DTT) to 
reduce the protein. The ratio of 6.5:2.5:1, protein: LDS: reducing agent was 
maintained for all experiments. Samples were then incubated at 70°C in a heat block 
for 10 minutes and stored in -20°C freezer until required.  
Samples were then defrosted at room temperature, incubated at 70°C for 10 minutes 
and briefly centrifuged in a microfuge, before proteins were separated through 4-12% 
NOVEX Bis-Tris pre-cast gels (Life technologies, UK). In all experiments, 10-20µg 
protein was loaded and samples run in NuPAGE MES/SDS running buffer with 
500µl/L of NuPAGE antioxidant added. Proteins were then transferred onto 
nitrocellulose membrane (GE Healthcare Lifesciences) using a BioRad mini-Trans 
Blot system with NuPAGE transfer buffer (cat number NP0006-1). 
Membranes were then blocked in TBS-T (Tris-Base, NaCl, pH 7.6 and Tween-20 
(Fisher Scientific, UK) 1ml/L) containing 5% skimmed milk for 1 hour at room 
temperature. Following 3 X 5 minute washes in TBS-T, membranes were incubated 
with primary antibodies overnight at 4°C, diluted as detailed in Table 1. Following 3 X 
5 minute washes in TBS-T membranes were then incubated with appropriate 
hydrogen-peroxidase secondary antibody (Vectorlabs, UK), again as described in 
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Table 1 prior to 3 X 5 minute washes and detection of primary antibody expression 
using an ECL plus kit (Amersham GE healthcare) according to manufacturer’s 
instructions. Imaging was carried out using a phosphoimager (Fujifilm FLA-3000) or 
Licor Odyssey FC system and with densitometry carried out using ImageJ software 
or Image Studio software (version 5.0) to quantify protein expression relative to 
GAPDH loading control. 
 
Table 1 Summary of antibodies and respective incubation conditions used for immunoblotting 
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2.6. Immunofluorescence staining 
 
Sections of OCT processed epidermal equivalents (4µm) were cut using a cryostat 
onto SuperFrost Ultra Plus slides (VWR, UK) and stored at -20°C until required. 
Upon staining, slides were defrosted at room temperature and washed with PBS for 1 
minute to wash off excess OCT. A hydrophobic pen was used to mark the tissue area 
prior to fixation for 10 minutes in ice cold acetone, methanol, acetone/methanol or 
4% paraformaldehyde at room temperature, depending on the optimised fixative 
method for each specific antibody. Sections were washed again with PBS and 
permiablised with 0.2% Triton-X-100 (Fisher Scientific, UK) for 10 minutes at room 
temperature. After washing 3 times with PBS containing 0.05% Tween 20 (Fisher 
Scientific, UK) (PBS-T) sections were then blocked in goat serum for 30 minutes 
(1:60) in PBS containing 2% BSA (PBS/BSA) before further washing in PBS-T and 
incubation with primary antibody or isotype control (dilution antibody dependent, as 
described in Table 2) for 1 hour at room temperature. Sections were subsequently 
washed again 3 times in PBS-T, blotted and then incubated with specific AlexaFluor® 
568 secondary antibody (ThermoFisher Scientific, UK) (1:300 in PBS-BSA) with 
Hoechst nuclear stain (1:3000) (Life Technologies, UK) for 1 hour at room 
temperature in the dark. After 3 final washes with PBS-T, sections were then 
mounted with a glass cover slip using Mowiol mounting medium (consisting of 
glycerol, Mowiol 4-88, distilled water and 0.2M Tris buffer pH 8.5) and stored at 4°C 
in the dark. Image analysis was conducted by confocal microscopy using a Nikon A1 
Upright microscope and with all images captured with a 20x objective and with 1.54 
magnification and processed using Nikon Elements software. Tiled images of 
epidermal equivalents stained for caspase-3 or Ki67 were captured using a Zeiss 
Axioimager and images acquired at 10x magnification using Zen 2 Pro software 
(Zeiss, Germany). For quantification of immunofluorescent staining, image J was 
used to measure intensity of differentiation marker expression. One representative 
image per epidermal equivalent was used and data expressed relative to vehicle 
control, or siNT/shNT vehicle control in knockdown studies.  
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Table 2 Summary of antibodies used for immunofluorescence staining 
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2.7. Cell viability assays 
 
Both MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and SRB 
(sulfohodamine B) colorimetric assays were used as a measure of cell viability. 
Specifically, the SRB assay measures total cellular protein content based on the 
ability of SRB to bind to basic amino acid residues (Voigt et al., 2005). In contrast, 
the MTT assay, requires the reduction of yellow MTT to a purple formazan product by 
metabolically active and therefore, viable cells (Stockert et al., 2012). 
For both assays, primary human keratinocytes were seeded at a density of 10,000 
cells per well into 48 well tissue culture plates (Corning, SLS, UK) in a volume of 
500µl of complete MCDB 153 media before being left to attach over night at 37°C. 
Cells were then treated accordingly.  
For commercial MTT assays, cell viability was assessed by the addition of 40µl of 
MTT in PBS (5mg/ml) to each well with continued incubation for 3.5 hours at 37°C 
prior to the removal of the MTT solution and the direct addition of 300µl/well of MTT 
solvent (4mM HCL and 0.1% Nondent P-40 in isopropanol). Following agitation, 
150µl from each well, was placed into a 96 well plate and absorbance measured at 
590nM using a SpectraMax 250 plate reader (Molecular Devices, UK). 
For SRB assays, cell viability was assessed by removing media from each well and 
replacing with 200µl/well of freshly made 10% trichloracetic acid and incubating for 1 
hour at 4°C. Plates were then washed 5 times by immersion in distilled water and 
allowed to air dry. Once dry, 200µl of 0.4% (W/V) SRB dissolved in 1% (V/V) glacial 
acetic acid was added to each well for 30 minutes at room temperature. Plates were 
then washed with 1% glacial acetic acid 5-10 times until all residual dye was 
removed and then dried at 60°C for 1 hour or at room temperature overnight. The 
protein bound SRB was then solubilised in 400µl of 10mM unbuffered Tris base (pH 
10) and the plate agitated on an orbital shaker for 10 minutes before, as for MTT cell 
viability assays, 150µl of the solution was taken from each well into a 96 well plate 
and absorbance measured at 530nm using a SpectraMax 250 plate reader. 
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2.8. qPCR 
 
2.8.1. RNA Extraction 
 
Before any RNA work was carried out, the lab area was thoroughly cleaned and 
decontaminated with RNase ZAP (Thermo Fisher Scientific, UK). Additionally, all 
water used was nuclease-free.  
RNA was extracted from epidermal equivalent samples using a ReliaPrep tissue kit 
(Promega, UK) following manufacturer’s instructions with certain modifications. 
Epidermal equivalents were initially disrupted on ice using a pellet pestle in BL lysis 
buffer supplemented with 1% 1-Thioglycerol and all polycarbonate membranes 
removed. Samples were then centrifuged for 5 minutes at 14,000g to remove excess 
debris prior to RNA precipitation and purification according to the manufacturer’s 
protocol.  After an on-column DNase digestion (Promega, UK) step, RNA was initially 
eluted with 15µl of nuclease free water into PCR tubes with a second identical elution 
step to ensure collection of RNA. RNA concentration was then determined using a 
NanoDrop (NanoDrop 2000 Thermo Scientific, UK) and samples stored at -80°C prior 
to use. 
 
2.8.2. Reverse Transcription 
 
Preparation of cDNA from epidermal equivalents was carried out using a 
standardised amount of RNA in each reaction, random hexamers and dNTPs. 
Moloney murine leukaemia virus enzyme (MMLV), DTT (DL-Dithiothreitol) and buffers 
were then used in a 20µl reaction with the recombinant ribonuclease inhibitor, RNase 
OUT, according to manufacturer’s instruction (all from Life Technologies, UK). 
Reverse transcription was carried out using standard PCR cycle conditions in an 
Applied Biosystems GeneAmp PCR system 9700 machine (Invitrogen, UK). cDNA 
was then diluted appropriately for gene expression qPCR assays. 
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2.8.3. Real time qPCR 
 
Exon-spanning probe based assays were purchased from a variety of suppliers 
(Table 3) and consisted of two primers (forward and reverse) and a hydrolysis probe. 
Primers were used at 400nM and probes at 100nM. These were used in combination 
with GoTaq probe master mix according to manufacturer’s instructions (Promega, 
UK). Total volume per reaction was reduced to 10µl and reaction mixes were sealed 
before being briefly centrifuged on a plate spinner. Subsequent PCR was performed 
using a StepOne plus qPCR machine (Life Technologies, UK) and standard PCR 
cycle conditions were used: 
1. 50°C for 2 minutes 
2. 95°C for 10 minutes 
3. 95°C for 15 seconds 
4. 60°C for 60 seconds 
5. Plate read 
6. Steps 3-5 were repeated 40 times 
 
mRNA expression was determined through Ct (cycle threshold) value. Ct values are 
the relative measure of target per reaction, and defined as the number of PCR cycles 
needed to exceed background levels of the target, also known as the threshold.  Ct 
values are inversely proportional to the amount of target nucleic acid in the sample; 
therefore, a lower Ct value means a greater amount of target nucleic acid is present.  
Histone H4 expression was used as a validated housekeeping gene and the Delta-
Delta Ct method was used for analysis (Livak and Schmittgen. 2001) without PCR 
efficiency correction. The difference between the two Ct values was expressed as fold 
change.  
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Table 3 qPCR targets and assay ID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9. ShRNA Lentiviral knockdown in primary keratinocytes 
 
For long term knock down, primary keratinocytes were transduced with short hair-pin 
(sh)RNA.  
Glycerol stocks of competent E.Coli with lentiviral shRNA pGIPZ vectors for 
cathepsin D (CTSD) and BECLIN-1 (Open Biosystems) (Table 4) were purchased. 
Glycerol stocks of E.Coli previously transformed with shRNA packaging plasmid 
(pCMVdeltaR8.91) and envelope plasmid (pMD2.G) were already available in the 
lab. Each shRNA vector contained target shRNA, GFP and puromycin resistance 
genes under the control of a constitutive CMV promoter. As such, transduced 
keratinocytes could be identified using puromycin selection and green fluorescence 
in image analysis.  
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Initially, bacterial colonies were spread and grown on lysogeny broth (LB) agar plates 
with 50µg/ml ampicillin under standard sterile conditions. Single colonies were 
selected and expanded in LB broth at 37°C. Plasmid DNA was then purified using a 
hi-speed Maxi-Prep kit (Qiagen, UK) according to manufacturer’s instructions.  
 
Table 4 Lentiviral constructs purchased 
 
 
 
 
 
 
 
 
 
 
 
The following sections outline the procedures including transfection into HEK293T 
cells and transduction of primary keratinocytes, all of which were adapted from the 
Trono laboratory, Switzerland (Klages et al., 2000 and Naldini et al., 1996).  
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2.9.1. Production of virus in HEK293T cells 
 
HEK293T cells were cultured as described in section 2.2.3 and seeded at 250,000 
cells per 10cm culture petri dishes in 10ml of complete DMEM/FBS and left to attach 
overnight at 37°C. Medium was then removed carefully and replaced with 10ml 
transfection media (DMEM/FBS no PSA). The HEK293T cells were then transfected 
using standardised calcium precipitation. 
Briefly, a mixture containing 5µg of envelope plasmid, 15µg of packaging plasmid 
and 20µg of target shRNA plasmid, was mixed in a sterile Eppendorf tube and the 
volume adjusted to 250µl with special water (0.63mM hepes buffered water, pH 7.3) 
and 250µl of 0.5M CaCl2 solution was then added. This was mixed with 500µl of 2X 
HeBS (HEPES-buffered saline solution) whilst air bubbling and left to stand for no 
longer than 40 minutes to avoid formation of too large a precipitate. The precipitate 
was then added slowly; dropwise onto the HEK293T cells and dishes gently rocked 
for 10 seconds to ensure the media and precipitate were well mixed. Cells were then 
incubated overnight at 37°C. 
The following day, medium was removed; the cells washed with warm PBS and the 
media replaced with 10ml viral production media (DMEM with 20% FCS and PSA) 
before continued incubation for 3 days at 37°C at 5% CO2 in air as normal. After this 
time, the viral supernatant was collected into a 50ml falcon tube and centrifuged at 
1900g for 5 minutes. The virus was then sterilised through 0.45µm filters (Millipore, 
UK) aliquoted and stored at -80°C for up to 6 months. 
 
2.9.2. Transduction of primary keratinocytes  
 
Primary keratinocytes were seeded in complete Epilife medium into 6 well tissue 
culture plates at a density of 100,000cells/well in 2ml media per well and left to attach 
overnight. The following day, media was removed, the cells washed in PBS, and the 
medium replaced with 2ml of a viral supernatant mix. This contained 3ml of 
appropriate virus, 9ml of DMEM/FBS with no PSA and 4ug/ml hexadimethrine 
bromide. Following centrifugation of plates at 310g for 90 minutes at room temp, the 
viral supernatant was removed, cells washed with PBS and the medium replaced 
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with 2ml of fresh complete Epilife. After 48 hours further incubation at 37°C to allow 
transgene expression, cells were detached with trypsin/EDTA as described in section 
2.2.2 and placed into T175 flasks in a volume of 20ml complete Epilife containing 
1µg/ml puromycin to select successfully transduced keratinocytes. Images were 
taken after a further 48 hours with the fluorescent microscope (DMRIB Leica) to 
check for GFP and transduction efficiency. Cells were then allowed to expand prior to 
inclusion in epidermal skin equivalents with high calcium Epilife as described in 
section 2.4.  
 
2.10. Transient siRNA knockdown of ATG7 in primary keratinocytes 
 
The siRNA for ATG7 was purchased from life Technologies, UK and already 
available in the lab (Lovat group).  A Stealth RNAi negative control medium GC 
content siRNA was purchased from Thermo Fisher Scientific (Table 5).  
siRNA constructs were transfected into primary keratinocytes using lipofectamine 
LTX plus (ThermoFisher Scientific, UK) according to manufacturer’s 
recommendations. Keratinocytes were seeded into 6 well plates (100,000/well) in 2ml 
complete MCDB 153/well and allowed to culture to approximately 70% confluency 
(usually requiring at least overnight incubation at 37°C). Media was then removed 
from keratinocytes and cells washed with PBS prior to replacement with 1ml/well of 
Opti-MEM (Life Technologies, UK) and the dropwise addition of 250µl of combined 
transfection siRNA containing mix, ensuring the final concentration of siRNA was 
40nM. Incubation was then continued for 6 hours at 37°C before removing the siRNA 
media mix, a brief wash with PBS and replacement of the media with 2ml of complete 
MCDB 153. The following day, cells were treated appropriately every 48 hours. 
For experiments in which keratinocytes were cultured in monolayer and 
differentiated, the media was changed 24 hours after transfection to high calcium 
complete MCDB153 medium, replacing the medium every 48 hours for 5 days to 
induce differentiation whilst cells were treated appropriately,  
For siRNA mediated knockdown of ATG7 in epidermal equivalents, primary 
keratinocytes were first seeded into T75 flasks in 12ml complete MCDB 153 media 
and allowed to culture to approximately 70% confluency at 37°C. The same 
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transfection protocol was used, but volumes were scaled up appropriately by adding 
2ml of the combined transfection siRNA mix into 7ml Opti-MEM. The cells were then 
allowed to become confluent before trypsinising, counting and seeding as normal into 
epidermal equivalent models as described in section 2.4.  
 
Table 5 siRNA constructs purchased 
 
 
 
 
 
2.11. Fractionation of epidermal skin equivalents for proteomic analysis 
 
Optimisation of epidermal equivalent fractionation was carried out prior to preliminary 
proteomic analysis performed in collaboration with AstraZeneca. Initially, whole cell 
lysates of epidermal equivalents lysed in urea buffer (as described in section 2.5) 
were analysed however, results revealed proteins of interest were masked by 
cytoskeletal proteins present.  
Consequently, the use of two different fractionation kits was tested. For this, larger 
samples of epidermal equivalents were lysed (1/2 compared to 1/4 of an epidermal 
equivalent usually lysed) to ensure protein concentrations in all fractions were high 
enough. Firstly, a NE-PER Nuclear Protein Extraction kit (Life technologies, UK) was 
used for cell lysis and stepwise extraction of cytoplasmic and nuclear protein 
fractions. Secondly, a Subcellular Protein Fractionation Kit (Life Technologies, UK) 
was employed to isolate cytoplasmic, soluble nuclear, chromatin-bound, membrane 
and cytoskeletal fractions from epidermal equivalents. 
In both kits, fractions were separated using a reagent-based protocol following 
manufacturer’s instructions. This involved initially lysing the sample with a pellet 
pestle, then the addition and incubation with a series of lysis buffers specific to each 
fraction followed by centrifugation steps. After each centrifugation step, the 
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supernatant (fraction of interest) was removed. Protein concentration of each fraction 
was then determined (as described in section 2.5) and samples stored at -80°C until 
shipment.  
Although fractionation of samples was performed at Newcastle University, proteomics 
analysis was carried out by collaborator Dr Rachel Rowlinson at AstraZeneca, 
Macclesfield using a standardised protocol. Briefly, this involved preparation of 
samples and 50µg of sample was loaded onto a Synapt G2-si high definition mass 
spectrometer (Waters, UK) via a Nano Acquity LC using the 110min MSE ion mobility 
method for data collection. Samples were processed using the Waters Progenesis 
Software. Results were then sent for analysis by Dr Simon Cockell (Bioinformatics 
Unit, Newcastle University).  
 
2.12. Statistical analysis 
 
All statistical analyses were performed using GraphPad Prism 6 (SanDiego, CA). 
Data unless stated otherwise were represented as the mean value of at least 3 
replicates +/- the standard error of the mean (SEM). Individual figure legends 
describe the precise statistical analyses performed in a given experiment where “n” 
denotes the number of biological repeats, i.e. independent donors whilst “N” 
represents the number of technical repeats, i.e. number of wells analysed.  
All protein expression data were quantified by densitometry from at least three 
different donors. Protein levels were normalised to GAPDH loading control values of 
the respective sample and expressed relative to vehicle control of an individual donor 
(to account for varied expression between varied skin donors). One-way ANOVA 
analysis was used to compare effects of experimental treatments, with Dunnett’s or 
Tukey’s multiple comparison tests. In experiments with more than two variables, for 
example in RNA interference studies, two-way ANOVA analysis was carried out with 
either Tukey’s or Bonferroni’s multiple comparison tests. Protein was  normalised to 
GAPDH loading control of a given sample and expressed relative to protein 
expression following transfection with non-targeting siRNA or ShRNA (siNT or shNT) 
vehicle treated control.  
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In time and dose range experiments, a post-test for linear trend was also performed, 
giving a R2 value and p value to determine whether there was a significant linear 
increase or decrease in samples.  
mRNA expression data derived from delta Ct values, were from at least three 
individual donors all normalised to levels of histone H4 housekeeping gene within a 
given sample and  expressed relative to vehicle control from the same original donor 
sample.  
For MTT and SRB assays data were collected from kertainocytes derived from three 
different donors, all in triplicate, i.e. for each treatment three technical repeats were 
performed for each donor. For each donor, treated wells were expressed relative to 
to the mean absolute absorbance data derived from from the three vehicle treated 
control wells. Data was presented according to calcium conditions or treatment 
length and as such statistical analysis was performed using a simple one-way 
ANOVA with Dunnett’s multiple comparison test.  
Measurements of viable cell layer thickness with epidermal skin equivalents were 
derived using Image J software with 6 measurements taken along the length of each 
skin equivalent image and expressed relative to the mean thickness of vehicle control 
treated epidermal equivalents and represented as the mean relative viable thickness. 
Differing statistical analysis were applied depending on the number of variables and 
experiment. For analysis of epidermal equivalents treated over 3, 5 and 7 days, a 
two-way ANOVA with Bonferroni’s multiple comparison test was performed. For 
simply comparing effects of treatments e.g. vehicle vs. TCDD treated epidermal 
equivalents, an unpaired t-test was used in order to compare differences between 
independent random measurements.  
Finally, for analysis of the effect of chemical inhibitors or knockdown on TCDD 
induced apoptosis or proliferation in epidermal equivalents, tiled images of caspase-3 
and Ki67 stained epidermal equivalents were acquired. Hoechst positive nuclei and 
caspase-3/Ki67 positive cells were counted manually. The mean percentage of 
caspase-3/Ki67 expressing cells compared to total Hoechst positive nuclei was then 
determined and data expressed as fold change relative to vehicle control, or vehicle 
treated siNT/shNT controls. 
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 Statistical analysis was subsequently performed using two-way ANOVA with Tukey’s 
multiple comparison post hoc correction test for all ATG7 or cathepsin D knockdown 
experiments or by one-way ANOVA with Tukey’s multiple comparison test for 
analysis in treated (pepstatin A or bafilomycin) epidermal equivalents without 
knockdown.  
For all experiments statistical significance was reported ****p<0.0001, ***p<0.001, 
**p=<0.01 and *p<0.05, where a value of <p= 0.05 was considered significant. 
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 Exposure to TCDD results in a chloracne phenotype Chapter 3
associated with AhR degradation, autophagy induction and 
deregulated differentiation in a 3D epidermal equivalent model 
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3.1. Introduction 
 
The most severe and typical form of TCDD cutaneous toxicity is chloracne, a chronic 
hyperkeratoic skin disorder with comedones and cysts, resulting in scarring and 
disfigurement (Ray and Swanson, 2009). However, the pathogenesis underlying 
chloracne is still incompletely understood and it seems resistant to most treatments 
(Ju et al., 2009). Since chloracne affects both hair follicles and the interfollicular 
epidermis, suitable animal models have proved difficult to derive. Not only this, there 
are significant differences between mouse and human AhR, with mouse AhR having 
increased affinity for ligands such as TCDD (Hao et al., 2013, Ema et al., 1994). 
Therefore, due to the drawbacks of using animal models, human keratinocyte cell 
lines such as the HaCaT cell line and normal human epidermal keratinocytes 
(NHEKs) are often used. Although monolayer cultures can be used to study 
biochemical and molecular mechanisms, organotypic models or epidermal 
equivalents more accurately reproduce the morphology and differentiation of human 
epidermal tissue (Loertscher et al., 2001a). 
Although AhR activation by TCDD is thought to alter epidermal differentiation (Van 
den Bogaard et al., 2015, Forrester et al., 2014), the role of endogenous AhR 
signalling and direct impact on keratinocyte signalling still requires further research. 
Recent studies showing increased expression of AhR-related mRNA in skin biopsies 
derived from patients with atopic dermatitis and psoriasis has increased interest in 
this area (Kim et al., 2014). In addition, observations demonstrating coal tar, used in 
the treatment of atopic dermatitis, induces AhR pathway activation and the 
restoration of normal epidermal differentiation (Van den Bogaard et al., 2013) has 
further highlighted the role of AhR in regulating epidermal homeostasis. Further 
research reported the ability of AhR activating ligands to reduce inflammation 
associated with psoriasis, whilst AhR antagonists induced inflammation (Di Meglio et 
al., 2014). Collectively, this data suggests AhR regulates key homeostatic 
mechanisms in cutaneous biology and AhR may provide a valuable therapeutic 
target for cutaneous diseases such as atopic dermatitis.  
Similarly, the molecular mechanisms mediating TCDD-induced toxicity and the 
resultant chloracne phenotype are not fully understood (Loertscher et al., 2002). In 
vitro, in both organotypic skin models and keratinocyte monolayer cultures, TCDD 
treatment results in the altered expression of epidermal differentiation markers 
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(Loertscher et al., 2001a, Sutter et al., 2009). In a previous study in the lab, TCDD 
treatment was also found to induce dysregulated differentiation in epidermal 
equivalents. However, in contrast to the literature TCDD treatment reduced filaggrin 
protein expression whilst TGM-1 expression was increased (Forrester et al., 2014). 
Previous studies from the Reynolds lab (Forrester thesis) also reported that the 
induction of a TCDD chloracne phenotype was associated with increased autophagic 
activity. Electron microscopy of epidermal equivalents treated with TCDD found 
evidence of double membrane autophagosomes, as well as vacuolisation indicative 
of autophagy. Since autophagy also plays an integral role in normal skin homeostasis 
and epidermal differentiation (Yoshihara et al., 2015) these studies provide further 
support for the likely impact of TCDD on altered epidermal differentiation. 
Building upon earlier preliminary studies, (Forrester et al., 2014), the principle aim of 
the present chapter was to further develop, refine and characterise a physiologically 
relevant and robust epidermal skin equivalent model of a TCDD-induced chloracne 
phenotype. Our focus was to characterise the mechanisms mediating TCDD-induced 
chloracne and the specific effects of TCDD on keratinocyte/epidermal differentiation, 
autophagy, apoptosis and the physiological role of AhR pathway activation in the 
skin. 
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3.2. Results 
3.2.1. TCDD induces a chloracne phenotype in human 3D epidermal skin 
equivalents. 
 
TCDD has previously been reported to induce a chloracne phenotype in epidermal 
skin equivalents in vitro (Forrester et al., 2014); however, the mechanisms mediating 
this effect remain incompletely understood. To further characterise mechanisms 
associated with TCDD-induced chloracne, human epidermal skin equivalents were 
generated and initially treated with 10nM TCDD or vehicle (DMSO) control 
systematically every 48 hours for a period of 3, 5 or 7 days. Histological staining of 
formalin fixed and paraffin embedded (FFPE) sections with haemotoxilin and eoisin 
(H&E), revealed as expected a reduction in the viable cell layer (Fig. 3.1), with 
apparent maximal effect after 7 days. This was in addition to a more compacted 
stratum corneum, again with maximal effect after 7 days treatment with TCDD (Fig. 
3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 TCDD–induced chloracne in epidermal skin equivalents.  
Representative immunohistochemical images of epidermal skin equivalents (n=3 independent donors) 
stained with H&E following treatment every 48 hours for 3, 5 or 7 days with vehicle (DMSO) or TCDD 
(10nM), scale bar=20µm.  
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Quantitative analysis of the viable cell layer demonstrated a significant decrease in 
the thickness of the viable cell layer in all epidermal skin equivalents treated for 3, 5 
or 7 days with TCDD compared to those treated for identical time points with vehicle 
(DMSO) control (Two-way ANOVA with Bonferroni’s multiple comparison test, 
p<0.01, p<0.05, p<0.001 Fig. 3.2A). This was more significant and notably greater in 
epidermal skin equivalents treated with TCDD for 7 days (p<0.001). Additional 
quantitative analysis also revealed a slight reduction in the viable cell layer thickness 
of epidermal skin equivalents treated with vehicle (DMSO) control after 7 days (Fig. 
3.2B), although treatment with TCDD for 7 days still revealed a significant affect 
(Two-way ANOVA Bonferroni’s multiple comparison test p<0.0001, Fig. 3.2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 TCDD treatment induced a significant reduction in viable cell layer thickness in 
epidermal skin equivalents. 
 A) Mean viable cell layer thickness (VCL) of epidermal skin equivalents treated with vehicle 
(DMSO) control (blue bars) or TCDD (10nM) (red bars) every 48 hours for 3, 5 or 7 days 6 
measurements were taken per treatment, per donor. Data is expressed relative the average VCL 
thickness taken from 6 images of vehicle (DMSO) control at day 3, 5 or 7 respectively (n=3 
independent donors) ±SEM. B) Mean VCL thickness of epidermal skin equivalents treated every 
48 hours for 3, 5 or 7 days with vehicle (DMSO) control (blue bars) or TCDD (10nM) (red bars). 
Date is expressed relative to the average VCL thickness taken from 6 images of vehicle (DMSO) 
control at day 3(n=3 independent donors). Statistics were acquired using two-way ANOVA 
Bonferroni’s multiple comparison test, *** P< 0.0001. 
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These experiments were repeated on several occasions and collectively 
demonstrated the consistent induction of a TCDD-induced chloracne phenotype at 7 
days, with a consistent and significant reduction in the viable cell layer (Un-paired t-
test, p<0.0001, Fig. 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 TCDD-induced reduced viable cell layer of the chloracne phenotype model is 
reproducible at 7 days.  
A) Representative immunohistochemical images of epidermal skin equivalents (n=8 independent 
donors) stained with H&E following treatment with vehicle (DMSO) control or TCDD (10nM) every 
48 hours for 7 days. Scale bar = 20µm B) Mean viable cell layer (VCL) thickness of epidermal skin 
equivalents treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days. Each bar is 
expressed relative to vehicle (DMSO) control (n= 8 independent donors) ±SEM.  Statistics were 
acquired by un paired t test ****p=<0.0001. 
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3.2.2. TCDD induces AhR degradation and CYP1A1 mRNA expression 
 
As AhR activation leads to AhR protein degradation (Forrester et al., 2014, Ma and 
Baldwin, 2000), AhR protein expression in TCDD treated epidermal skin equivalents 
was determined by western blotting as a read out of AhR pathway activation in this 
model. Epidermal skin equivalents were treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 3, 5 or 7 days (Fig. 3.4).  
 
 
 
 
 
 
 
Results showed relative to GAPDH loading control, AhR protein expression 
significantly decreased after 7 days treatment with TCDD compared to vehicle 
(DMSO) control (two-way ANOVA with Bonferroni’s multiple comparison test, p<0.01, 
Fig. 3.4 A, B). Furthermore, repeated experiments of TCDD treatment in epidermal 
skin equivalents, derived from 7 independent donors, for 7 days confirmed the 
consistent and significant degradation of AhR protein expression (paired t-test, 
Figure 3.4 TCDD induces AhR protein degradation in epidermal skin equivalents.  
A) Representative western blot of AhR protein expression in epidermal skin equivalents (n=3 
independent donors) following treatment with vehicle (DMSO) control or TCDD (10nM) every 48 
hours for 3, 5 or 7 days. B) Densitometric analysis of AhR protein expression after vehicle (DMSO) 
(blue bar) or TCDD (10nM)  treatment (red bar) each bar is normalised to GAPDH loading control 
and relative to vehicle (DMSO) control at day 3, 5 or 7 (n=3 independent donors) ± SEM. Statistics 
were acquired by two-way ANOVA with Bonferroni’s multiple comparison test **p= <0.01 C) 
Densitometric analysis of AhR protein expression after vehicle (DMSO) (blue bar) or TCDD (10nM) 
treatment (red bar) every 48 hours for 7 days each bar is normalised to GAPDH loading control and 
relative to vehicle (DMSO) control (n=7 independent donors) ±SEM. Statistics were acquired by 
paired t test ****p=<0.001. 
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p<0.001, Fig. 3.4 C). To gain further evidence of TCDD-induced activation of AhR, 
mRNA levels of AhR as well as CYP1A1 (as a downstream target of AhR activation) 
(Ma, 2001, Veldhoen et al., 2009) were quantified by qPCR of lysates prepared from 
epidermal skin equivalents treated for 7 days with either vehicle (DMSO) control or 
TCDD (10nM) (Fig. 3.5). 
  
 
Figure 3.5 TCDD-induced AhR mRNA degradation and CYP1A1 mRNA induction.  
A) AhR mRNA expression in epidermal skin equivalents (n=3 independent donors) following treatment 
with vehicle (DMSO) (blue symbols) or TCDD (10nM) (red symbols) every 48 hours for 7 days, each 
symbol is normalised to housekeeper gene H4 and relative to vehicle (DMSO) control , line represents 
mean value. Statistics were acquired by paired t-test (NS) B) CYP1A1 mRNA expression in epidermal 
skin equivalents (n=3 independent donors) following treatment with vehicle (DMSO) (blue symbols) or 
TCDD (10nM) (red symbols) every 48 hours for 7 days each symbol is normalised housekeeper gene 
H4 and relative to vehicle (DMSO) control, line represents mean value. Statistics were acquired by 
paired t-test (NS). 
 
Results revealed a trend for decreased AhR mRNA expression and increased 
CYP1A1 mRNA in epidermal skin equivalents following 7 days treatment with TCDD 
further supporting the evidence for TCDD-induced AhR activation in a chloracne 
phenotype.  
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3.2.3. TCDD induces de-regulated epidermal differentiation in epidermal skin 
equivalents  
 
Previous reports have shown that TCDD causes de-regulated differentiation, 
inducing a switch from proliferation to differentiation of keratinocytes (Berkers et al., 
1995). In order to further delineate the impact of TCDD treatment on epidermal 
differentiation in the context of chloracne, the immunofluorescent expression of 
epidermal differentiation markers filaggrin, loricrin and cytokeratin 10 (CK10 or K10) 
was determined in epidermal skin equivalents treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 7 days (Fig. 3.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 TCDD induces de-regulated expression of late epidermal differentiation markers. 
 A) Representative photomicrographs of epidermal equivalents treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 7 days depicting Hoechst nuclear staining (blue fluorescence) and filaggrin 
(i), CK10 (ii) or loricrin (iii) staining (red fluorescence). n=3 independent donors, scale bar 62.15µm. B) 
Mean relative filaggrin (Bi) loricrin (Bii) or CK10 (Biii) expression in epidermal equivalents treated for 7 
days with vehicle (DMSO) (blue bars) or TCDD (10nM) (red bars). Each bar is expressed relative to 
vehicle (DMSO) control filaggrin (i) CK10 (ii) or loricrin (iii) expression, n= 3 independent donors, ± SEM. 
Statistics were acquired by paired t-test *p=<0.05, **p=<0.01 
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Results demonstrated a significant reduction in filaggrin expression (paired t-test 
p<0.05, Fig. 3.6 A, B i) and CK10 (p<0.01, Fig. 3.6 A, B iii) in response to treatment 
with TCDD (10nM) treatment for 7 days. Loricrin expression was also reduced, 
although this was not significant (Fig. 3.6 A, B ii). Conversely, analysis of mRNA 
expression of loricrin, filaggrin, CK10 and involucrin revealed opposing results (Fig. 
3.7), in which TCDD induced an apparent increase in the mRNA expression levels of 
each marker (Fig. 3.7). Collectively, these data thereby suggest that a TCDD-induced 
chloracne phenotype is associated with deregulated epidermal differentiation.  
 
 
 
 
 
 
Figure 3.7 TCDD-induced mRNA expression of epidermal differentiation markers.  
Loricrin, CK10, filaggrin or involucrin mRNA expression in epidermal skin equivalents (n=3 
independent donors) following treatment with vehicle (DMSO) (blue symbols) or TCDD (10nM) (red 
symbols) every 48 hours for 7 days each symbol is normalised to housekeeper gene H4, relative to 
vehicle (DMSO) control, line represents mean value. Statistics were acquired by paired t-test (NS) 
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3.2.4. TCDD treatment causes no significant change in cell proliferation but 
does induce active caspase-3 staining in epidermal skin equivalents  
 
To further delineate the TCDD-induced chloracne phenotype and specifically the 
mechanisms involved in the TCDD-induced reduction in viable cell layer, caspase-3 
dependent cell death and cellular proliferation were explored. Human epidermal skin 
equivalents were generated and then treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days. After harvesting, immunofluorescence staining on OCT 
frozen sections for caspase-3 or Ki67 was carried out. Images were taken along the 
entire length of the epidermal skin equivalents and Hoechst positive cells and 
caspase-3 or Ki67 positive cells were counted (Fig 3.8 A-D). Further representative 
tiled images of capsase-3 staining are also displayed in Appendix G.  
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Figure 3.8 TCDD significantly induced caspase-3 positive cells but caused no change to 
proliferation.  
Mean percentage of caspase-3 positive cells (A) or Ki67 positive cells (B) to Hoechst positive cells 
presented as fold change in epidermal equivalents treated with vehicle (DMSO) (blue bar) or TCDD (10nM) 
(red bar) every 48 hours for 7 days  relative to vehicle (DMSO) control. n=7 (A) or n=3 (B) independent 
donors, ± SEM. Statistics were acquired by paired t-test **p=<0.01 (A) NS (B). Mean number of caspase-3 
positive cells (C) or Ki67 positive cells (D) to Hoechst positive cells presented as raw number in epidermal 
equivalents treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days relative to vehicle 
(DMSO) control. n=7 (C) or n=3 (D) independent donors, ± SEM. Statistics were acquired by two-way 
ANOVA with Bonferroni’s multiple comparison test **p=<0.01 (C) NS (D). Representative photomicrographs 
(E) taken at 20x magnification of epidermal skin equivalents treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days depicting Hoechst nuclear staining (blue fluorescence) or caspase-3 expression 
(red fluorescence). Scale bar=62.15µm 
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Statistical analysis revealed TCDD treated epidermal skin equivalents had 
significantly increased caspase-3 positive cells compared to vehicle (DMSO) alone 
(Paired t-test p<0.01 Fig. 3.8 A). This data suggests the reduced viable cell layer may 
be due to TCDD inducing a form of apoptotic cell death. In contrast, TCDD did not 
cause a significant change in proliferation, although staining for Ki67 was reduced 
slightly in TCDD treated epidermal skin equivalents (Fig. 3.8 B). Statistical analysis of 
the raw number of Hoechst positive cells and caspase-3 positive cells along the 
entire tiled image revealed a significant reduction in Hoechst positive cells (two-way 
ANOVA p<0.01) in TCDD treated epidermal equivalents compared to vehicle 
(DMSO) treated (Fig 3.8 C). Data also suggested the number of Ki67 positive cells 
decreased proportionally compared to number of Hoechst positive cells in TCDD 
treated epidermal equivalents compared to control (Fig 3.8 D). However, the number 
of caspase-3 positive cells remained similar to vehicle treated epidermal equivalents, 
despite the reduced number of cells in total after TCDD treatment (Fig 3.8 C). 
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3.2.5. TCDD induces autophagy in epidermal skin equivalents 
 
Preliminary data leading to the present study suggested a TCDD-induced chloracne 
phenotype is associated with autophagy activation (Forester thesis). To provide 
further evidence for TCDD-induced autophagy activation, LC3 lipidation was also 
determined by western blotting in the same epidermal skin equivalents from sections 
3.1.1 and 3.1.2, treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 3, 5 
and 7 days (Fig 3.9) and probed for LC3II. 
 
 
 
 
 
 
 
 
Figure 3.9 TCDD induces LC3II accumulation in epidermal skin equivalents.  
A) Representative western blot of LC3 I/II protein expression in epidermal skin equivalents (n=3 
independent donors) following treatment with vehicle (DMSO) control or TCDD (10nM) every 48 hours 
for 3, 5 or 7 days. B) Densitometric analysis of LC3II expression after vehicle (DMSO) (blue bar) or 
TCDD (10nM) treatment (red bar) every 48 hours for 3, 5 or 7 days. Each bar is normalised to 
GAPDH loading control relative to vehicle (DMSO) control at day 3, 5 or 7 (n=3 independent donors) 
±SEM. Statistics were acquired by two way ANOVA with Bonferroni’s multiple comparison test *p= 
<0.05) Densitometric analysis of LC3II protein expression after vehicle (DMSO) (blue bar) or TCDD 
(10nM) treatment (red bar) every 48 hours for 7 days each bar is normalised to GAPDH loading 
control relative to vehicle (DMSO) control (n=7 independent donors) ±SEM. Statistics were acquired 
by paired t test *p=<0.05. 
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Results demonstrated TCDD treatment gradually increased LC3II expression, 
compared to vehicle (DMSO) control over 7 days, supportive of autophagy induction 
(Fig. 3.9 A). Densitometric analysis further revealed significant induction of LC3II 
after treatment with TCDD for 7 days (two-way ANOVA with Bonferroni’s multiple 
comparison test, p<0.001, Fig. 3.9 B). This effect was significantly reproducible 
following analysis in epidermal skin equivalents derived from 7 independent donors 
(Paired t-test, p<0.05, Fig. 3.9. C). Additional Immunofluorescence analysis of TCDD 
treated epidermal skin equivalents showed significant increased endogenous LC3 
expression (Fig. 3.10 A i and ii) as well as significantly decreased expression of P62 
(Fig. 3.10 Bi and ii) throughout the epidermis, following 7 days treatment with 10nM 
TCDD (paired t-test, p<0.05). Collectively these data strongly support that a TCDD-
induced chloracne phenotype is associated with the activation of autophagy in the 
epidermis.  
 
 
 
 
Figure 3.10 TCDD induced a significant increase in endogenous LC3 and P62 degradation in 
epidermal skin equivalents.  
Representative photomicrographs of epidermal skin equivalents treated with vehicle (DMSO) or 
TCDD (10nM) every 48 hours for 7 days depicting Hoechst nuclear staining (blue fluorescence) or 
endogenous LC3 (Ai) or P62 expression (Bi) (red fluorescence). n=3 independent donors, scale 
bar=100µm. Mean LC3 (Aii) or P62 (Bii) expression of epidermal skin equivalents treated with vehicle 
(DMSO) or TCDD (10nM) every 48 hours for 7 days. Each bar is relative to vehicle (DMSO) control, 
n=3 independent donors, ± SEM. Statistics were acquired paired t-test (p<0.05). 
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3.3. Discussion 
 
Using an optimised and robust in vitro human epidermal skin equivalent model, data 
from the present chapter characterises the time course and inter-relationship 
between histological changes, AhR activation, induction of autophagy and apoptosis 
and altered keratinocyte differentiation. Together this demonstrates TCDD treatment 
leads to a significantly reduced viable cell layer and more compact stratum corneum, 
typical of a chloracne phenotype observed in vivo (Forrester et al., 2014 and Ju et al., 
2009). Whilst TCDD has previously been shown to induce a chloracne phenotype 
model within the lab, data demonstrating the temporal regulation and detailed time 
course of development over 7 days is novel.  
In humans, chloracne is the most consistently observed pathology after TCDD 
exposure and therefore, dermato-pathology is the most widely accepted and reliable 
means of identifying associated toxicity (Neuberger et al., 1991, Loertscher et al., 
2001b). To date, suitable animal models have been difficult to derive and as such, 
recent research has focussed on the use of organotypic skin equivalent models. 
Previous studies have described the development of a full thickness organotypic 
model, by co-culturing near immortalised diploid human keratinocytes (NIKS) and 
dermal fibroblasts (Loertscher et al., 2001b and De Abrew et al., 2014), which, 
although contain a dermal compartment still lacks appendages such as hair follicles. 
Although the application of TCDD to these models resulted in altered/de-regulated 
epidermal differentiation, there was no obvious reduction in viable cell layer thickness 
or the induction of a chloracne-like phenotype, reflective of an in vivo setting 
(Loertscher et al., 2001b and De Abrew et al., 2014). Nevertheless, studies by De 
Abrew et al noted the increase in intracellular spaces, between keratinocytes of the 
basal and suprabasal layers following treatment with TCDD (De Abrew et al., 2014). 
Interestingly, additional studies of primary human keratinocytes cultured in monolayer 
and subjected to treatment with TCDD demonstrated a reduction in cell number 
(Loertscher et al., 2001a). In vivo, observations of a TCDD mediated reduction in 
viable cell layer and compacted stratum corneum are evident within the follicle wall 
resulting in a follicular plug or comedone, both characteristic features of chloracne 
(Forrester et al., 2014 and Ju et al., 2009). In the present study, a consistent and 
distinct chloracne-like phenotype was evident after treatment with TCDD for 7 days. 
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This therefore, highlights the suitability of the model to elucidate the mechanisms 
behind the pathology of chloracne.  
 
3.3.1. TCDD treatment activates the AhR pathway in epidermal skin equivalents 
 
Results from the present study further confirmed the ability of TCDD to activate AhR 
signalling, specifically causing a reduction of AhR expression, both at the protein and 
mRNA level, as expected (Hao et al., 2013) in epidermal equivalents. Furthermore, 
consistent with previous studies, including studies on skin lesions from dioxin-
exposed humans with chloracne (Tang et al., 2008, Sutter et al., 2011), TCDD 
treatment of epidermal skin equivalents also resulted in the induction of CYP1A1 
mRNA induction after 7 days.  
After exposure to exogenous ligands, AhR is thought to be degraded by the 26S 
proteasome ubiquitination pathway (Ma and Baldwin, 2000, Ma, 2011).  Interestingly, 
previous reports noted TCDD-induced AhR degradation occurred quickly, but differed 
between cell types. In the normal lung cell line Hs 115. LU, for example, AhR 
degradation occurred after 2 hours, whilst maximal degradation in the colorectal 
adenocarcinoma cell line LS 180 only occurred after 16 hours of TCDD treatment 
(Pollenz et al., 2006). In contrast, TCDD induced AhR degradation in the present 
study was only significant at 7 days, and this coincided with CYP1A1 mRNA 
induction. Such variable time and magnitude of AhR degradation may be reflected by 
the use of differing in vitro models and as such in the present model this process may 
take longer. It would be interesting to explore the temporal changes in CYP1A1 
induction after TCDD treatment and determine if the induction of CYP1A1 is also 
delayed in addition to AhR degradation. However, this late induction of CYP1A1 is 
indicative of the long half-life of TCDD and sustained induction of the AhR pathway is 
also seen in vivo. Saurat et al (2009) found CYP1A1 mRNA expression to be 
increased 170.1 fold above control in chloracne skin lesions, 5 months after TCDD 
poisoning. 
As well as exposure to exogenous ligands, AhR localisation and activity can be 
affected by other factors. A study using the HaCaT cell line found at low confluency 
AhR was mainly localised in the nucleus, but at sub-confluent levels was localised 
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both in the nucleus and cytoplasm. In contrast, at 100% confluency AhR expression 
was predominantly in the cytoplasm, collectively suggesting confluency of 
keratinocytes may impact on cellular localisation. In addition to its effect of sub 
cellular localisation, the confluency of keratinocytes in monolayer also impacts on 
AhR activity: AhR activity apparently falls to basal levels in confluent cells (Ikuta et 
al., 2009, Ikuta et al., 2004). Of note, in murine keratinocytes differentiation status 
was also found to effect induction of genes in response to TCDD (Jones et al., 1997). 
Both proliferating and differentiating keratinocytes expressed AhR and ARNT 
proteins, but there was a higher induction of CYP1A1 and other target genes 
including CYP1B1 in the differentiating population. In the present epidermal 
equivalent model, primary human keratinocytes were seeded at high density and fully 
differentiated. Therefore, according to the literature, this may result in altered AhR 
activity and delayed AhR degradation following treatment with TCDD. It would be 
beneficial, therefore, to carry out immunofluorescence staining to establish 
localisation of AhR and explore any differential cellular distribution.  
 
3.3.2. TCDD treatment de-regulates epidermal differentiation in epidermal skin 
equivalents 
 
Results from the present study showed TCDD clearly de-regulates epidermal 
differentiation in vitro, with observed decreased protein, but increased mRNA 
expression of the differentiation-associated proteins loricrin, filaggrin and CK10. The 
induction of mRNA expression of late differentiation markers by TCDD is in keeping 
with published literature. For example, Sutter et al reported TCDD treatment of 
primary human keratinocytes cultured in monolayer resulted in increased filaggrin 
mRNA expression (Sutter et al., 2011). Additionally, TCDD treatment of NHEKs has 
been found to increase involucrin expression at both RNA and protein level (Gaido 
and Maness, 1994). In fact, TCDD has been found to increase the expression of 40% 
of genes of the epidermal differentiation complex (EDC) located on chromosome 
1q21 in humans, which encodes for proteins involved in cornified envelope formation 
(Kennedy et al., 2013). This included increased expression of filaggrin and hornerin.  
The observed reduction in filaggrin, loricrin and CK10 protein levels has also been 
previously reported. Proteomic analysis of primary monolayer keratinocytes, exposed 
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to TCDD reported significant suppression of filaggrin, keratin 1 and keratin 10 
proteins (Hu et al., 2013). Furthermore, using the present epidermal equivalent 
model, Forrester et al (2014) found TCDD treatment caused aberrant changes in 
expression of filaggrin, involucrin and TGM-1. Protein expression of filaggrin and 
involucrin was downregulated by TCDD treatment, however, TGM-1 expression 
increased (Forrester et al., 2014). TGM-1 was not examined in the studies reported 
here. 
In contrast, TCDD treatment of an organotypic skin model previously described, 
found a fully differentiated cornified layer developing quicker than in vehicle treated 
control (Loertscher et al., 2001a). TCDD treated cultures were found to have a more 
extensive layer of keratinised tissue compared to vehicle control and measurements 
taken from electron micrographs confirmed this, with the ratio of keratinised to 
monokeratinised layers being far greater in TCDD treated samples (Loertscher et al., 
2001b). Of note, staining for differentiation markers revealed all markers were 
present in vehicle and TCDD treated equivalents, but the pattern of expression was 
altered by TCDD treatment. This was particularly notable in filaggrin, with expression 
reported as patchy in the granular layers and evident in cellular layers more proximal 
to the basal layer compared to control samples (Loertscher et al., 2001b), consistent 
with the findings reported here. Together this data suggested TCDD treatment alters 
both temporal and spatial expression of filaggrin. Similarly, altered expression of 
involucrin was also detected with evidence of expression in basal keratinocytes after 
TCDD treatment rather than supra-basal cells (Loertscher et al., 2001b). TGM-1 was 
found to also be irregular and disrupted after TCDD treatment. However, it should be 
noted that, in contrast to the present model, Loertscher et al (2001b) used a full 
thickness model with a dermis consisting of neonatal fibroblasts mixed with collagen. 
Additionally, near immortalised keratinocytes were seeded on top of the dermis, 
rather than primary keratinocytes. Models were also treated 2 hours post plating and 
cultured for only 8 days.  
Results from the present study indicate TCDD treatment induces de-regulated 
differentiation, which is in keeping with the literature. However, in the present model 
keratinocytes are in culture, able to differentiate and the epidermis to stratify for 12 
days before beginning treatment for a further 7 days with TCDD. As such, this 
treatment regime may alter the effect of TCDD treatment on differentiation, as the 
cells are mostly differentiated before treatment begins. The effect of adding 
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treatments at different time points during the generation of the human skin 
equivalents has been explored previously by Van den Bogaard et al (2015). In this 
study, AhR antagonists were added when keratinocytes were submerged 
(proliferation/attachment phase), after the culture had been brought to air/liquid 
interface or much later during the last phase of air/liquid culture. Interestingly, results 
demonstrated addition on antagonists in the last phase did not affect involucrin of 
filaggrin expression, whereas when added in the submerged or early air/liquid 
interface phase addition of AhR antagonists caused late differentiation marker 
expression to reduce and the stratification process was suppressed. Van den 
Bogaard also found differences between cultures on inert filters, as used in the 
present model, and skin equivalents using de-epidermised dermis. It would therefore, 
be interesting to explore this further in the present model, by treating with TCDD at 
different time points and then investigating full differentiation marker expression.  
Adding to the complexity of autophagy, this process also plays an integral role in 
cellular differentiation and more over in epidermal differentiation (Aymard et al., 2011, 
Yoshihara et al., 2015). Interestingly, a recent study in monolayer primary human 
keratinocytes, explants and mouse tissue has explored autophagy marker expression 
in developing epidermis and again found autophagy plays an integral role in 
epidermal differentiation. Autophagy was found to be constitutively active in the 
granular layer and likely mediated by epidermal MTORC1 (Akinduro et al., 2016). Of 
note, in human psoriatic skin biopsies LC3 marker expression was found to be 
reduced, suggesting autophagy is impaired and could potentially be targeted 
therapeutically to restore epidermal barrier function (Akinduro et al., 2016). 
As to whether TCDD-induced autophagy in the current model directly or indirectly 
impacts on the deregulation of epidermal differentiation is unclear and investigating 
the link between autophagy and loss of a viable cell layer following TCDD treatment 
of epidermal equivalents, is addressed in the following chapter.  
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3.3.3. TCDD treatment causes no significant change in cell proliferation but 
does induce caspase-3 staining in epidermal skin equivalents 
 
Data in the present chapter also demonstrated TCDD treatment caused an increase 
in active caspase-3 staining. Caspase-3 is an executioner caspase, activated by 
either caspase-9 (intrinsic apoptosis) or caspase-8 (extrinsic apoptosis) and results in 
the induction of apoptosis (McIlwain et al., 2015). Therefore, it is frequently used as a 
marker for both apoptosis pathways and increased expression is associated with the 
initiation of cell death or apoptosis. The induction of apoptosis by TCDD treatment 
has been reported in a variety of models including human breast carcinoma cells (Lin 
et al., 2007), choriocarcinoma cells (Chen et al., 2010) and human neuronal cell lines 
(Morales-Hernandez et al., 2012). In contrast, work in primary human keratinocytes in 
monolayer found TCDD treatment caused a reduction in cell number, but apoptosis 
was not induced (Loertecher et al., 2001a). Nucleosomal fragmentation, 
morphological changes, and caspase-3 activity were all measured and there was no 
significant difference between TCDD treated or vehicle (DMSO) treated cells 
(Loertscher et al., 2001a). However, Loertcher et al. (2001a) conducted studies in 
monolayer as opposed to the more physiologically relevant epidermal skin equivalent 
model used in the present study. As such, the unique microenvironment of the 
epidermal skin equivalent model may account for differences in results. Regardless, 
data suggests TCDD-induced apoptosis may to some extent be responsible for the 
significant reduction in viable cell layer. In addition, the number of Hoechst positive 
cells was significantly reduced after TCDD treatment compared to vehicle (DMSO) 
control (Appendix G), further confirming the reduction in the number of viable cells 
after TCDD treatment.  
To establish whether the TCDD-induced reduction in viable cell layer thickness was a 
consequence of decreased proliferation, Ki67 staining was also performed. However, 
TCDD treatment did not cause a significant change in Ki67 positive staining, although 
expression was reduced slightly. TCDD has previously been found to reduce 
proliferation in the ovarian cancer cell line OVCAR-3 and this was blocked by AhR 
siRNA knockdown (Li et al., 2014). In contrast, results in monolayer human 
keratinocyte cultures, after treatment for 48 hours with AhR antagonists, showed the 
percentage of Ki67 positive cells had reduced (Van den Bogaard et al., 2015). In the 
same study, however, Ki67 positive basal cells were increased in skin equivalent 
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models compared to untreated, again demonstrating the differences between 
monolayer and 3D cultures.  Importantly in neither the Van den Bogaard study or the 
results reported here was a reduction in Ki67 staining observed following treatment of 
skin equivalents with TCDD.  These data suggest that reduction in proliferation by 
TCDD does not account for the phenotype observed (reduced viable cell layer). 
 
3.3.4. TCDD treatment induces autophagy in epidermal skin equivalents 
 
As discussed, preliminary data (Forrester thesis) suggested TCDD treatment induced 
autophagy. Although not significant, in monolayer primary keratinocytes TCDD 
treatment increased LC3II protein expression with maximal effect at day 8 and a 
dose dependent downregulation of P62, detected through western blotting. Electron 
microscopy of epidermal equivalents also suggested autophagic induction. In TCDD 
treated epidermal equivalents, increased vacuolisation was noted as well as 
identification of both early and late autophagosomes, however, this was only 
performed in one donor (Forrester Thesis). In the present study, confirmation of 
autophagic activity in epidermal skin equivalents and potential role in the chloracne 
phenotype model was therefore pursued.  
Interestingly, TCDD treatment of epidermal skin equivalents in the present study also 
resulted in a significant increase in protein expression of the autophagic marker LC3II 
(by western blotting) and endogenous LC3 (by immunofluorescence) with concurrent 
downregulation of P62. Although endogenous LC3 is ubiquitously expressed, 
immunofluorescent staining can accurately measure autophagosome number and 
increased puncta suggests increased autophagic activity (Mizushima et al., 2010, 
Klionsky et al., 2016). Indeed, in the present study, a variety of techniques to detect 
autophagic activity were harnessed and therefore results can be interpreted with 
confidence that TCDD induces an increase in autophagic activity or flux (Mizushima 
et al., 2010, Menzies et al., 2012). Autophagy, the principle catabolic process for the 
lysosomal mediated degradation and recycling of damaged/excess proteins and 
organelles, is a well-recognised mechanism of cell survival for which the induction of 
LC3II and decreased expression of P62 are accepted markers of the induction of this 
process (Mizushima et al., 2010, Klionsky et al., 2016). However, autophagy 
induction can also result in cell death (Tsujimoto and Shimizu, 2005), suggesting the 
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hypothesis that the observed TCDD mediated reduction in viable cell layer and likely 
cell death, observed in epidermal skin equivalents, may be mediated by autophagy. 
There is known cross talk between autophagy and apoptosis (Maiuri et al., 2007, 
Gozuacik and Kimchi, 2007) and this concept is supported by TCDD induced 
caspase-3 staining in the current study as well as previous observations of TCDD-
induced cell death of primary human keratinocytes cultured in monolayer (Loertscher 
et al., 2001a). Nevertheless, the extent of TCDD-induced apoptosis appears to be 
model and cell type dependent.  
In the context of skin, a link between autophagy and apoptosis has already been 
established; eravirenz, a retroviral therapy given to patients with HIV, causes 
phenotypic alterations in normal human keratinocytes (NHKs) (Dong et al., 2013) 
resulting in autophagy dependent cytotoxic effects. Senescent NHEKs also display 
excessive autophagic activity, resulting in their subsequent death (Gosselin et al., 
2009), an effect again dependent on the level (i.e. excessive) of autophagy induction 
(Deruy et al., 2014). 
In contrast, autophagy is also known to be involved in skin homeostasis (Yoshihara 
et al., 2015) and act as a cytoprotective mechanism after UV exposure (Misovic et 
al., 2013, Vitale et al., 2013). In addition, remifentanil an opioid analgesic was 
recently found to exert a protective mechanism in human keratinocytes subject to 
hypoxia-reoxygenation injury, again through activation of signalling pathways 
associated with autophagy (Kwon et al., 2015). 
Whether the TCDD-induced loss of viable cell layer observed in the present study is 
mediated by the induction of cytotoxic autophagy and/or subsequent apoptosis or if 
autophagy is induced as a stress response to survive TCDD toxicity remains unclear, 
and is the subject of the subsequent chapter to this thesis.  
In summary, data in the present chapter demonstrate TCDD induces a chloracne 
phenotype in a robust reproducible in vitro skin equivalent model, associated with the 
reduction of a viable cell layer, AhR degradation, and an increase in CYP1A1. TCDD 
also causes significant induction of autophagy, apoptotic cell death and the 
deregulation of epidermal differentiation. The intimate relationship between 
autophagy, cell death and deregulated differentiation in TCDD-induced cytotoxicity is 
addressed in the following chapter.    
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3.4. Summary 
 
 TCDD treatment of epidermal equivalents induces a chloracne-like phenotype 
with a significantly reduced viable cell layer and compacted stratum corneum, 
after 7 days 
 
 TCDD treatment activates AhR, causing AhR degradation and CYP1A1 
induction 
 
 TCDD causes de-regulated differentiation at protein and mRNA level 
 
 TCDD induces caspase-3 cell death but causes no significant change to 
proliferation 
 
 TCDD induces LC3II accumulation and P62 reduction, indicative of autophagy 
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 Exploring the interplay between de-regulated epidermal Chapter 4
differentiation and autophagy in TCDD-induced chloracne 2D and 
3D models 
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4.1. Introduction 
 
The epidermal skin equivalent model optimised in the previous chapter is both 
reproducible and physiologically relevant. However, generation of such models is 
time consuming and relatively low throughput. Therefore, a monolayer primary 
human keratinocyte model of chloracne, particularly if differentiated, would be 
beneficial. Although not as physiologically relevant, it would provide a quicker and 
easier method to determine specific pathways of interest induced by TCDD 
treatment, without the complexity of the epidermal skin equivalent model. Such a 
model may be adapted for high-through put screening assays applicable for drug 
development (to minimise the risk of chloracne for example).  Further relevant 
mechanisms or pathways of interest could then be verified and investigated in the 
TCDD-induced chloracne phenotype epidermal skin equivalent model. 
Results from the previous chapter revealed 10nM TCDD treatment induced de-
regulated differentiation. Epidermal skin equivalents are a well-established model to 
investigate differentiation, with keratinocytes migrating from the basal layers to 
stratum corneum and forming a fully stratified epidermis. However, it is also possible 
to differentiate monolayer primary keratinocytes by increasing extracellular calcium 
concentration. Although the precise mechanism is not fully understood, it is well 
known that calcium plays an integral part of keratinocyte differentiation (Shrestha et 
al., 2016). Under low or normal calcium conditions (0.05-0.1mM Ca2+) keratinocytes 
proliferate and can grow rapidly. When extracellular calcium concentration is 
increased (1.2-1.3mM Ca2+) cells start to differentiate, cell-cell contact increases and 
after 5 days a state of terminal differentiation is reached (Hennings et al., 1980, Pillai 
et al., 1990, Yuspa et al., 1989). This induction of differentiation by calcium has been 
well researched and involves many signalling pathways which help maintain cell-cell 
adhesion and increase intracellular calcium concentration, as reviewed by Bikle et al 
(2012).  
This method of differentiating monolayer keratinocytes is frequently used in research, 
particularly when exploring the role or effect of differentiation in comparison to 
proliferating cells (Karlsson et al., 2010, Lanzafame et al., 2015). Of note, this 
method was used when exploring the physiological role of AhR of endogenous 
signalling in keratinocyte differentiation, by van den Bogaard et al (2015). Initially 
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monolayer primary keratinocytes were cultured in both growth media (0.05mM) and 
high calcium (0.12mM) differentiation-inducing media to investigate AhR dependent 
genes and the effect of AhR antagonists on differentiation. They then explored this 
further in epidermal equivalents models. Interestingly, monolayer human 
keratinocytes treated with AhR antagonists GNF351 and CH223191 showed 
impaired terminal differentiation with reduced expression of loricrin, filaggrin and 
hornerin, whilst similar results were seen in human skin equivalents. Results 
demonstrated impaired epidermal stratification and altered stratum corneum 
formation in the 3D model, although the timing of AhR antagonist treatment did alter 
the effect on differentiation marker expression, as discussed in Chapter 3, section 
3.3.2 (Van den Bogaard et al., 2015).  
Results from the previous chapter also revealed significant autophagy induction by 
TCDD treatment. As discussed, autophagy induction in keratinocytes has been well 
researched and is involved in many processes, from expression of early 
differentiation markers (Aymard et al., 2011) to acting as a cytoprotective mechanism 
after UV exposure (Misovic et al., 2013, Vitale et al., 2013). The role of autophagy in 
this chloracne phenotype model is yet to be determined and is therefore a key focus 
of this current chapter. To explore this, modulation of autophagy is essential and 
there are a variety of chemical inhibitors available to target specific points of the 
pathway. Autophagosome formation can be blocked using PI3-kinase inhibitors such 
as 3-MA or wortmannin, (Wu et al., 2010). Later stages in the pathway can also be 
targeted, using microtubule disrupting agents such as vinblastine which blocks 
autophagosome-lysosome fusion or bafilomycin A1, a V-ATPase inhibitor which also 
prevents autolysosome degradation (Mizushima et al., 2010, Yamamato et al., 1998). 
However, as expected, chemical inhibitors can have off-target effects. Therefore, it is 
useful to also pursue genetic modulation of the pathway to confirm data obtained with 
chemical inhibitors. Key autophagy genes can be knocked down, such as ATG7 
(Aymard et al., 2011) or BECLIN-1 (Zhang et al., 2015) through stable (shRNA) or 
transient (siRNA) transfection.  
Finally, TCDD treatment of epidermal skin equivalents caused significant reduction in 
viable cell layer thickness. TCDD could be inducing a variety of pathways or 
processes responsible for this reduction of viability. For example, TCDD has 
previously been found to simply reduce proliferation in ovarian cancer cells (Li et al., 
2014) and a pre-osteoblast cell line (Yu et al., 2014). However, Ki67 staining in 
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epidermal skin equivalents in the previous chapter revealed TCDD caused no 
significant reduction in proliferation.  Alternatively, reduced viable cell layer thickness 
may be due to the well documented induction of terminal differentiation by TCDD as 
shown in monolayer normal human keratinocytes (Sutter et al., 2011, Sutter et al., 
2009). In the previous chapter TCDD was found to de-regulate differentiation causing 
increased mRNA expression of differentiation markers, whilst protein expression 
decreased. Although TCDD did not induce terminal differentiation fully, this de-
regulation of differentiation could also affect viable cell layer thickness.  
As discussed in Chapter 3, TCDD has also previously been reported to reduce cell 
number in NHEKs; although Loertecher et al. (2001a) found no evidence for 
apoptosis induction. Similarly, in previous studies (Forrester Thesis) data suggested 
TCDD induced a caspase-independent form of cell death.  In contrast, there have 
been reports of increased caspase-3 staining after TCDD treatment in other non-
keratinocyte cell models (Morales-Hernández et al., 2012, Huang et al., 2005). 
Interestingly, TCDD treatment was found to also induce increased caspase-3 positive 
staining in the present epidermal skin equivalent model. There is known cross talk 
between autophagy and apoptosis (Maiuri et al., 2007, Gozuacik and Kimchi, 2007) 
and whether in this model TCDD is inducing death through apoptosis or autophagy 
remains unclear. 
The aims of this chapter therefore, were to develop a differentiated and un-
differentiated monolayer primary human keratinocyte model in which TCDD caused 
AhR degradation, LC3II induction and reduced cell viability. Using this model as well 
as epidermal skin equivalents, the role of autophagy in TCDD induced de-regulated 
differentiation, AhR degradation and induction of cell death, was explored with both 
chemical inhibition and genetic modulation of the autophagy pathway.   
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4.2. Results 
4.2.1. Effect of a TCDD dose response in monolayer primary human 
keratinocytes on AhR degradation and LC3II accumulation  
 
The principle aim of this project was to investigate the mechanisms behind the 
TCDD-induced chloracne phenotype. After initial work with epidermal equivalents 
(Chapter 3) a more high-throughput model was pursued in order to determine 
pathways of interest. These individual pathways would then be investigated further in 
the more physiological relevant epidermal equivalent model. 
Firstly, to establish an optimum treatment regime, monolayer keratinocytes cultured 
in 0.06mM calcium medium were seeded and treated the following day with vehicle 
(DMSO) and a range of TCDD concentrations (0.1nM, 1nM, 10nM or 20nM). The 
keratinocytes were then treated every 48 hours for a total of 7 days, and harvested 
every 24 hours. To confirm TCDD induced AhR degradation and LC3II induction, as 
seen in the epidermal equivalent model, expression was determined by western 
blotting (Fig. 4.1, Fig. 4.2, Fig. 4.3). 
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Figure 4.1 TCDD treatment alters AhR protein expression but not LC3II protein 
expression in monolayer primary keratinocyte cultures.  
Representative western blots of AhR protein expression and LC3I/II expression in monolayer 
primary human keratinocytes (n=3 independent donors) following treatment with vehicle 
(DMSO) control, or TCDD (0.1nM, 1nM, 10nM or 20nM) every 48 hours for 7 days. 
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Figure 4.2 TCDD treatment induces dose dependent AhR protein degradation in monolayer primary 
keratinocyte cultures.  
Densitometric analysis of AhR protein expression in monolayer primary human keratinocytes after treatment 
with vehicle (blue symbols) or TCDD (0.1nM, 1nM, 10nM or 20nM) (pink and red symbols) every 48 hours for 
7 days. Each point is normalised to GAPDH loading control and expressed relative to vehicle (DMSO)  
control at each day. n=3 independent donors, ± SEM. Statistics were acquired by one-way ANOVA with 
Dunnett’s multiple comparison test *p= <0.05, **p=<0.01, ***p= <0.001, ****p= <0.0001. A post-test for linear 
trend was also carried out (Individual R2 and P values displayed on graph) 
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Figure 4.3 TCDD treatment does not induce a significant dose dependent increase in LC3II 
protein accumulation.  
Densitometric analysis of LC3II protein expression in monolayer primary human keratinocytes 
after treatment with vehicle (blue symbols) or TCDD (0.1nM, 1nM, 10nM or 20nM) (pink and red 
symbols) every 48 hours for 7 days. Each symbol is normalised to GAPDH loading control and 
expressed relative to vehicle (DMSO) control at each day. n=3 independent donors, ± SEM. 
Statistics were acquired by one-way ANOVA with Dunnett's multiple comparison test *p= <0.05. A 
post-test for linear trend was also carried out (NS). 
 84 
 
Densitometric analysis of AhR and LC3II protein expression on western blots were 
adjusted relative to GAPDH loading control and normalised to the vehicle controls at 
each respective time point. AhR protein expression decreased in a time and 
concentration dependent manner following treatment with TCDD and a 
dose/response curve was evident across most time points. Levels of expression were 
similar after treatment with both 10nM and 20nM concentrations, and seemed to 
flatten out, suggesting this was close to the top of a dose/response curve. Therefore, 
data clearly demonstrated functional interaction of TCDD with its cognate AhR 
receptor (Fig. 4.2). This was further verified by performing a post-test for linear trend 
which found this trend to be significant across all time points. Interestingly, 10nM and 
20nM TCDD treatments caused significant reduction in AhR protein degradation 
across all time points (one-way ANOVA with Dunnett’s multiple comparison test 
p<0.05, p<0.01, p<0.001) compared to vehicle (DMSO) control.   
In contrast, TCDD treatment of monolayer primary keratinocytes cultures did not 
induce any significant increase in LC3II expression (Fig. 4.3) (one-way ANOVA with 
Dunnett’s multiple comparison test). At day 7 there does appear to be a trend of 
increased LC3II expression as TCDD concentration is increased, however, this was 
not significant (one-way ANOVA with post-test for linear trend p=0.2136, R2=0.1492). 
In general, unlike in TCDD treated epidermal equivalents, LC3II expression was very 
variable and overall did not seem to be significantly induced. This was also supported 
by the R2 values which were all below 0.5, much lower than R2 values for trend in 
AhR expression.  
Of note, there was no significant change in LC3II or AhR protein expression in 
vehicle DMSO (1:1000) treated monolayer primary keratinocytes, over time 
(Appendix Fig D, [A and B]).  
The concentration of TCDD used to produce the chloracne phenotype in epidermal 
equivalents is 10nM (Chapter 3). Therefore, statistical analysis was carried out to 
look into this concentration in monolayer in more detail (Fig. 4.4). Specifically, a two-
way ANOVA was used to look at the difference between vehicle (DMSO) and TCDD 
treatment over time.  
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Analysis revealed that relative to GAPDH loading control, AhR protein expression 
was significantly reduced after 10nM TCDD treatment of monolayer primary 
keratinocytes, at every time point. Although AhR degradation was significant at day 2 
and 3 (two-way ANOVA with Bonferroni’s multiple comparison test p<0.01 and 
p<0.001 respectively) degradation from day 4 onwards was more significant 
(p<0.0001).  These data reinforce that TCDD was activating AhR from day 2. 
In contrast there was no significant increase in LC3II expression with 10nM TCDD 
treatment across any time point (two-way ANOVA with Bonferroni’s multiple 
comparison test). However, at day 4 and day 7 expression of LC3II was slightly 
increased.  
Figure 4.4 TCDD (10nM) treatment induces AhR protein degradation in monolayer primary 
keratinocyte cultures over time, but does not cause significant LC3II accumulation.  
Densitometric analysis of A) AhR or B) LC3II protein expression in monolayer primary human 
keratinocytes after vehicle (blue bars) or TCDD (10nM) treatment (red bars) every 48 hours for 7 
days. Each bar is normalised to GAPDH loading control and expressed relative to vehicle (DMSO) 
control at each day. n=3 independent donors, ± SEM. Statistics were acquired by two-way ANOVA 
with Bonferroni’s multiple comparison test. A) **p=<0.01, ***p= <0.001, ****p= <0.0001 B) (NS) 
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4.2.2. High calcium conditions cause monolayer primary keratinocytes to 
differentiate after 5 days 
 
After analysing the results of the time–dose response experiment (in which cells were 
treated every 48 hours for 7 days), the treatment regimen was modified. At 5 days 
10nM TCDD treatment caused significant and reproducible AhR degradation and 
treating the cells for any longer may have caused cells to become over-confluent 
which may have caused increased variation in results. Therefore, in subsequent 
experiments monolayer primary keratinocytes were seeded, treated the following day 
and again 48 hours later then harvested at 5 days. 
To further develop the high throughput monolayer model of chloracne, differentiation 
of keratinocytes was explored. As autophagy has been implicated in regulating 
keratinocyte differentiation (Akinduro et al., 2016), we hypothesised that high calcium 
differentiation-promoting media might modulate induction of autophagy by TCDD.   
Calcium induced differentiation has been previously studied in many labs (Shrestha 
et al., 2016) and culture conditions used in the present study had been previously 
optimised in parallel studies within the lab (Martina Elias, unpublished observations). 
Data showed increasing extracellular calcium concentration to 1.3mM for 5 days 
caused a phenotypic loricrin expression to significantly increase. Filaggrin expression 
was technically difficult to detect and consequently expression was variable, 
therefore in present monolayer experiments loricrin alone was used as a terminal 
differentiation marker.  
For the current study, primary keratinocytes were seeded and treated with vehicle 
(DMSO) or TCDD (10nM) in high (1.3mM calcium) and normal calcium conditions for 
5 days. Loricrin expression was determined by western blotting to confirm calcium-
induced differentiation was achievable (Fig. 4.5) 
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Results demonstrated, treatment of monolayer keratinocytes in high calcium media 
for 5 days did induce increased loricrin expression, relative to GAPDH loading control 
regardless of whether co-treated with TCDD or vehicle (Fig. 4.5 B) although not 
significant (paired t-test). 
 
 
  
Figure 4.5 High calcium conditions induced differentiation with increased loricrin 
expression in monolayer primary human keratinocytes independent of treatment.  
A) Representative western blot of loricrin protein expression in monolayer primary human 
keratinocytes following treatment with vehicle (DMSO) control or TCDD (10nM) every 48 hours 
for 5 days in normal and high calcium conditions. B) Densitometric analysis of loricrin 
expression after vehicle (DMSO) (i) or TCDD (10nM) (ii) treatment in normal calcium media 
(light blue bars) or high calcium media (dark blue bars) normalised to GAPDH loading control 
expressed relative to the respective treatments in normal calcium conditions, n=3 independent 
donors, ± SEM. Statistics were acquired by paired t-test (NS) 
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4.2.3. TCDD induces AhR degradation in differentiated and un-differentiated 
monolayer primary keratinocytes but does not cause a significant induction of 
LC3II  
 
After confirming calcium induced differentiation in monolayer primary keratinocytes 
(Fig. 4.5) development of the monolayer model continued. Although earlier results 
(Fig. 4.4 B) suggested TCDD treatment did not induce LC3II expression in 
undifferentiated monolayer keratinocytes, in the fully differentiated epidermal 
equivalent model (which is grown under high calcium conditions) autophagy was 
clearly significantly induced by TCDD (Chapter 3 Fig. 3.9, Fig. 3.10). Therefore, to 
explore the role of differentiation further, monolayer primary keratinocytes were 
seeded and treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 5 days 
in both normal media and high calcium media. TCDD-induced AhR degradation and 
potential LC3II accumulation was explored by western blotting (Fig. 4.6). 
 
Figure 4.6 TCDD induces AhR degradation in differentiated and un-differentiated monolayer 
primary keratinocytes but does not cause a significant induction of LC3II.  
Representative western blot of AhR protein expression and LC3II protein expression following 
treatment of monolayer primary human keratinocytes with vehicle (DMSO) control or TCDD (10nM) 
every 48 hours for 5 days in normal calcium (Ai) or high calcium (Bi). Densitometric analysis of AhR 
protein expression (A and B ii) or LC3II protein expression (A and B iii) after vehicle (blue bars) or 
TCDD (10nM) (red bars) treatment, normalised to GAPDH loading control expressed relative to 
vehicle (DMSO) n=4 (B) or n=7 (A) independent donors, ± SEM. Statistics were acquired by paired t-
test 
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Results demonstrated TCDD treatment caused significant AhR degradation in 
primary keratinocytes treated in both normal (paired t-test p<0.001) and high calcium 
(paired t-test p<0.05) conditions (Fig. 4.6 A and B ii). In contrast, LC3II accumulation 
was not significantly induced after TCDD treatment, in either low or high calcium 
conditions (Fig. 4.6 A and B iii). However, there was a very slight increase in 
expression under high calcium conditions compared to normal calcium conditions as 
evident in Fig 4.6Bi although results were variable and more donors would be 
needed to confirm significance.  
Overall data from monolayer experiments, using LC3II as a readout for autophagy 
induction, suggested TCDD did not significantly induce autophagy in either 
differentiated and un-differentiated cultures. However, results from both LC3II and 
P62 expression studies in epidermal skin equivalents (Chapter 3) did demonstrate 
TCDD caused significant autophagy induction. As such, the next phase of 
experiments continued to explore autophagy in monolayer but was approached from 
a different perspective, by manipulating autophagy flux.   
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4.2.4. Chemical inhibition of autophagy alters LC3II accumulation but has little 
effect on TCDD-induced AhR degradation in differentiated and un-differentiated 
monolayer primary keratinocyte cultures  
 
To explore the role of autophagy further, the autophagy inhibitor bafilomycin A1 
(bafilomycin) was initially used. Bafilomycin (as described in section 4.1) blocks 
autophagic flux by preventing fusion of lysosomes and autophagosomes. Monolayer 
primary keratinocytes were seeded and treated with vehicle (DMSO), TCDD (10nM), 
bafilomycin (5nM) or TCDD with bafilomycin co-treatment every 48 hours for 5 days 
in both normal media and high calcium media. Initially, the influence of blocking 
autophagy on TCDD-induced AhR degradation and potential LC3II accumulation was 
explored by western blotting.  
 
 
 
 
 
 
 
 
 
  
Figure 4.7 Bafilomycin co-treatment caused TCDD induced AhR degradation to be 
somewhat accentuated in normal calcium conditions, but had no effect in in high calcium 
conditions, whilst bafilomycin treatment in both conditions causes LC3II accumulation.  
Representative western blot of AhR protein expression and LC3II protein expression following 
treatment of monolayer primary human keratinocytes with vehicle (DMSO) control, TCDD (10nM), 
bafilomycin (5nM) or TCDD with bafilomycin co-treatment every 48 hours for 5 days in normal 
calcium (Ai) or high calcium (Bi). Densitometric analysis of AhR protein expression (A and B ii) or 
LC3II protein expression (A and B iii) after vehicle (blue bars), TCDD (10nM) (red bars), 
bafilomycin (5nM) (dark green bars) or TCDD with bafilomycin co-treatment (light green bars). 
Each bar is normalised to GAPDH loading control expressed relative to vehicle (DMSO). n=4 (A) 
or n=3 (B) independent donors, ± SEM. Statistics were acquired by one-way ANOVA with Tukey's 
multiple comparison test *p= <0.05, **p=<0.01, ***p= <0.001, ****p=<0.0001. 
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Densitometric analysis revealed in normal (low) calcium conditions, TCDD (10nM) 
treatment caused significant AhR protein degradation (Fig. 4.7 A ii) (one-way ANOVA 
with Tukey’s multiple comparison test, p<0.001). Bafilomycin treatment alone also 
caused a significant reduction in AhR protein expression (p<0.001), whilst 
bafilomycin co-treatment accentuated TCDD-induced AhR protein degradation, 
compared to TCDD treatment alone (p<0.05).  
TCDD (10nM) treatment did not cause a significant increase in LC3II expression (Fig. 
4.7 A iii), in contrast to results in epidermal equivalents. However, both bafilomycin 
treatment alone and co-treatment with bafilomycin caused a significant increase in 
LC3II accumulation compared to vehicle (DMSO) control (p<0.01), indicating 
bafilomycin did block or attenuate flux of basal autophagy.  
In high calcium, TCDD (10nM) treatment caused significant AhR protein degradation 
compared to vehicle (DMSO) control (Fig. 4.7 B ii) (one-way ANOVA with Tukey’s 
multiple comparison test, p<0.05). Interestingly, in contrast to results in normal 
calcium conditions, bafilomycin treatment alone caused slightly increased AhR 
protein expression above that of vehicle (DMSO) control, although not significant. In 
addition, bafilomycin co-treatment had no effect on TCDD-induced AhR protein 
degradation.  
However, TCDD (10nM) treatment of monolayer primary keratinocytes again did not 
cause LC3II accumulation (Fig. 4.7 B iii) but bafilomycin treatment alone and co-
treatment did induce LC3II expression significantly above vehicle (DMSO) control 
levels (one-way ANOVA with Tukey’s multiple comparison test p<0.01) indicating 
bafilomycin blocked or attenuated flux of basal autophagy.  
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4.2.5. Chemical inhibition of autophagy alters loricrin expression in 
differentiated monolayer primary keratinocyte cultures  
 
To investigate the potential role of autophagy in TCDD-induced de-regulated 
differentiation, monolayer primary keratinocytes were treated with vehicle (DMSO), 
TCDD (10nM), bafilomycin (5nM) or TCDD with bafilomycin co-treatment in high 
calcium conditions every 48 hours for 5 days. Expression of the differentiation marker 
loricrin was then determined by western blotting (Fig. 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Densitometric analysis revealed TCDD (10nM) treatment of monolayer primary 
keratinocytes induced no significant change in loricrin protein expression compared 
to vehicle (DMSO) control (one-way ANOVA with Tukey’s multiple comparison test). 
However, bafilomycin treatment alone caused loricrin expression to decrease 
significantly compared to vehicle (DMSO) control levels (p<0.05). Interestingly, 
bafilomycin co-treatment with TCDD also induced a decrease in loricrin expression, 
with significantly lower expression compared to both vehicle and TCDD (10nM) 
treated cells (p<0.05). However, levels were similar to that of epidermal equivalents 
Figure 4.8 TCDD does not significantly alter loricrin protein expression in 
monolayer primary keratinocytes cultured in high calcium medium but 
bafilomycin treatment causes reduced expression.  
A) Representative western blot of loricrin protein expression following treatment of 
monolayer primary human keratinocytes with vehicle (DMSO) control, TCDD (10nM), 
bafilomycin (5nM) or TCDD with bafilomycin co-treatment every 48 hours for 5 days in 
high calcium media. B) Densitometric analysis of loricrin expression after vehicle (blue 
bar), TCDD (10nM) (red bar), bafilomycin (5nM) (dark green bar) or TCDD with 
bafilomycin co-treatment (light green bar). Each bar is normalised to GAPDH loading 
control and expressed relative to vehicle (DMSO) n=3 independent donors, ± SEM. 
Statistics were acquired by one-way ANOVA with Tukey's multiple comparison test *p= 
<0.05 
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treated with bafilomycin alone and as such further investigation would be required to 
confirm if bafilomycin reduced loricrin expression in general, or if co-treatment 
blocked the TCDD induced effect. 4.2.6. TCDD treatment causes no significant 
reduction in cell viability in differentiated and un-differentiated monolayer primary 
keratinocytes  
In the TCDD-induced chloracne phenotype, viable cell layer thickness is significantly 
reduced after TCDD treatment and TCDD induces caspase-3 positive staining (Fig. 
3.3 and Fig. 3.8A). Therefore, to validate the high throughput monolayer primary 
keratinocyte model further, basic colorimetric cell viability/proliferation assays were 
performed. Assays included 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays (Fig 5.9) and Sulforhodamine B (SRB) assays (Fig. 4.10). 
Cells were seeded and treated with vehicle (DMSO), TCDD (10nM) bafilomycin alone 
(1.25nM, 2.5nM or 5nM) or TCDD with bafilomycin co-treatment, in both high and 
normal calcium conditions, every 48 hours for 3 or 5 days.  
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Figure 4.9 TCDD causes no significant induction of reduced cell viability at day 3 (A) or 
day 5 (B) in high or normal calcium conditions.  
Analysis of cell viability (MTT assay) in monolayer primary human keratinocytes, in high and 
normal calcium following treatment with vehicle (DMSO) control (blue bars), TCDD (10nM) (red 
bars), bafilomycin (1.25nM, 2.5nM or 5nM) (dark green bars) or TCDD with bafilomycin co-
treatment (light green bars), every 48 hours for 3 or 5 days. Each bar is normalised to GAPDH 
loading control expressed relative to vehicle (DMSO). n=3 independent donors, in triplicate (N=9) 
± SEM. Statistics were acquired by one-way ANOVA with Dunnett’s multiple comparison test 
*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001.   
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 TCDD causes no significant induction of reduced cell viability at day 3 (A) or 
day 5 (B) in high or normal calcium conditions.  
Analysis of cell viability (SRB assay) in monolayer primary human keratinocytes following 
treatment in normal and low calcium with vehicle (DMSO) control (blue bars), TCDD (10nM) (red 
bars), bafilomycin (1.25nM, 2.5nM or 5nM) (dark green bars) or TCDD with bafilomycin co-
treatment (light green bar), every 48 hours 3 and 5 days. Each bar is normalised to GAPDH 
loading control expressed relative to vehicle (DMSO) control. n=3 independent donors, in 
triplicate (N=9) ± SEM. Statistics were acquired by one-way ANOVA with Dunnett’s multiple 
comparison test *p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001. 
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In cells treated in normal calcium conditions, MTT assays (Fig. 4.9) revealed a 
significant increase with TCDD treatment at day 3 and day 5 compared to vehicle 
(DMSO) control (one-way ANOVCA with Dunnett’s multiple comparison test, p<0.001 
and p<0.01 respectively). Surprisingly, bafilomycin treatment alone caused a 
significant dose dependent decrease in cell viability at both day 3 and day 5 
(p<0.0001, p<0.01). In cells treated with TCDD (10nM) with bafilomycin co-treatment 
(1.25nM, 2.5nM or 5nM) cell viability was also significantly reduced compared to 
vehicle (DMSO) control (p<0.0001). At day 5, this decrease in cell viability with 
bafilomycin co-treatment was also dose dependent, as concentration of bafilomycin 
increased, cell viability decreased (p<0.0001). However, at day 3 cell viability was 
slightly more variable. In general, cell viability was higher after treatment with TCDD 
and bafilomycin-co-treatment compared to cells treated with bafilomycin alone. 
In cells treated in high calcium conditions, MTT assays revealed no significant 
change in cell viability at day 3 or day 5 with TCDD (10nM). At day 3, bafilomycin 
treatment (1.25nM, 2.5nM and 5nM) all caused a significant decrease in cell viability 
compared to vehicle (DMSO) control (p<0.01, p<0.05, p<0.0001 respectively). 
However, this decrease in cell viability was not as high as cells treated in normal 
calcium conditions. Interestingly, at day 5, bafilomycin treatment had no significant 
effect on cell viability. In addition, TCDD with bafilomycin co-treatment caused no 
significant change in cell viability, apart from a slight decrease in viability in cells 
treated for 3 days with TCDD and 1.25nM bafilomycin (p<0.05).  
In cells treated in normal calcium conditions, SRB assays (Fig. 4.10) revealed a 
similar increase in cell number after treatment with TCDD (10nM) at day 3 and day 5 
compared to vehicle (DMSO) control, but this was not significant (one-way ANOVA 
with Dunnett’s multiple comparison test). At day 3, bafilomycin treatment alone 
caused significant reduction in viability at 2.5nM and 5nM (p<0.01). This was similar 
to results at day 5 where bafilomycin treatment caused a dose dependent decrease 
in cell viability, although only 5nM bafilomycin caused significant reduction (p<0.01). 
Co-treatment with TCDD and bafilomycin did decrease cell viability at day 3, but only 
TCDD with 1.25nM bafilomycin caused a significant change (p<0.05). In contrast, at 
day 5, co-treatment caused a dose dependent decrease in cell viability, with TCDD 
and 5nM bafilomycin causing a significant reduction in viability (p<0.05). 
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In cells treated in high calcium conditions, SRB assays revealed no significant 
change in cell viability at day 3 or day 5 in cells treated with TCDD (10nM). 
Additionally, the only significant change in cell viability was in cells treated with 5nM 
bafilomycin at day 5 (p<0.05). Bafilomycin treatment alone or co-treatment with 
TCDD caused no other significant change in cell viability at either day 3 or day 5 in 
high calcium conditions.  
Bafilomycin treatment clearly attenuated basal flux of autophagy as evidenced by 
LC3II accumulation (Fig. 4.3, Fig. 4.4). However, bafilomycin acts primarily as a V-
ATPase inhibitor, targeting lysosomal function and consequently blocking autophagy 
(as described in section 5.1). Therefore, although a useful tool when investigating 
autophagic flux, bafilomycin should really be used in the context of lysosomal activity. 
In the following chapter work with bafilomycin continues in epidermal skin equivalent 
models, investigating the role of the lysosome in the chloracne phenotype. 
Therefore, to continue work exploring the role of autophagy in the present chapter, 
manipulation of specific autophagy genes was explored. Initially, knockdown of 
ATG7, required for autophagosome biogenesis (Komatsu et al., 2007) was 
established in monolayer (both un-differentiated and differentiated models). Once 
optimised, this was then taken into epidermal skin equivalents. Knockdown of 
BECLIN-1, involved in the beginning of the autophagy pathway, was also pursued 
and provided interesting results.    
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4.2.6. Successful siRNA knockdown of ATG7 in un-differentiated monolayer 
primary keratinocytes causes increased AhR and LC3II protein expression 
 
Firstly, knockdown was established in un-differentiated monolayer primary 
keratinocytes. Cells were transfected with siRNA non-target (siNT) or siRNA ATG7 
(siATG7). Cells were treated with either vehicle (DMSO) or TCDD (10nM) every 48 
hours for 5 days. Initially, ATG7 protein expression was determined by western 
blotting, to verify knockdown. Protein expression of AhR and LC3II expression was 
then measured to investigate any effect of knockdown (Fig. 4.11). 
 
 
 
 
 
 
 
 
Figure 4.11 Successful siRNA knockdown of ATG7 in monolayer primary human 
keratinocytes causes increased AhR expression and LC3II accumulation. 
A) Representative western blot of ATG7, AhR and LC3I/II protein expression following treatment of 
siNT or siATG7 transduced monolayer primary human keratinocytes with vehicle (DMSO) control or 
TCDD (10nM), every 48 hours for 5 days. Densitometric analysis of ATG7 (B) AhR (C) or LC3II (D) 
protein expression after vehicle (DMSO) (blue bar) or TCDD (10nM) (red bar) treatment. Each bar is 
normalised to GAPDH loading control relative to siNT vehicle (DMSO) control. n=3 independent 
donors, ± SEM. Statistics were acquired by two-way ANOVA with Tukey's multiple comparison test 
*p=<0.05, ***p=<0.001, ****p=<0.0001. Row factor (knockdown) is significant p=0.0163 (D). 
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Densitometric analysis revealed successful knockdown of ATG7 in siATG7 cells 
compared to siNT cells, regardless of treatment (two-way ANOVA with Tukey’s 
multiple comparison test p<0.0001). AhR protein expression was significantly higher 
in vehicle treated siATG7 cells compared to vehicle treated siNT cells (p<0.05). 
TCDD treatment in siNT cells induced significant AhR degradation (two-way ANOVA 
with Tukey’s multiple comparison test p<0.01) compared to vehicle (DMSO) 
treatment, as expected. TCDD also induced significant AhR degradation in siATG7 
cells (p<0.001). Interestingly, AhR expression was higher in TCDD treated siATG7 
cells than in TCDD treated siNT cells. However, there was no significant change in 
LC3II expression in TCDD treated siNT cells, or TCDD treated siATG7 cells 
compared to vehicle controls, although in siATG7 cells, TCDD treatment did cause a 
slight increase in LC3II. 
However, siATG7 knockdown in general caused an increase in LC3II expression. 
ATG7 is the conjugating enzyme for LC3, as such, by knocking down ATG7 it would 
be expected that LC3I expression would increase whilst LC3II expression would 
decrease due to lack of conjugation of LC3I to PE. Therefore, this data suggests 
functional ATG7 knockdown was not entirely successful and the autophagy pathway 
may not be fully attenuated. 
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4.2.7. Successful siRNA knockdown of ATG7 in differentiated monolayer 
primary keratinocytes does not cause significant increased AhR protein 
expression 
 
Knockdown of ATG7 was also carried out in differentiated monolayer cells.  Cells 
were transduced with siRNA non-target (siNT) or siRNA ATG7 (siATG7) and treated 
with either vehicle (DMSO) or TCDD (10nM) in high calcium (1.3mM) media every 48 
hours for 5 days. Initially, ATG7 protein expression was determined by western 
blotting, to verify knockdown. Protein expression of AhR and LC3II expression was 
then measured to investigate any effect of knockdown (Fig. 4.12). 
 
 
 
 
 
 
 
Densitometric analysis revealed successful knockdown of ATG7 in siATG7 cells 
compared to siNT cells after treatment with vehicle (DMSO) (two-way ANOVA with 
Tukey’s multiple comparison test p<0.05) or TCDD (10nM) (p<0.01). In contrast to 
results in un-differentiated cells (Fig 4.11) siATG7 knockdown did not increase AhR 
Figure 4.12 Successful siRNA knockdown of ATG7 in differentiated monolayer primary 
human keratinocytes causes no increase in AhR expression or LC3II accumulation.  
A) Representative western blot of ATG7, AhR and LC3I/II protein expression following 
treatment of siNT or siATG7 transduced monolayer primary human keratinocytes in high 
calcium media with vehicle (DMSO) control or TCDD (10nM), every 48 hours for 5 days. 
Densitometric analysis of ATG7 (B) AhR (C) or LC3II (D) protein expression after vehicle 
(DMSO) (blue bar) or TCDD (10nM) (red bar) treatment. Each bar is normalised to GAPDH 
loading control expressed relative to siNT vehicle (DMSO) control. n=3 independent donors, ± 
SEM. Statistics were acquired by two-way ANOVA with Tukey's multiple comparison test 
*p=<0.05, ***p=<0.001, ****p=<0.0001 
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expression in vehicle treated cells and there was no significant change in LC3II 
accumulation after either vehicle (DMSO) or TCDD treatment. 
TCDD treatment in siNT cells did induce significant AhR degradation (two-way 
ANOVA with Tukey’s multiple comparison test p<0.01) compared to vehicle (DMSO) 
treatment, as expected. TCDD also induced AhR degradation in siATG7 cells, 
although not significant. However, there was no increase in LC3II expression in 
TCDD treated siNT or siATG7 cells compared to vehicle control cells. 
 
 
 
 
  
 102 
 
4.2.8. siRNA knockdown of ATG7 in differentiated monolayer primary 
keratinocytes reduces loricrin protein expression 
 
To investigate the impact of autophagy on TCDD induced de-regulated 
differentiation, the effect of ATG7 knockdown on loricrin expression was explored. 
Cells transduced with siNT and siATG7 were treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 5 days in high calcium (1.3mM) media. Loricrin expression 
was then determined by western blotting (Fig. 4.13). 
 
 
 
 
 
 
 
 
Densitometric analysis revealed a slight decrease in loricrin expression in TCDD 
treated siNT cells compared to vehicle treated. Interestingly, however, loricrin 
expression was lower in both vehicle (DMSO) treated and TCDD (10nM) treated 
siATG7 cells, compared to siNT (two-way ANOVA with Tukey’s multiple comparison 
test, row factor p=0.0233). 
 
Figure 4.13 siATG7 knockdown reduces expression of loricrin in differentiated monolayer 
primary human keratinocytes.  
A) Representative western blot of loricrin protein expression following treatment of siNT or siATG7 
transduced monolayer primary human keratinocytes with vehicle (DMSO) control or TCDD (10nM), 
every 48 hours for 5 days in high calcium media. B) Densitometric analysis of loricrin expression after 
vehicle (DMSO) (blue bar) or TCDD (10nM) (red bar). Each bar is normalised to GAPDH loading 
control expressed relative to siNT vehicle (DMSO) control. n=3 independent donors, ± SEM. Statistics 
were acquired by two-way ANOVA with Tukey's multiple comparison test (NS). Row factor 
(knockdown) is significant p=0.0233 
 103 
 
4.2.9. Successful siRNA knockdown of ATG7 in epidermal skin equivalents 
causes increased AhR and LC3II protein expression  
 
After successful knockdown in monolayer, siATG7 and siNT primary human 
keratinocytes were then seeded into epidermal equivalents, to establish a more 
physiologically relevant model. To understand the impact of knocking down ATG7 on 
AhR protein expression and LC3II accumulation, epidermal skin equivalents with 
siNT and siATG7 were generated and treated every 48 hours for 7 days with vehicle 
(DMSO) or TCDD (10nM). Western blotting was then used to determine ATG7, AhR 
and LC3II protein expression (Fig. 4.14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Successful siRNA knockdown of ATG7 in epidermal equivalents causes an increase in 
AhR expression and LC3II accumulation.  
A) Representative western blot of ATG7, AhR and LC3I/II protein expression following treatment of siNT 
or siATG7 transduced monolayer primary human keratinocytes in high calcium media with vehicle 
(DMSO) control or TCDD (10nM) treatment, every 48 hours for 5 days. Densitometric analysis of ATG7 
(B) AhR (C) or LC3II (D) expression after vehicle (DMSO) (blue bar) or TCDD (10nM0 (red bar) treatment. 
Each bar is normalised to GAPDH loading control expressed relative to siNT vehicle (DMSO) control. n=3 
independent donors, ± SEM. Statistics were acquired by two-way ANOVA with Tukey's multiple 
comparison test *p=<0.05, ***p=<0.001, ****p=<0.0001. Row factor (knockdown) is significant (C) 
p=0.0074, (D) p=0.0164. 
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Results revealed significant knockdown of ATG7 in siATG7 epidermal skin 
equivalents compared to siNT control, after both vehicle (DMSO) and TCDD (10nM) 
treatment (two-way ANOVA with Tukey’s multiple comparison test, p<0.001 and 
p<0.01 respectively). AhR protein expression was also higher in siATG7 cells 
compared to siNT cells, regardless of treatment. In addition, siATG7 knockdown in 
general caused an increase in LC3II expression, suggesting the autophagy pathway 
had not been fully attenuated as shown previously (Fig. 4.11) 
TCDD treatment in siNT and siATG7 cells causes little change to AhR protein 
expression and there was no significant AhR degradation compared to vehicle 
(DMSO) treatment. Although there was no significant change in LC3II expression in 
TCDD treated siNT cells, expression did increase, but there was no change in 
siATG7 cells compared to vehicle.  
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4.2.10. siRNA knockdown of ATG7 in epidermal skin equivalents prevents 
TCDD-induced reduced viable cell layer thickness 
 
To further explore the role of autophagy in the TCDD-induced chloracne phenotype, 
particularly the reduction in viable cell layer thickness, siNT and siATG7 epidermal 
equivalents were generated and treated with vehicle (DMSO) or TCDD (10nM) every 
48 hours for 7 days. Histological staining of formalin fixed and paraffin embedded 
(FFPE) sections with haemotoxilin and eoisin (H&E) was then carried out (Fig. 4.15). 
 
 
 
 
 
 
 
Quantitative analysis of viable cell layer thickness was performed and revealed as 
expected, TCDD treatment of siNT epidermal skin equivalents caused a significant 
reduction in viable cell layer thickness (two-way ANOVA with Tukey’s multiple 
comparison test p<0.0001). Interestingly, siATG7 knockdown of epidermal skin 
equivalents treated with vehicle (DMSO) control caused no significant change in 
viable cell layer thickness. Notably, siATG7 knockdown significantly blocked TCDD-
induced reduction in viable cell layer thickness (p<0.0001).  
Figure 4.15 TCDD-induced reduced viable cell layer of the chloracne phenotype model is 
abrogated by siATG7 knockdown.  
A) Representative immunohistochemical images of siNT and siATG7 transduced epidermal skin 
equivalents (n=3 independent donors) stained with H&E following treatment with vehicle (DMSO) 
control or TCDD (10nM) every 48 hours for 7 days. Scale bar = 20µm B) Relative mean viable cell 
layer (VCL) thickness of epidermal skin equivalents treated for 7 days with vehicle (DMSO) or TCDD 
(10nM) for 7 days. Each bar is expressed relative to vehicle (DMSO) control, n=3 independent 
donors, ± SEM.  Statistics were acquired by two-way ANOVA. ****p=<0.001. 
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4.2.11. Effect of siRNA knockdown of ATG7 on filaggrin protein expression in 
epidermal skin equivalents 
 
To explore the role of autophagy in the chloracne phenotype model, particularly the 
influence on TCDD-induced de-regulated differentiation, siNT and siATG7 
knockdown epidermal skin equivalents were treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 7 days. After harvesting, immunofluorescence staining on 
OCT frozen sections for filaggrin was performed (Fig. 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
After quantification and statistical analysis (two-way ANOVA with Tukey’s multiple 
comparison test) results suggested an increase in filaggrin expression after TCDD 
treatment in siNT and siATG7 epidermal skin equivalents compared to those treated 
with vehicle (DMSO) control however this was not significant. Filaggrin expression 
overall was higher in siATG7 knockdown epidermal skin equivalents compared to 
siNT regardless of treatment although again not significant and results were variable.  
 
Figure 4.16 TCDD treatment induces filaggrin protein expression in siNT epidermal equivalents but 
not in siATG7 knockdown epidermal equivalents.  
A) Representative photomicrograph of siNT and siATG7 epidermal skin equivalents treated with vehicle 
(DMSO) control or TCDD (10nM) every 48 hours for 7 days depicting blue Hoechst nuclear staining and 
Filaggrin expression (red staining). Scale bar = 100µm B) Mean filaggrin expression of siNT and siATG7 
epidermal skin equivalents treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days. Each 
bar is expressed relative to to siNT vehicle (DMSO) control, n=3 independent donors, ± SEM. Statistics 
were acquired by two-way ANOVA with Tukey's multiple comparison test (NS). 
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4.2.12. siRNA knockdown of ATG7 in epidermal skin equivalents abrogates 
TCDD-induced caspase-3 positive staining  
 
To explore TCDD-induced cell death and the potential influence of autophagy, 
caspase-3 immunofluorescence was performed on frozen OCT sections of siNT and 
siATG7 epidermal skin equivalents treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days (Fig. 4.17) raw values are presented in Appendix K.  
 
 
 
 
 
 
 
Images were taken along the entire length of each epidermal skin equivalent model 
and caspase-3 positive cells and Hoechst positive cells were counted. After 
quantification and statistical analysis (two-way ANOVA with Tukey’s multiple 
comparison test) a clear trend was apparent. TCDD treatment of siNT epidermal skin 
equivalents caused increased caspase-3 positive staining relative to siNT vehicle 
treated. In general, siATG7 epidermal skin equivalents had less capase-3 positive 
staining compared to siNT epidermal skin equivalents. Of particular interest, TCDD 
treated siATG7 epidermal skin equivalents had significantly less caspase-3 positive 
cell staining compared to siNT TCDD treated epidermal skin equivalents (p<0.05). 
  
Figure 4.17 TCDD-induced increase of caspase-3 positive cells is prevented by siATG7  
Mean percentage of caspase-3 positive cells presented as fold change in siNT and siATG7 
transduced epidermal skin equivalents treated with vehicle (DMSO) or TCDD (10nM) every 48 
hours for 7 days. Each bar is normalised relative to GAPDH loading control and expressed 
relative to siNT vehicle (DMSO) control n= 3 independent donors, ± SEM.  Statistics were 
acquired by two-way ANOVA with Tukey’s multiple comparison test *p=<0.05. 
 108 
 
4.2.13. Successful shRNA knockdown of BECLIN-1 alters morphology of 
epidermal skin equivalents 
 
After successful siRNA knockdown of ATG7 in epidermal skin equivalents, a longer 
term lentiviral shRNA knockdown of another autophagy gene, BECLIN-1, was 
pursued. Initially, optimisation of the most effective BECLIN-1 shRNA construct to 
use was carried out in monolayer primary human keratinocytes (Appendix C). After 
this, keratinocytes were transduced with non-target control (shNT) or the selected 
BECLIN-1 (shBEC-1) shRNA lentivirus construct, then puromycin treated. Successful 
transfection efficiency was verified by imaging for GFP expression (Appendix F) and 
the cells were then expanded. Cells were seeded into epidermal equivalents and 
grown for 12 days then treated appropriately every 48 hours for a further 7 days. To 
establish whether successful knockdown of BECLIN-1 had occurred, epidermal 
equivalents were harvested and protein expression was established by western 
blotting (Fig. 4.18 A, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Successful BECLIN-1 shRNA knockdown causes altered morphology in 
epidermal skin equivalents.  
A) Representative western blot of BECLIN-1 protein expression in epidermal skin 
equivalents. B) Densitometric analysis of BECLIN-1 expression in shNT and shBEC-1 
epidermal skin equivalents. Expression is normalised to GAPDH loading control relative to 
shNT control. n=3 independent donors, ± SEM. Statistics were acquired by paired t-test 
(NS). C) Representative immunohistochemical images of shNT and shBEC-1 epidermal 
skin equivalents stained with H&E Scale bar = 20µm 
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Densitometric analysis showed successful knockdown, with decreased expression of 
BECLIN-1 in shBEC-1 epidermal skin equivalents compared to shNT control. 
However, unlike siATG7 knockdown epidermal equivalents, histological staining with 
haemotoxilin and eosin (H&E), revealed shBEC-1 epidermal skin equivalents to have 
repeatedly disrupted morphology compare to shNT (Fig. 4.18 C).  Although time 
constraints precluded pursuit of further studies, these data suggest that BECLIN-1 
might play a critical role in epidermal homeostasis and formation of an intact 
epidermal barrier.   
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4.3. Discussion 
 
Despite optimisation of a high-throughput, monolayer chloracne model, including the 
use of high calcium differentiation promoting conditions, results from this chapter 
revealed differential effects of TCDD treatment in monolayer cultures and epidermal 
equivalents. Although earlier results provided clear evidence that TCDD significantly 
induced autophagy activation in epidermal skin equivalents (Chapter 3, Fig 3.9, Fig 
3.10) there was no significant induction of LC3II in monolayer, in either normal or 
high calcium conditions. Furthermore, in contrast to results in epidermal skin 
equivalents, TCDD treatment in monolayer did not significantly reduce the number of 
viable cells. However, TCDD did cause significant AhR degradation in monolayer and 
as such these differential results are likely not due to differential activation of AhR. 
Rather, these data suggest that whether AhR activation activates autophagy is 
dependent on the specific environment and state of keratinocyte differentiation.  
Another key finding of this chapter was thorugh work in epidermal equivalents which 
indicated ATG7 knockdown blocked TCDD-induced caspase-3 expression above that 
of non-target control suggesting autophagy likely plays a role in TCDD-induced 
apoptosis.  
 
4.3.1 Differences in response after TCDD treatment between monolayer and 
epidermal equivalent models of chloracne 
 
Epidermal skin equivalents can be treated or genetically manipulated to provide a 
physiologically relevant model in which disease states can be researched.  
Nevertheless, parallel monolayer cultures can also be valuable particularly to develop 
more high-throughput systems when exploring biochemical and molecular pathways 
of interest. However, results in this chapter revealed key differences between 
epidermal skin equivalents and monolayer cultures.  
AhR degradation is a hallmark for ligand binding and subsequent AhR activity (Ma 
and Baldwin, 2000) and as such AhR degradation can be used as a read out when 
comparing the effects of TCDD treatment in monolayer cultures and in epidermal 
equivalents. Results initially revealed TCDD treatment caused a dose-dependent 
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decrease in AhR protein expression in monolayer. Importantly, this decrease in 
expression, or increase in degradation continued throughout the time course 
suggesting TCDD was stable and not metabolically cleared by the cell, as seen in 
previous studies (Swanson and Bradfield, 1993, Pollenz et al., 2006).   
However, after treatment with 10nM TCDD, results demonstrated that significant AhR 
degradation in monolayer occurred after only 24 hours. In contrast, AhR degradation 
did not occur until day 7 in epidermal skin equivalents (Chapter 3). Interestingly, 
similar differences in time taken for AhR degradation were seen between monolayer 
and epidermal equivalents (Forrester thesis). Thus, Forrester reported that in 
monolayer, AhR degradation occurred after only 2 days compared to 7 days in 
epidermal skin equivalents, although full time course experiments were not carried 
out (Forrester thesis). Studies in a variety of cell types have also previously shown 
differences in TCDD-induced AhR degradation, with degradation occurring as quickly 
as 3 hours post treatment in the breast tumour cell line T47D (Wormke et al., 2000) 
or 16 hours post treatment in HepG2 cells (Davarinos et al.,1999). Furthermore, other 
factors can affect AhR expression as discussed in Chapter 3, section 3.3.1, such as 
confluency which can alter AhR localisation and activity (Ikuta et al., 2009, Ikuta et 
al., 2004). Previous studies (Ikuta et al., 2009, Ikuta et al., 2006) demonstrated AhR 
localises to the cytoplasm when cells reach 100% confluency. Therefore, this may 
affect AhR degradation, as AhR is degraded in the cytoplasm. Perhaps this would 
explain why levels of AhR degradation increased over time in the monolayer study as 
cells became more confluent (reaching 100% confluency around day 5) and AhR 
localised to the cytoplasm. However, this hypothesis was not tested in the present 
study and results in high confluency epidermal equivalents do not support the idea, 
as one would expect AhR degradation to be quicker given the high number of cells 
seeded per insert. It should be noted, however, a 3D epidermal equivalent model in 
which cells are in contact and able to interact with other cells in all directions is very 
different to a simple monolayer. Therefore, to explore the effect of confluency further, 
it would be interesting to compare localisation of AhR in these two models and 
explore differences in transcriptional activity in monolayer, by measuring CYP1A1 
expression.  
In contrast to the significant and reproducible increase in LC3II expression after 
TCDD treatment seen in epidermal skin equivalents, LC3II expression did not 
significantly increase even at higher concentrations of TCDD in monolayer, at any 
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time point. There was a slight increase at day 4 after 10nM TCDD treatment and at 
day 7 after 10nM and 20nM TCDD treatment, but individual donors varied greatly.  
Consistent with these results, previous published studies have also found differences 
in autophagic flux between cells in monolayer (2D) and 3D cultures (Follo et al., 
2016). For example, in malignant cancer cell lines grown in both 2D cultures and 3D 
multicellular spheroids, LC3II immunoblotting varied greatly. Autophagic flux was 
found to be higher in 2D in three cell lines and lower in 2D in the other three cell 
lines, compared to 3D cultures. These differences in 2D and 3D were also verified by 
LC3 immunofluorescence (Follo et al., 2016). However, bafilomycin treatment did 
successfully block LC3 flux in monolayer and caused accumulation of LC3II, 
suggesting basal autophagy was attenuated. 
Although not the same treatment length as in epidermal skin equivalents, cells for 
monolayer experiments were still treated every 48 hours and harvested 48 hours 
post final treatment, as in epidermal equivalents. In addition, 7 days in monolayer 
culture may have affected the responsiveness of the cells, for example if they 
became over confluent. Furthermore, TCDD-induced AhR activity was significantly 
induced in both models and as such results were still comparable.  
As well as un-differentiated monolayer cultures, in some experiments cultures were 
differentiated under high calcium conditions (1.3nM Ca2+) throughout the treatment 
period. As epidermal equivalents are fully stratified and cells differentiated, it was 
important to investigate whether differentiation status altered the effect of TCDD 
treatment. As expected, data confirmed monolayer primary human keratinocytes did 
undergo differentiation when exposed to increased extracellular calcium 
concentration (1.3mM) for 5 days. Loricrin expression was increased regardless of 
treatment, in cells cultured in high calcium conditions compared to those in normal 
growth media (0.5mM Ca2+). This confirmed the calcium differentiation technique 
previously optimised (Reynolds lab) was reproducible and effective.  
However, one of the major issues with the monolayer chloracne model was in both 
high and low calcium conditions TCDD treatment did not cause any reduction in cell 
viability at 3 or 5 days, as assessed by SRB and MTT assays. In contrast, TCDD 
treatment in epidermal skin equivalents caused a dramatic and significant reduction 
in viable cell layer thickness and significantly induced active caspase-3 staining, 
indicative of apoptotic cell death (Chapter 3). In addition, bafilomycin treatment alone 
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in normal calcium conditions caused a significant decrease in cell viability in 
monolayer. Although initially an unexpected result, autophagy is a well-known cell 
survival mechanism, and can protect cells from apoptotic cell death (Thorburn, 2008).  
Therefore, if autophagy is blocked by bafilomycin, this protective homeostatic 
mechanism may be reduced, potentially accounting for loss of cell viability following 
treatment with bafilomycin. However, in contrast reduced cell viability after 
bafilomycin treatment was not seen in high calcium conditions, in differentiated cells. 
Interestingly, these results are in corroboration with siATG7 knockdown data in 
epidermal skin equivalents where ATG7 knockdown prevented TCDD-induced 
caspase-3 expression (Fig 4.17). These results suggest blocking autophagy, by 
bafilomycin treatment or ATG7 knockdown in differentiated models prevents cell 
death through apoptosis. Together these data highlight differential effects of 
autophagy in differentiated and undifferentiated models, whilst autophagy may be a 
cell survival mechanism in undifferentiated cells; it may have a cytotoxic effect in 
differentiated cells. Data also highlights the potential cross talk between autophagy 
and apoptosis in this system. However, further experiments would be required to 
confirm the specific role of autophagy in differentiated and undifferentiated cells and 
the effect on cytotoxicity. The effect of bafilomycin treatment on caspase-3 
expression and the TCDD-reduced viable cell layer is explored further in Chapter 5 
using the epidermal skin equivalent model.   
To investigate the effect of TCDD on cell viability further, experiments were also 
carried out at different seeding densities to determine the effect of confluency on 
TCDD-induced reduced viability as studies have shown confluency can affect AhR 
activity (as discussed in Chapter 3 section 3.3). In addition, monolayer cultures were 
treated with TCDD for a longer period, up to 7 days but there was still no significant 
loss in cell viability in either experiment (see Appendix A and B). This result could be 
due to the lack of autophagy induction by TCDD in monolayer, compared to 
epidermal equivalents. However, this would need to be explored further as results in 
undifferentiated keratinocytes also suggested bafilomycin reduced cell viability. 
Both SRB and MTT assays are high throughput assays frequently used to indicate 
reductions in cell number. However, these assays do not provide mechanistic 
insights into underlying mechanisms of cell death/loss of viability and results with 
colorimetric assays have previously been found to be variable under certain 
conditions (Van Tonder et al., 2015). Issues with the MTT assay include sensitivity to 
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compounds and environmental factors (Marqués-Gallego et al., 2010) which can lead 
to altered metabolism of MTT to formazan (Pagliacci et al., 1993) as well as 
underestimating cell number in a well (Haselsberger et al., 1996). SRB assays do 
have advantages over MTT assays and seem generally preferred; however, perhaps 
a more sensitive method providing mechanistic insight would be useful. To look into 
this further, and for completeness, immunofluorescence for caspase-3 could be 
pursued, in keeping with the staining carried out in epidermal skin equivalents 
(Chapter 3 Fig. 3.8 and Fig. 3.17). Cleaved caspase-3 in monolayer cultures was 
probed for by western blotting although the antibody used needs further optimisation 
as detection was not successful.  
 
4.3.2. Effect of autophagy modulation on AhR expression and potential role of 
chaperone mediated autophagy in AhR degradation  
 
As discussed in Chapter 1, section 1.2.2, AhR degradation is thought to be 
performed by the 26S proteasome system (Ma and Baldwin, 2000).  Interestingly, 
however, research suggests cross-talk between autophagy and the ubiquitin-
proteasome system, both of which are major protein degradation pathways (as 
reviewed by Lilienbaum, 2013).  
Unlike autophagy, proteasome mediated degradation only occurs within the cytosol, 
rather than in lysosomes and it does not degrade as wide a spectrum of substrates. 
Proteasome mediated degradation also involves ubiquitination of target material, this 
ubiquitin “tagging” is used as a recognition motif (Kraft et al., 2010). Similarly, in a 
specific form of autophagy, chaperone mediated autophagy; substrates are also 
specifically targeted by ubiquitination but then delivered to the lysosome for 
degradation (Korolchuk et al., 2009).  
This cross talk is evidenced by studies showing proteasome inhibition inducing 
autophagy (Ding et al., 2007) whilst genetic studies in mice revealed knockout of 
autophagy genes ATG5 or ATG7 caused accumulation of ubiquitinated proteins 
(Korolchuk et al., 2009, Hara et al., 2006, Komatsu et al., 2006).  
Ma and Baldwin (2000) also discovered ubiquitination of AhR for degradation 
requires the ubiquitin activating enzyme E1. Interestingly, ATG7 is known to act as 
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an E1-like enzyme involved in two ubiquitin like reactions, ATG12 ubiquitination and 
LC3 lipidation which are required for the initiation of autophagy and formation of 
autophagosomes (Tanida et al., 2012). In addition, the autophagy marker protein 
P62, shown to be degraded in Chapter 3 after TCDD treatment, is a known ubiquitin-
binding scaffold protein involved in chaperone-mediated autophagy. However, it has 
also been implicated in targeting material for proteasome degradation (Pankiv et al., 
2009). Pankiv et al (2009) demonstrated P62 to be involved in the fast shuttling of 
material between nuclear and cytoplasmic compartments. As such they suggest P62 
could be involved in the redistribution of proteins such as AhR which are degraded in 
the cytoplasm, if for example the nuclear export signal (NES) was inhibited.  
Results from the present study support these findings and suggested autophagy 
modulation altered TCDD induced AhR degradation and AhR expression to some 
extent. Results were variable in monolayer studies and between calcium conditions, 
but transient knockdown of ATG7 in epidermal equivalents did reveal AhR 
expression to be increased after knockdown. However, as discussed previously, 
although ATG7 protein expression was reduced after knockdown, whether ATG7 
function was fully attenuated remains unclear, as LC3II protein levels were unusually 
high (Fig 4.14). Experiments confirming successful autophagy inhibition after 
treatment with bafilomycin or ATG7 knockdown would need to be carried out to 
validate these results. In addition, measurement of other autophagy markers such as 
expression of P62 protein levels would be beneficial. Although the siRNA construct 
used for these experiments was previously optimised within the lab, it would also be 
useful to use additional siRNA constructs in order to confirm results and to assess 
which construct is most efficient within the present system. As such, whether ATG7 is 
specifically required for ubiquitination of AhR, or ATG7 knockdown prevents 
degradation by blocking chaperone mediated autophagy would need to be explored. 
The present data supports the notion of crosstalk between autophagy and the 
ubiquitin protease pathway and suggests chaperone mediated autophagy may play a 
role in AhR degradation. To explore this hypothesis further, it would be interesting to 
measure AhR degradation after treatment with autophagy inducer rapamycin, and 
establish if AhR degradation was induced further. However, preliminary results (data 
not shown) with rapamycin treatment in monolayer keratinocytes did not show a 
significant change in AhR expression. However, given the issues with autophagy 
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induction in monolayer primary human keratinocytes, it would be preferential to treat 
epidermal equivalents with rapamycin.  
The role of chaperone mediated autophagy in AhR protein degradation, specifically 
from the perspective of lysosomal function, is explored further in the following 
chapter.  
 
4.3.3 TCDD-induced caspase-3 expression and reduction in viable cell layer 
thickness may involve autophagic activity 
 
There are two principal forms of programmed cell death (PCD) which includes 
apoptosis (type 1) and autophagic cell death (type II). Autophagic cell death is a 
caspase-independent mechanism described as the large scale sequestration of 
cytoplasmic material by double-membraned autophagosomes (Kroemer and Levine, 
2008). Cells undergoing autophagic cell death can appear vacuolated and have 
distinct non-apoptotic morphology. However, whether this increased vacuolization is 
actually indicative of defects in autophagosome maturation remains unclear 
(Kroemer and Levine, 2008). Autophagic cell death still remains relatively 
controversial and indeed cells often display both apoptotic and autophagic markers.   
Many researchers believe that although large scale autophagy can occur, it is 
unlikely the cell dies through excessive autophagy alone (Kroemer and Levine, 
2008). Instead, research suggests there is crosstalk between autophagy and 
apoptosis with interactions between autophagy and apoptotic machinery (Maiuri et 
al., 2007, Gonzalez-polo et al., 2005). Studies have shown autophagy preceding 
apoptosis and induction of apoptosis has been found to depend on autophagy 
activation. For example, work by Xue et al (1999) showed the autophagy inhibitor 3-
MA was found to delay caspase-activation. Previous studies have also found 
BECLIN-1 knockdown to prevent feroniellin A (a novel organic furanocoumarin) 
induced-apoptosis and rapamycin increased feroniellin-induced apoptosis in lung 
cancer cells (Kaewpiboon et al., 2014). Interestingly, as found in the present study, 
inhibition of the autophagy pathway by chemical inhibitors (bafilomycin or 3-MA) or 
genetic inhibition by knockout of ATG7 or BECLIN-1 prevented cleaved caspase-3 
activity and prevented apoptosis in CD4+ T cells (Espert et al., 2006).  
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Results from the current chapter indicate cross-talk between apoptosis and 
autophagy is occurring. Knockdown of siATG7 significantly blocked the TCDD-
induced reduced viable cell layer in epidermal equivalents. Furthermore, TCDD-
induced caspase-3 staining, indicative of apoptotic cell death, was also blocked by 
siATG7 knockdown. It is unlikely TCDD-induced autophagy in epidermal skin 
equivalents is solely a stress induced protective response, as blocking autophagy 
would exacerbate caspase-3 staining. Instead, caspase-3 staining is prevented with 
siATG7 knockdown. Therefore, it is hypothesised that TCDD induces autophagy and 
this induces death through apoptosis. 
To further confirm TCDD-induced apoptosis, knockout of key apoptosis genes e.g. 
from the bcl-2 family (as discussed in section 1.6.1) or chemical inhibition of 
caspases through Z-VADFMK would be useful to confirm TCDD-induced apoptosis.   
 
4.3.4. The role of autophagy in TCDD-induced de-regulated differentiation 
 
Data in Chapter 3 revealed TCDD treatment of epidermal equivalents induced a 
reduction in differentiation protein expression. In addition, as discussed in Chapter 1, 
section 1.5.3, studies have shown autophagy plays a role in skin homeostasis and 
keratinocyte differentiation.  
Specifically, studies in ATG7 knockout mice reveal autophagy to somewhat be 
required for and play a significant role in, differentiation (Yoshihara et al., 2015). Skin 
from ATG7 knockout mice was found to not only have impaired hair growth, but 
hyperkeratosis and reduced immunostaining of differentiation proteins including 
filaggrin, loricrin and involucrin. In addition, studies carried out on the HaCat cell line 
have suggested autophagy may be used as a signal to initiate keratinocyte 
commitment to differentiation in vitro (Aymard et al., 2011). In accordance with this, 
results in the present study demonstrated inhibition of autophagy by bafilomycin 
treatment or siATG7 knockdown, also altered differentiation patterns and caused 
loricrin expression to decrease in the differentiated monolayer model. 
In addition, data from preliminary BECLIN-1 knockdown epidermal skin equivalent 
models found morphology of the skin equivalents to be disrupted to the extent that 
they were not useable. Although interesting, the role of BECLIN-1 in epidermal 
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homeostasis was not able to be explored further in this thesis. However, unpublished 
data (Lovat group, Newcastle University) has found a significant correlation between 
AMBRA-1 and epidermal differentiation. With AMBRA-1 found to promote 
differentiation. AMBRA-1 is an activating molecule in BECLIN-1 mediated autophagy 
and promotes the binding between BECLIN-1 and target kinase VPS34 (Yazdankhah 
et al., 2014). Together these data suggest both BECLIN-1 and AMBRA-1 may de-
regulate differentiation. As morphology was disrupted, work with BCELIN-1 
knockdown was not continued to explore the role of autophagy in the TCDD induced 
chloracne phenotype. 
In contrast to monolayer studies and previous studies in epidermal equivalents 
(Chapter 3 Fig. 3.6), TCDD treatment appeared to increase filaggrin expression in 
siNT epidermal equivalents although this was not significant. Knockdown of ATG7 
also caused increased filaggrin in vehicle treated epidermal skin equivalents, and 
expression was higher again in TCDD treated, although again this was not significant 
and individual donors varied greatly. This potential increase in filaggrin expression 
may be due to donor variability, but it is possible that the siRNA transfection process 
de-regulated the morphology of the epidermal equivalents somewhat and may have 
induced a compensatory acceleration of differentiation. However, regardless of the 
precise role of autophagy, as the literature suggests, autophagy can influence 
differentiation status and as such the study should be repeated to rule out donor 
variability.  
Data in this chapter presents novel findings that autophagy is indeed involved in the 
chloracne phenotype model and is likely involved in TCDD-induced apoptotic cell 
death. Due to the issues discussed with monolayer keratinocytes, including variable 
results and lack of TCDD-induced autophagy, subsequent experiments were carried 
out in the more physiologically relevant epidermal skin equivalent models. Studies in 
the next chapter continue to explore mechanisms involved in the chloracne 
phenotype model. Focus is particularly on the potential role of the lysosome in 
TCDD-induced autophagy and apoptosis. In addition, the role of the lysosomal 
protease cathepsin D is explored, following on from preliminary data (Forrester 
thesis) which found TCDD induced cathepsin D expression 
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4.4. Summary 
 
 TCDD treatment in monolayer cultures induced AhR degradation, but did not 
cause LC3II accumulation indicative of autophagy induction 
 
 TCDD treatment in monolayer cultures did not cause a reduction in cell 
viability 
 
 siATG7 knockdown in epidermal skin equivalents blocked the TCDD-induced 
reduction in viable cell layer 
 
 TCDD induced increased caspase-3 staining in siNT epidermal skin equivalent 
models, indicative of apoptosis 
 
 siATG7 knockdown in epidermal skin equivalent models prevented TCDD-
induced caspase-3 positivity, suggesting autophagy causes apoptotic cell 
death 
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 Crosstalk of lysosomal processing in the TCDD-induced Chapter 5
chloracne phenotype 
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5.1. Introduction 
 
Degradation of cytoplasmic material via autophagy is dependent on lysosomal 
function and the two pathways are very much inter-related. As discussed in previous 
chapters, autophagy induction contributes to the TCDD induced chloracne phenotype 
model. The present chapter explores the potential role of lysosomal function, with a 
focus on the lysosomal protease cathepsin D, as outlined below. 
Lysosomes are single membraned, digestive organelles present in almost all 
eukaryotic cells (Shen and Mizushima, 2014). Within the lysosome are more than 50 
acid hydrolases, specific for degradation of a range of macromolecule targets 
(Mindell, 2012). Therefore, a key feature of a lysosome is its acidic environment (pH 
4.5-5.0) to maintain optimum enzymatic activity (Shen and Mizushima, 2014). This 
acidic environment is maintained by the lysosomal membrane which contains over 20 
lysosomal membrane proteins, one of the most important membrane proteins is the 
vacuolar type H(+)-ATPases (V-ATPases) which uses ATP to pump protons into the 
lumen of the lysosome and create an acidic environment (Mindell. 2012). Of note, 
bafilomycin used throughout this study targets lysosomal V-ATPases and alters 
acidification of the lysosome which has been found to prevent autophagosome and 
lysosome fusion (Yamamoto et al., 1998, Klionsky et al., 2008). Indeed, increasing 
the pH of acidic compartments independent of V-ATPases also effects fusion of 
autophagosomes and lysosomes (Kawai et al., 2007). Kawai et al (2007) hypothesise 
that autophagosome and lysosome fusion is regulated by pH to prevent inefficient 
fusion, as material would not be successfully degraded if the pH in the lysosome (and 
autolysosomes) is incorrect. In contrast, Mauvezin et al suggest lysosomal 
acidification is not a prerequisite for fusion, and that bafilomycin inhibits fusion 
independent of its effect on lysosomal pH (Mauvezin et al., 2015) 
Although LC3II protein expression data suggested that bafilomycin caused basal 
autophagy blockade, it would perhaps be more appropriate to consider bafilomycin in 
the context of lysosomal activity. Indeed, literature published from early studies using 
bafilomycin and its subsequent binding to the lysosomal V-ATPase, found treatment 
reduced lysosomal degradation of target material, such as 125I-labeled epidermal 
growth factor (EGF) in A431 cells (Yoshimori et al., 1991). Consequently, although 
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treatment with bafilomycin continued in this chapter in epidermal skin equivalents, 
results are considered from the perspective of its effects on lysosomal function. 
As described in Chapter 1 (section 1.8) lysosomal membrane permeabilisation (LMP) 
in which the contents of the lysosome are leaked into the cytosol initiating 
degradation of cellular components, can induce cell death. The extent of LMP 
determines the morphological features of cell death (Aits and Jatattela, 2013). 
Complete disruption of the lysosome provokes uncontrolled death by necrosis, whilst, 
of importance to the present study, partial or selective LMP induces apoptosis (Boya 
and Kroemer, 2008). The release of cathepsins into the cytosol is now widely 
accepted to be associated with both intrinsic (Johansson et al., 2003) and extrinsic 
apoptosis (Guicciardi et al., 2000). Specifically, cathepsin D, B and L are all 
recognised as having a role in apoptosis signalling (Johansson et al., 2010, Repnik et 
al., 2010, Chwieralski et al., 2006). For example, inhibition of cathepsin D by 
treatment with pepstatin A in human foreskin fibroblasts prevented staurosporine-
induced cytochrome c release, caspase activation and consequently delay cell death 
(Johansson et al., 2003). Similarly, in mouse models of acute kidney injury, inhibition 
of cathepsin D with pepstatin A improved kidney function, reduced apoptosis and 
improved cell viability even in hypoxic conditions (Cocchiaro et al., 2016) 
Interestingly, studies have also already revealed AhR expression can influence 
lysosomal mediated apoptosis. In a study using the lysosomal sensitiser NPe6 and 
photo dynamic therapy (PDT) to induce lysosomal disruption and apoptosis, the 
development of apoptosis was delayed and expression of lysosomal contents was 
reduced in AhR deficient cells compared to the parental line (Caruso et al., 2004). 
Later studies also supported these findings, with AhR content effecting susceptibility 
to TNF-α induced apoptosis (Caruso et al., 2006).  
The lysosomal aspartic protease cathepsin D is of particular interest in this project. 
Previous studies (Forrester thesis) found TCDD treatment of epidermal skin 
equivalents to de-regulate cathepsin D expression. Ingenuity Pathway Analysis (IPA) 
conducted by Astra Zeneca (Forrester thesis) also revealed interactions between 
cathepsin D and AhR as described in Chapter 1 sections 1.7.1).  Data suggests a 
role for AhR in cathepsin D transcription, even in the absence of an AhR agonist 
(Wang et al., 1999). Cathepsin D has also been found to have a role epidermal 
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differentiation, particularly in regulation and activation of TGM-1 (as described in 
Chapter 1 section 1.7.2) a key transglutaminase enzyme required for cornification.  
The aims of this chapter were therefore, to explore the role of lysosomal processing 
in a TCDD-induced chloracne phenotype model. Results have already demonstrated 
that TCDD significantly induces autophagy as well as caspase-3 positive staining, 
indicative of apoptotic cell death. In addition, data suggested autophagy, possibly 
chaperone-mediated autophagy, influenced levels of AhR degradation. Given the 
involvement of lysosomes in (macro) autophagy, chaperone mediated autophagy and 
apoptosis, it was important to also explore the role of lysosomal function. Cathepsin 
D was also of particular interest after previous preliminary data (Forrester Thesis) as 
well as the documented relationship with AhR and the role of cathepsin D in 
epidermal differentiation. Both chemical and genetic inhibition of lysosomal function 
and cathepsin D were performed in epidermal skin equivalents and the effect on AhR 
degradation, LC3II accumulation, differentiation and cell viability were explored.  
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5.2. Results 
5.2.1. TCDD treatment induces LAMP2 expression in primary human epidermal 
skin equivalents. 
 
The transmembrane glycoprotein LAMP2 (lysosomal associated membrane protein 
2) is found in the lysosomal membrane and is ubiquitously expressed (Eskelinen, 
2006). It plays a key role in lysosome biogenesis and is important in trafficking and 
fusion with autophagosomes (Saftig et al., 2010). Previous studies have suggested 
LAMP2 expression may be related to an increase in phagocytic or immunological 
responses as well as accumulation of lysosomes (Hua et al 1998, Wu et al., 2011). 
Therefore, immunofluorescence staining for LAMP2 was carried out to explore the 
effect TCDD treatment has on lysosome expression. Human epidermal skin 
equivalents were generated and then treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days. After harvesting, immunofluorescence staining on OCT 
frozen sections revealed an increase in LAMP2 expression after TCDD treatment 
relative to vehicle control (Fig. 5.1). LAMP2 was detected in both the high suprabasal 
layer and basal layer, although only in the basal layer did expression appear to be 
induced after TCDD treatment. Quantification and statistical analysis (paired t-test) 
found this increased expression to be not significant, however, there was a clear 
trend. 
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Figure 5.1 TCDD-induced LAMP2 expression in epidermal skin equivalents.  
A) Representative photomicrograph of epidermal equivalents treated with vehicle (DMSO) or TCDD 
(10nM) every 48 hours for 7 days depicting Hoechst nuclear staining (blue fluorescence) and LAMP2 
staining (red fluorescence). n=3 independent donors, scale bar 100µm. B) Mean relative LAMP2 
expression in epidermal equivalents treated for 7 days with vehicle (DMSO) or TCDD (10nM). Each 
bar is expressed relative to vehicle (DMSO) control LAMP2 expression, n= 3 independent donors, ± 
SEM.  Statistics were acquired by paired t test (NS).  
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5.2.2. Inhibition of lysosomal function alters TCDD-induced AhR degradation, 
LC3II accumulation and CYP1A1 expression in primary human epidermal skin 
equivalents. 
 
As discussed in Chapter 4 (sections 4.2.4, 4.2.5 and 4.2.6), bafilomycin A1 can be 
used as an autophagy pathway inhibitor, by preventing autophagosome and 
lysosomal fusion. However, specifically, bafilomycin is a V-ATPase inhibitor 
(Yamamoto et al., 1998) which can prevent acidification of the lysosome and 
therefore successful degradation of material. As such bafilomycin can also be used 
to investigate lysosomal processing and function. Studies in monolayer keratinocytes 
indicated bafilomycin altered AhR protein expression (Chapter 4, section 4.7).  To 
explore the potential role of the lysosomes in the TCDD-induced chloracne 
phenotype, human epidermal skin equivalents were treated with vehicle (DMSO), 
TCDD (10nM), bafilomycin (5nM) or TCDD with bafilomycin co-treatment every 48 
hours for 7 days. Firstly, to confirm TCDD induced AhR degradation and LC3II 
induction, expression was determined by western blotting (Fig. 5.2).  
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Results suggested AhR protein expression decreased with TCDD treatment, 
compared to vehicle (DMSO) control, consistent with earlier data (Chapter 3, Fig. 
3.4). Interestingly, treatment with bafilomycin alone suggested an increase in AhR 
protein expression. Similarly, bafilomycin co-treatment caused TCDD-induced AhR 
degradation to be reduced. Results also showed TCDD treatment of human 
epidermal skin equivalents to cause LC3II accumulation, again, in keeping with 
earlier data in which TCDD caused a significant increase in LC3II accumulation, due 
to increased donor numbers (Chapter 3 Fig. 3.6, Fig. 3.7). As expected, bafilomycin 
Figure 5.2 Bafilomycin co-treatment causes LC3II accumulation to be accentuated  and  AhR 
expression to increase slightly in epidermal equivalents 
A) Representative western blot of AhR and LC3II protein expression following treatment of epidermal 
equivalents with vehicle (DMSO), TCDD (10nM), 5nM bafilomycin or TCDD with bafilomycin co-
treatment every 48 hours for 7days. Densitometric analysis of AhR expression (B) or LC3II expression 
(C) after vehicle (blue bars), TCDD (10nM) (red bars), bafilomycin (dark green bars) or TCDD with 
bafilomycin co-treatment (light green bars). Each bar is normalised GAPDH loading control expressed 
relative to vehicle (DMSO) control. n=3 independent donors, ± SEM. Statistics were acquired by one-
way ANOVA with Tukey’s multiple comparison test *p= <0.05, **p=<0.01. 
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treatment caused a significant increase in LC3II expression (one-way ANOVA with 
Tukey’s multiple comparison test, p<0.05, p<0.01 Fig. 5.2 C) thus confirming 
lysosomal processing and LC3I/II flux was successfully attenuated.  To gain further 
evidence of TCDD-induced activation of AhR, mRNA levels of AhR as well as 
CYP1A1 (as a downstream target of AhR activation) were quantified. Epidermal skin 
equivalents were again treated for 7 days with vehicle (DMSO) or TCDD (10nM), 
bafilomycin (5nM) or TCDD with bafilomycin co-treatment (Fig. 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 TCDD-induced AhR mRNA degradation is partially blocked and CYP1A1 mRNA 
induction accentuated with bafilomycin co-treatment. 
 A) AhR mRNA expression in epidermal equivalents (n=3 independent donors ± SEM) following 
treatment with vehicle (DMSO) (blue symbols), TCDD (10nM) (red symbols), bafilomycin (5nM) 
(dark green symbols) or TCDD with bafilomycin co-treatment (light green symbols) every 48 hours 
for 7 days. Each symbol represents an individual donor and is normalised to housekeeper gene 
H4, relative to vehicle (DMSO), line represents mean value. Statistics were acquired by one-way 
ANOVA with Tukey’s multiple comparison test (NS) B) CYP1A1 mRNA expression in epidermal 
skin equivalents (n=3 independent donors ± SEM) following treatment with vehicle (DMSO) (blue 
symbols), TCDD (10nM) (red symbols), bafilomycin (5nM) (dark green symbols) or TCDD with 
bafilomycin co-treatment (light green symbols) every 48 hours for 7 days each symbol represents 
an individual donor and is normalised to housekeeper gene H4, relative to vehicle (DMSO) control, 
line represents mean value. Statistics were acquired by one-way ANOVA with Tukey’s multiple 
comparison test *p=<0.05. 
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As expected, and previously shown (Fig. 3.5), TCDD treatment of epidermal skin 
equivalents caused AhR mRNA expression to decrease relative to vehicle control, 
whereas bafilomycin treatment alone caused no significant change in expression 
(Fig. 5.3 A). Interestingly, AhR mRNA expression in epidermal skin equivalents 
treated with TCDD and bafilomycin co-treatment was on average higher than in 
epidermal skin equivalents treated with TCDD alone, but only slightly. 
TCDD treatment of epidermal skin equivalents caused an increase in CYP1A1 mRNA 
expression, as previously shown (Fig. 3.5), whilst bafilomycin treatment alone was 
found to have no significant induction of CYP1A1 mRNA (Fig. 5.3 B). In contrast, 
epidermal skin equivalents treated with TCDD and bafilomycin co-treatment had 
significantly increased CYP1A1 expression compared to bafilomycin alone (one-way 
ANOVA with Tukey’s multiple comparison test p<0.05 Fig. 5.3 B) and a clear trend 
for increased expression in comparison to both vehicle and TCDD treated epidermal 
skin equivalents.  
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5.2.3. Inhibiting lysosomal function rescues the TCDD-induced chloracne 
phenotype 
 
As previously described, treatment of human epidermal skin equivalent models with 
10nM TCDD every 48 hours for 7 days induces a reproducible chloracne phenotype. 
TCDD treatment significantly reduces viable cell layer thickness and the stratum 
corneum becomes compacted, consistent with physiological features found in 
chloracne. To try to delineate the mechanism behind this reduction in viable cell 
layer, epidermal skin equivalents were treated with vehicle (DMSO), TCDD (10nM), 
bafilomycin (5nM) or TCDD with bafilomycin co-treatment (Fig. 5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 TCDD-induced reduced viable cell layer of the chloracne phenotype model is 
prevented by bafilomycin co-treatment.  
A) Representative immunohistochemical images of epidermal equivalents stained with H&E following 
treatment with vehicle (DMSO), TCDD (10nM), bafilomycin (5nM) or TCDD with bafilomycin co-
treatment every 48 hours for 7 days. Scale bar = 20µm B) Mean viable cell layer (VCL) thickness of 
epidermal equivalents treated with vehicle (DMSO) (blue bar), TCDD (red bar), bafilomycin (dark green 
bar) or TCDD with bafilomycin co-treatment (light green bar) Each bar is expressed relative to vehicle 
(DMSO) control, n=3 independent donors, ± SEM.  Statistics were acquired by one-way ANOVA with 
Tukey’s multiple comparison test **p=<0.01, ****p=<0.0001. 
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Histological staining of formalin fixed and paraffin embedded (FFPE) sections with 
haemotoxilin and eosin (H&E), again revealed a significant and consistent reduction 
in the viable cell layer and more compact stratum corneum with TCDD treatment as 
previously described (Chapter 4, Fig. 3.3) (Fig. 5.4 A). In contrast, bafilomycin co-
treatment appeared to block this TCDD induced phenotype.  
Quantitative analysis of the viable cell layer demonstrated a significant decrease in 
thickness in all epidermal skin equivalents treated for 7 days with TCDD compared to 
those treated with vehicle (DMSO) (one-way ANOVA with Tukey’s multiple 
comparison test p<0.01 Fig. 5.4 B). Interestingly, bafilomycin co-treatment with 
TCDD in epidermal skin equivalents blocked this and viable cell layer thickness was 
increased significantly compared to TCDD treatment alone (Two-way ANOVA with 
Tukey’s multiple comparison test p<0.0001 Fig. 5.4 B).  
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5.2.4. Bafilomycin co-treatment causes TCDD induction of late differentiation 
marker mRNA expression to be significantly prevented, but has no clear effect 
at protein level 
 
In Chapter 3, data showed TCDD treatment of epidermal skin equivalent models to 
de-regulate late epidermal differentiation. In epidermal skin equivalents treated with 
TCDD mRNA levels of filaggrin, loricrin and cytokeratin 10 (CK10) were increased 
whilst expression at protein level was decreased (Fig. 3.8, Fig. 3.9). To investigate 
the potential influence of lysosomal processing in TCDD-induced de-regulated 
differentiation, mRNA expression of differentiation markers was measured in human 
epidermal skin equivalents treated with vehicle (DMSO), TCDD (10nM), bafilomycin 
(5nM) or TCDD with bafilomycin co-treatment every 48 hours for 7 days (Fig. 5.5) 
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Figure 5.5 Bafilomycin co-treatment prevents TCDD induced filaggrin, loricrin and CK10 
increased mRNA expression.  
mRNA expression of filaggrin (A), loricrin (B) and CK10 (C) in epidermal equivalents (n=3 
independent donors) ± SEM following treatment with vehicle (DMSO) (blue symbols), TCDD 
(10nM) (red symbols), bafilomycin (5nM) (dark green symbols) or TCDD with bafilomycin co-
treatment (light green symbols) every 48 hours for 7 days. Each symbol represents an individual 
donor and is normalised to housekeeper gene H4, relative to vehicle (DMSO) control, line 
represents mean value. Statistics were acquired by one-way ANOVA with Tukey’s multiple 
comparison test *p=<0.05, **p=<0.01. 
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As expected, TCDD treatment caused significantly increased mRNA expression of 
filaggrin and a trend in increased loricrin and CK10 expression in human epidermal 
skin equivalent models (Fig. 5.5). Interestingly, bafilomycin co-treatment prevented 
this induction and caused filaggrin, loricrin and CK10 mRNA expression to be 
significantly reduced compared to TCDD alone, bringing expression back to vehicle 
control levels, or lower (one-way ANOVA with Tukey’s multiple comparison test, 
p<0.05, p<0.01 Fig. 5.5). Epidermal skin equivalents treated with bafilomycin alone 
had similar levels of filaggrin, loricrin and CK10 expression compared to vehicle 
(DMSO) and consistently higher expression than epidermal skin equivalents treated 
with TCDD and bafilomycin co-treatment.  
In order to further delineate the impact of lysosomal processing on TCDD induced 
deregulated differentiation, the immunofluorescent expression of epidermal 
differentiation markers filaggrin, loricrin and CK10 was determined in epidermal 
equivalents treated with vehicle (DMSO), TCDD (10nM), bafilomycin (5nM) or TCDD 
with bafilomycin co-treatment 48 hours for 7 days (Fig. 5.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Bafilomycin co-treatment prevents TCDD induced reduction in filaggrin expression 
but not loricrin or CK10 reduced expression.  
A) Representative photomicrographs of epidermal equivalents treated with vehicle (DMSO), TCDD 
(10nM), bafilomycin (5nM) or TCDD with bafilomycin every 48 hours for 7 days depicting Hoechst 
nuclear staining (blue fluorescence) and filaggrin, CK10 or loricrin staining (red fluorescence). N=4 
independent donors, scale bar 62.15µm. B) Mean relative filaggrin (Bi) CK10 (Bii) or loricrin (Biii) 
expression in epidermal equivalents treated for 7 days with vehicle (DMSO) (blue bars) TCDD (10nM) 
(red bars) bafilomycin (5nM) (dark green bars) or TCDD with bafilomycin co-treatment (light green bars) 
for 7 days. Each bar is expressed relative to vehicle (DMSO) control for filaggrin (i) CK10 (ii) or loricrin 
(iii) expression, n= 3 independent donors, ± SEM. Statistics were acquired by one-way ANOVA with 
Tukey’s multiple comparison test *p=<0.05, **p=<0.01 
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As previously found, TCDD treatment of epidermal skin equivalents caused 
significant decreased expression of filaggrin (Fig. 5.6 A and B i) (one-way ANOVA 
with Tukey’s multiple comparison test, p<0.01) and reduced expression of CK10 and 
loricrin. Interestingly, bafilomycin co-treatment did not prevent TCDD induced loss of 
CK10 or loricrin protein expression, in fact, expression seemed further reduced (Fig. 
5.6 B ii and iii). In contrast, there was a slight recovery of filaggrin expression with 
bafilomycin co-treatment compared to TCDD alone, although this was not significant 
(Fig. 5.6 B i) 
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5.2.5. Inhibiting lysosomal function prevents TCDD-induced caspase-3 positive 
staining and increases Ki67 positive staining 
 
To explore the TCDD-induced chloracne phenotype and specifically the contribution 
of lysosomal activity in TCDD-induced apoptosis, the effect of bafilomycin on 
caspase-3 dependent cell death was investigated. Human epidermal skin equivalents 
were generated and then treated with vehicle (DMSO), TCDD (10nM), bafilomycin 
(5nM) or TCDD with bafilomycin co-treatment every 48 hours for 7 days. After 
harvesting, immunofluorescence staining on OCT frozen sections for caspase-3 was 
carried out. Images were taken along the entire length of the epidermal skin 
equivalents and Hoechst positive cells and caspase-3 positive cells were counted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis revealed TCDD treated epidermal skin equivalents had 
significantly increased caspase-3 positive cells compared to vehicle (DMSO) alone 
(one-way ANOVA with Tukey’s multiple comparison test p<0.01 Fig. 5.7). 
Interestingly, co-treatment with bafilomycin reduced the TCDD induced caspase-3 
positivity significantly (one-way ANOVA with Tukey’s multiple comparison test 
Figure 5.7 TCDD-induced increase of caspase-3 positive cells is prevented by 
bafilomycin co-treatment.  
Mean percentage of caspase-3 positive cells to Hoechst positive cells presented as fold change 
in epidermal equivalents treated with vehicle (DMSO) (blue bar) TCDD (10nM) (red bar) 
bafilomycin (5nM) (dark green bar) or TCDD with bafilomycin co-treatment (light green bar) 
every 48 hours for 7 days. Each bar is expressed relative to vehicle (DMSO) control. n= 3 
independent donors, ± SEM. Statistics were acquired by one-way ANOVA with Tukey’s multiple 
comparison test. **p=<0.01. 
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p<0.01), bringing levels back down to that of vehicle (DMSO) control treated 
epidermal skin equivalents (raw values are presented in Appendix J). 
In epidermal skin equivalents TCDD causes differentiation to be de-regulated and 
significantly reduces the viable cell layer thickness compared to vehicle control. 
Although TCDD did not significantly alter proliferation (Chapter 3 Fig. 3.8) bafilomycin 
treatment did seem to cause a slight increase in viable cell layer thickness (Fig. 5.4). 
Therefore, the effect of blocking lysosomal function on proliferation (Ki67 positive 
cells) was still explored. After harvesting, immunofluorescence staining on OCT 
frozen sections for Ki67 was performed. Images were taken along the entire length of 
the epidermal skin equivalents and Hoechst positive cells and Ki67 positive cells 
were counted. 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis (one-way ANOVA with Tukey’s multiple comparison test) revealed 
no significant change in Ki67 staining, with TCDD treatment compared to vehicle 
(DMSO) control treated epidermal skin equivalents (as previously presented in 
Chapter 3 Fig. 3.8). However, interestingly, in epidermal skin equivalents treated with 
bafilomycin alone or TCDD with bafilomycin co-treatment, Ki67 staining was 
increased above both vehicle and TCDD treatment levels, although not significant.  
Figure 5.8 TCDD does not increase Ki67 positive cells but bafilomycin treatment 
does. 
 Mean percentage of Ki67 positive cells to Hoechst positive cells presented as fold change 
in epidermal equivalents treated with vehicle (DMSO) (blue bar) TCDD (10nM) (red bar) 
bafilomycin (5nM) (dark green bar) or TCDD with bafilomycin co-treatment (light green bar) 
every 48 hours for 7 days. Each bar is expressed relative to vehicle (DMSO) control. n= 3 
independent donors, ± SEM.  Statistics were acquired by one-way ANOVA with Tukey’s 
multiple comparison test 
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5.2.6. Specific chemical inhibition of cathepsin D alters TCDD-induced AhR 
degradation and LC3II accumulation  
 
Although the chemical inhibitor bafilomycin, blocks lysosomal function, it also impacts 
the autophagy pathway as previously stated. Therefore, to further explore the 
influence of lysosomal processing in the chloracne phenotype model, a 
complementary approach was used by chemically inhibiting the lysosomal protease 
cathepsin D with pepstatin A. 
Firstly, epidermal skin equivalents were generated and treated with vehicle (DMSO), 
TCDD (10nM), pepstatin A (10µg/ml) or TCDD with pepstatin A co-treatment, every 
48 hours for 7 days. To confirm TCDD induced AhR degradation and LC3II induction, 
protein expression was determined by western blotting (Fig. 5.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 TCDD-induced AhR protein degradation is partially blocked and LC3II accumulation is 
accentuated by pepstatin A co-treatment.  
A) Representative western blot of AhR protein expression and LC3II expression in epidermal equivalents 
following treatment with vehicle (DMSO), TCDD (10nM), pepstatin A (10µg/ml) or TCDD with pepstatin A 
co-treatment every 48 hours for 7days. B) Densitometric analysis of AhR expression (i) or LC3II 
expression (ii) after vehicle (blue bar), TCDD (red bar), pepstatin A (turquoise bar) or TCDD with 
pepstatin A co-treatment (light green bar). Each bar is normalised to GAPDH loading control expressed 
relative to vehicle (DMSO) control. n=3 independent donors ± SEM. Statistics were acquired by one-way 
ANOVA with Tukey’s multiple comparison test *p= <0.05. 
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As expected, results showed relative to GAPDH loading control, AhR protein 
expression significantly decreased with TCDD compared to vehicle (DMSO) (Fig. 5.9 
B i) (one-way ANOVA with Tukeys multiple comparison test p<0.05). In epidermal 
skin equivalents co-treated with pepstatin A, TCDD-induced AhR degradation was 
partially prevented. In epidermal skin equivalents treated with pepstatin A alone, AhR 
protein expression was at the same level as that found in vehicle (DMSO) treated 
epidermal skin equivalents.  
Results also showed TCDD treatment of human epidermal skin equivalents caused a 
slight increase in LC3II protein expression (Fig. 5.9 B ii). Of interest, pepstatin A 
alone and co-treatment with pepstatin A caused an increase in LC3II expression, 
suggesting the inhibitor worked and lysosomal degradation or function was impaired.  
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5.2.7. Specific chemical inhibition of cathepsin D partially rescues the TCDD-
induced chloracne phenotype 
 
As described earlier, bafilomycin co-treatment was found to prevent the TCDD-
induced reduction in viable cell layer thickness. However, it is not clear if autophagy 
of lysosomal processing or both processes are involved in this. To gain more 
information, epidermal skin equivalents were treated with vehicle (DMSO), TCDD 
(10nM) pepstatin A (10µg/ml) or TCDD with pepstatin A co-treatment and histological 
staining of formalin fixed and paraffin embedded (FFPE) sections with haemotoxilin 
and eoisin (H&E) was carried out (Fig. 5.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 TCDD-induced reduced viable cell layer of the chloracne phenotype model is 
prevented by pepstatin A co-treatment.  
A) Representative immunohistochemical images of epidermal equivalents stained with H&E following 
treatment with for 7 days with vehicle (DMSO), TCDD (10nM), pepstatin A (10µg/ml) or TCDD with 
pepstatin A co-treatment. Scale bar = 20µm B) Mean viable cell layer (VCL) thickness of epidermal 
equivalents treated every 48 hours for 7 days with vehicle (DMSO) (blue bar), TCDD (red bar), 
pepstatin A (turquoise bar) or TCDD with pepstatin A co-treatment (light green bar) Each bar is 
expressed relative to vehicle (DMSO) control, n= 3 independent donors, ± SEM. Statistics were 
acquired by one-way ANOVA with Tukey’s multiple comparison test. **p=<0.01, ****p=<0.0001. 
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Imaging and subsequent quantitative analysis revealed a reduction in the viable cell 
layer with TCDD treatment as expected (Fig. 5.10 B) (one-way ANOVA with Tukey’s 
multiple comparison test p<0.0001). Of importance, co-treatment with pepstatin A 
significantly increased viable cell layer thickness above that of TCDD treated 
epidermal skin equivalents (p<0.0001). Interestingly, pepstatin A treatment alone 
caused a reduction in viable cell layer thickness compared to vehicle treated and a 
significant reduction in viable cell layer thickness compared to epidermal skin 
equivalents with TCDD and pepstatin A co-treatment (p<0.01). 
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5.2.8. Specific chemical inhibition of cathepsin D rescues the TCDD-induced 
reduction in filaggrin protein expression 
 
TCDD treatment of epidermal skin equivalents causes differentiation to be de-
regulated (Fig. 3.8, Fig. 3.9). To explore more specifically the role of lysosomal 
processing in the chloracne phenotype and in particular its potential role in de-
regulated differentiation, epidermal skin equivalents were treated in the presence and 
absence of pepstatin A (10µg/ml) and immunofluorescence staining for filaggrin 
protein expression was carried out (Fig. 5.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 TCDD induced downregulation of filaggrin protein expression is partially blocked by 
pepstatin A co-treatment.  
A) Representative photomicrographs of epidermal equivalents treated with vehicle (DMSO), TCDD 
(10nM), pepstatin A (10µg/ml) or TCDD with pepstatin A co-treatment depicting Hoechst nuclear staining 
(blue fluorescence) and Filaggrin expression (red fluorescence). Scale bar = 100µm B) Mean filaggrin 
expression of epidermal equivalents treated every 48 hours for 7 days with vehicle (DMSO) (blue bar), 
TCDD (red bar), pepstatin A (turquoise bar) or TCDD with pepstatin A co-treatment (light green bar). Each 
bar is expressed relative to vehicle (DMSO) control, n=3 independent donors, ± SEM. Statistics were 
acquired by one-way ANOVA with Tukey’s multiple comparison test *p=<0.05 
 144 
 
Results showed a significant reduction in filaggrin protein expression with TCDD 
treatment as expected (one-way ANOVA with Tukey’s multiple comparison test 
p<0.05). However, data suggested pepstatin A co-treatment restored filaggrin 
expression and partially prevented TCDD-induced downregulation of filaggrin. 
Pepstatin A treatment alone caused filaggrin expression to be slightly lower than 
vehicle control, although again this data was not significant. 
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5.2.9. Specific chemical inhibition of cathepsin D prevents TCDD-induced 
caspase-3 positive staining  
 
Previous data showed TCDD treatment significantly increased caspase-3 positive 
cells in epidermal skin equivalents and this is significantly reduced by co-treatment 
with bafilomycin (Fig. 5.6). To explore further the potential role of lysosomal 
processing, specifically the role of cathepsin D, in induction of caspase-3 positivity, 
epidermal equivalents were generated and treated in the presence and absence of 
pepstatin A and immunofluorescence staining for caspase-3 was carried out (Fig. 
5.12). 
 
 
 
 
 
 
 
 
 
Results suggested TCDD treatment caused an increase in caspase-3 positive 
staining compared to vehicle (DMSO) treated epidermal skin equivalents. This 
induction of caspase-3 positivity appeared to be reduced by pepstatin A co-
treatment, whilst pepstatin A treatment alone caused a slight increase in caspase-3 
positivity compared to vehicle (DMSO) control although this was not significant due to 
donor variability (raw values are presented in Appendix I). 
 
Figure 5.12 TCDD-induced increase of caspase-3 positive cells is prevented by pepstatin A 
co-treatment.  
Mean percentage of caspase-3 positive cells to Hoechst positive cells presented as fold change in 
epidermal equivalents treated with vehicle (DMSO), TCDD (10nM), pepstatin A (10µg/ml) or TCDD 
with pepstatin A co-treatment every 48 hours for 7 days. Each bar is expressed relative to vehicle 
(DMSO) control. n= 3 independent donors, ± SEM.  Statistics were acquired by one-way ANOVA 
with Tukey’s multiple comparison test (NS) 
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5.2.10. Successful shRNA knockdown of cathepsin D was achieved in 
epidermal skin equivalents  
 
Although pepstatin A is known as a specific inhibitor of cathepsin D as with any 
chemical inhibitor, off target affects are possible. Therefore, to verify work carried out 
with pepstatin A, shRNA lentiviral knockdown of cathepsin D in epidermal skin 
equivalents was pursued. Briefly, primary human keratinocytes were transduced with 
non-target control (shNT) or cathepsin D (shCTSD) shRNA lentivirus, puromycin 
selected and expanded. Cells were then seeded into epidermal equivalents and 
grown for 12 days then treated appropriately every 48 hours for a further 7 days. To 
establish whether successful knockdown of cathepsin D had occurred, epidermal 
equivalents were harvested and expression of all isoforms of cathepsin D protein 
(pre/pro, pro and active) was established by western blotting (Fig. 5.13) 
 
 
 
 
 
 
 
 
 
Figure 5.13 Successful knockdown of cathepsin D protein in shCTSD epidermal equivalents 
compared to shNT control.  
A) Representative western blot of Pre/Pro, Pro and active forms of cathepsin D (CTSD) protein 
expression following treatment of shNT and shCTSD knockdown epidermal equivalents with 
vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days. B) Densitometric analysis of Pre/pro 
and Pro forms of cathepsin D (i) or active cathepsin D (ii) after vehicle (blue bar) or TCDD (10nM) 
(red bar) treatment every 48 hours for 7 days. Each bar is normalised to GAPDH loading control 
relative to shNT vehicle (DMSO) control. n=3 independent donors, ± SEM. Statistics were acquired 
by two-way ANOVA with Tukey’s multiple comparison test **p= <0.01, ***p=<0.001 
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Results showed, relative to GAPDH loading control, pre/pro and pro isoforms of 
cathepsin D were significantly reduced in shCTSD epidermal equivalents compared 
to expression in shNT epidermal equivalents, after both vehicle (DMSO) and TCDD 
(10nM) treatment (one-way ANOVA with Tukey’s multiple comparison test p<0.01 
and p<0.001 respectively Fig. 5.13 B i, ii). Active cathepsin D protein expression was 
also reduced in shCTSD epidermal skin equivalents compared to shNT, with a row 
factor, or knockdown as a whole, significant (p=0.0133). Interestingly, in shNT 
epidermal equivalents treated with TCDD (10nM) expression of all isoforms of 
cathepsin D tended to increase, further supporting the involvement of cathepsin D in 
this phenotype. 
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5.2.11. shRNA knockdown of cathepsin D accentuates TCDD-induced AhR 
protein degradation and increases LC3II accumulation 
 
To understand the impact of knocking down cathepsin D on AhR protein expression 
and LC3II accumulation, epidermal skin equivalents with shNT and shCTSD were 
generated and treated every 48 hours for 7 days with vehicle (DMSO) or TCDD 
(10nM). Western blotting was then used to determine AhR and LC3II protein 
expression (Fig. 5.14). 
 
 
 
 
 
 
Data showed a trend for TCDD induced AhR degradation in both shNT and shCTSD 
epidermal skin equivalents as expected. Interestingly, cathepsin D knockdown in 
epidermal skin equivalents appeared to accentuate TCDD-induced degradation. 
LC3II accumulation also appeared induced by TCDD treatment in shNT epidermal 
equivalents as expected. Additionally, LC3II expression was increased by shCTSD 
knockdown regardless of treatment, confirming knockdown is actively attenuating 
lysosomal function. However, data was not significant due to donor variability and as 
such, more donors are required.  
Figure 5.14 shCTSD knockdown accentuates TCDD induced AhR degradation and causes 
LC3II accumulation.  
A) Representative western blot of AhR and LC3I/II protein expression following treatment of shNT and 
shCTSD knockdown epidermal equivalents with vehicle (DMSO) or TCDD (10nM) every 48 hours for 
7 days. B) Densitometric analysis of AhR (i) or LC3II (ii) after vehicle (DMSO) (blue bar) or TCDD 
(10nM) (red bar) treatment. Each bar is normalised to GAPDH loading control expressed relative to 
shNT vehicle (DMSO) control. n=3 independent donors, ± SEM. Statistics were acquired by two-way 
ANOVA with Tukey’s multiple comparison test (NS). 
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5.2.12. shRNA knockdown of cathepsin D rescues the TCDD-induced reduced 
viable cell layer thickness 
 
To further explore the role of cathepsin D in the TCDD-induced chloracne phenotype, 
particularly the reduction in viable cell layer thickness, shNT and shCTSD epidermal 
equivalents were generated and treated with vehicle (DMSO) or TCDD (10nM) every 
48 hours for 7 days. Histological staining of formalin fixed and paraffin embedded 
(FFPE) sections with haemotoxilin and eosin (H&E) was then carried out (Fig. 5.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 TCDD-induced reduced viable cell layer of the chloracne phenotype model is 
prevented by shCTSD knockdown. 
 A) Representative immunohistochemical images of shNT and shCTSD knockdown epidermal 
equivalents stained with H&E following treatment with vehicle (DMSO) or TCDD (10nM) for 7 
days. Scale bar = 20µm B) Mean viable cell layer (VCL) thickness of shNT and shCTSD 
knockdown epidermal equivalents treated with vehicle (DMSO) (blue bar) or TCDD (red bar) 
every 48 hours for 7 days. Each bar is expressed relative to shNT vehicle (DMSO) control, n= 
3 independent donors, ± SEM.  Statistics were acquired by two-way ANOVA with Tukey’s 
multiple comparison test ****p=<0.0001. 
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Quantitative analysis of viable cell layer thickness was then performed which 
revealed as expected, TCDD treatment of shNT epidermal skin equivalents caused a 
significant reduction in viable cell layer thickness (two-way ANOVA with Tukey’s 
multiple comparison test p<0.0001 Fig. 5.15 B). Interestingly, shCTSD knockdown 
epidermal skin equivalents treated with vehicle (DMSO) control caused no significant 
change in viable cell layer thickness. In contrast, shCTSD knockdown significantly 
blocked TCDD-induced reduction in viable cell layer thickness (two-way ANOVA with 
Tukey’s multiple comparison test, p<0.0001).  
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5.2.13. shRNA knockdown of cathepsin D partially rescues the TCDD-induced 
reduction in filaggrin protein expression 
 
To explore the role of cathepsin D in the chloracne phenotype model, in particular the 
influence on TCDD-induced de-regulated differentiation, shNT and shCTSD 
knockdown epidermal skin equivalents were treated with vehicle (DMSO) or TCDD 
(10nM). After harvesting, immunofluorescence staining on OCT frozen sections for 
filaggrin was performed (Fig. 5.16).  
 
 
 
 
 
 
 
 
After quantification and statistical analysis (two-way ANOVA with Tukey’s multiple 
comparison test) results surprisingly showed only a very slight decrease in filaggrin 
expression with TCDD (10nM) treatment in shNT epidermal equivalents. In contrast, 
TCDD treatment did cause reduced filaggrin expression in shCTSD epidermal skin 
equivalents. Surprisingly, filaggrin protein expression overall was higher in shCTSD 
knockdown epidermal skin equivalents compared to expression in shNT epidermal 
skin equivalents (Fig. 5.16). However, it is difficult to interpret this data given the 
donor variability and more donors would be required before firm conclusion can be 
drawn.  
Figure 5.16 shCTSD knockdown in epidermal skin equivalents causes increased filaggrin protein 
expression compared to shNT control. 
 A) Representative photomicrographs of shNT and shCTSD knockdown epidermal equivalents (n=3 
independent donors) treated with vehicle (DMSO) or TCDD (10nM) for 7 days depicting Hoechst nuclear 
staining (blue fluorescence) and Filaggrin expression (red fluorescence). Scale bar = 100µm. B) Mean 
filaggrin expression of shNT and shCTSD knockdown epidermal equivalents treated with vehicle 
(DMSO) (blue bar) or TCDD (10nM) (red bar) every 48 hours for 7 days. Each bar is expressed relative 
to shNT vehicle (DMSO) control, n=3 independent donors, ± SEM. Statistics were acquired by two-way 
ANOVA with Tukey’s multiple comparison test (NS).   
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5.2.14. shRNA knockdown of cathepsin D prevents TCDD-induced caspase-3 
positive staining  
 
In order to further confirm the involvement of cathepsin D in TCDD induced caspase-
3 staining, immunofluorescence was performed on frozen OCT sections of shNT and 
shCTSD epidermal skin equivalents treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days (Fig. 5.17).  
 
 
 
 
 
 
 
 
 
After imaging the individual epidermal skin equivalent sections along their entire 
length, caspase-3 positive cells and Hoechst positive cells were counted, as 
previously described (raw values are presented in Appendix L). After quantification 
and statistical analysis (two-way ANOVA with Tukey’s multiple comparison test) a 
clear trend was apparent. As previously seen, TCDD treatment of shNT epidermal 
skin equivalents caused increased caspase-3 positive staining relative to shNT 
vehicle (DMSO) treated. In general, shCTSD epidermal skin equivalents had less 
capase-3 positive staining overall. Of interest, TCDD treated shCTSD epidermal skin 
equivalents had far less caspase-3 positive cell staining compared to shNT TCDD 
treated epidermal skin equivalents.  
Figure 5.17 TCDD-induced increase of caspase-3 positive cells is prevented by shCTSD 
knockdown.  
Mean percentage of caspase-3 positive cells to Hoechst positive cells presented as fold change in 
shNT and shCTSD knockdown epidermal equivalents treated with vehicle (DMSO) or TCDD (10nM) 
every 48 hours for 7 days. Each bar is expressed relative to shNT vehicle (DMSO) control. n= 3 
independent donors, ± SEM.  Statistics were acquired by two-way ANOVA with Tukey’s multiple 
comparison test (NS) 
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5.3 Discussion 
 
Work in this chapter focused on using the established epidermal equivalent 
chloracne phenotype model whilst harnessing both chemical and genetic 
manipulation of lysosomal function and cathepsin D activity. These novel data 
revealed lysosomal activity was required for the TCDD-induced reduction in viable 
cell layer and increased expression of active capsase-3 positive cells. Furthermore, 
data suggests lysosomal activity may play a role in TCDD-induced AhR degradation 
in this model and also implies lysosomal activity is involved in TCDD-induced de-
regulated differentiation. Taken together it is likely lysosomal function plays a crucial 
role in the chloracne phenotype model.  
 
5.3.1. Involvement of lysosomes in AhR degradation  
 
As discussed in Chapter 4, section 4.3.2, results indicated autophagy, potentially 
chaperone mediated autophagy (CMA) may play a role in AhR degradation. Although 
AhR is thought to be degraded by the 26S proteasome ubiquitination pathway (Ma 
and Baldwin, 2000, Davarinos and Pollenz, 1999) there is known cross talk between 
this and chaperone mediated or selective autophagy as reviewed by Lilienbaum 
(2013).  
LAMP2 is a lysosomal membrane protein, required for lysosomal fusion and mobility 
and upregulation can indicate accumulation and storage of lysosomes (Wu et al., 
2011). Therefore, initial experiments investigated the expression LAMP2, in 
epidermal skin equivalents after TCDD treatment. Results demonstrated TCDD 
treatment induced LAMP2 expression, suggesting TCDD caused accumulation of 
lysosomes or increased the number of lysosomes.  
Although immunofluorescence was carried out using a general LAMP2 antibody, the 
LAMP2 gene is known to undergo alternative splicing resulting in three isoforms: A, B 
and C (Cuervo and Dice, 2000, Konecki et al., 1995). Of interest to this study, 
LAMP2A is thought to be a key factor in chaperone mediated autophagy (CMA), with 
the chaperone-substrate complex binding to LAMP2A on the lysosomal membrane 
(Saftig and Eskelinen, 2008). LAMP2A has a specific 12-amino residue sequence 
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which forms a unique cytosolic tail and antibodies are available to target this (Patel 
and Cuervo, 2015). The increase in LAMP2 staining with TCDD treatment did indeed 
indicate lysosomal accumulation; however, staining with a LAMP2A antibody would 
help elucidate the role of lysosomes in chaperone mediated autophagy specifically.  
Like AhR, misfolded or unfolded proteins are generally degraded by the proteasome 
system but when they become too large to pass through narrow proteasome 
channels, the autophagy pathway is often activated (Wang et al., 2015). To be 
degraded by chaperone mediated autophagy (CMA), the target protein must have a 
specific penta-peptide amino acid sequence, a KFERQ motif, which is recognised by 
hsc70 (heat shock-cognate chaperone, 70kDa) (Patel and Cuervo, 2015, Franch et 
al., 2001, Dice, 1990). Of interest, 30% of cytosolic proteins have this KFERQ motif. 
Interestingly, a lysosomal form of hsp90 is also involved in CMA, essential to 
preserve the stability of LAMP2A at the lysosomal membrane (Patel and Cuervo, 
2015, Bandyopadhyay et al., 2008).  
An association between the chaperone protein hsp90 and AhR has already been well 
established (as described in Chapter 1, section 1.2.2). In the cytoplasm before 
activation by ligands, AhR is known to bind to hsp90 as well as P23 and AIP to 
prepare AhR for ligand binding (Tsuji et al., 2014). Although hsp90 is known to 
chaperone over 300 proteins, this already established interaction between hsp90 and 
AhR may provide additional evidence of CMA being involved in AhR degradation.  
Results from the present chapter support these studies and the hypothesis that CMA 
may be involved in AhR degradation. Data showed bafilomycin co-treatment partially 
blocked TCDD-induced AhR protein degradation and results indicated that the 
specifically the lysosomal protease cathepsin D may have a role, through 
experiments using the chemical inhibitor pepstatin A. In contrast, although shRNA 
knockdown of cathepsin D was achieved in epidermal skin equivalents, AhR protein 
expression data was variable, with large error bars due to donor variability, possibly 
because of a low donor number. However, data from experiments with bafilomycin 
and the pepstatin A still implies lysosomal function is somewhat required for AhR 
degradation in keratinocytes.  
Interestingly, results also demonstrated treatment of epidermal skin equivalents with 
bafilomycin accentuated TCDD-induced CYP1A1 mRNA expression, indicative of 
AhR activity.  
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Accentuation of TCDD induced CYP1A1, or CYP1A1 “super induction” has been 
described previously in studies exploring models of AhR degradation. Mouse 
hepa1c1c7 cells treated with TCDD in combination with the 26S proteasome inhibitor 
MG-132 or another proteasome inhibitor lactacystin for 5 hours enhanced CYP1A1 
gene expression 4-3.5 fold. In contrast, PMSF the serine protease inhibitor did not 
affect induction (Ma and Baldwin, 2000). However, although all relative, cells in the 
published study were only treated with 1nM TCDD compared to 10nM in the present 
model and as previously discussed, AhR expression and activity varies significantly 
between mouse and human models (as discussed in Chapter 1, section 1.3.1). 
Nevertheless, bafilomycin induced super induction of CYP1A1 mRNA levels in the 
present model suggests lysosomal degradation of AhR is also regulating ligand-
bound or active AhR in the nucleus and consequently transcription of target genes.  
Taken together, the data presented suggests AhR is degraded to some extent by 
lysosomal proteins, likely through CMA due to the unique cross talk with the 26S 
proteasome system. 
 
5.3.2. Further evidence of a role for lysosomal activity and cathepsins in 
epidermal differentiation  
 
Treatment of epidermal skin equivalents with TCDD over 7 days was previously 
found to de-regulate epidermal differentiation and potentially contributes to the 
chloracne phenotype (Chapter 3, section 3.2.3). As such, the role of lysosomal 
function in TCDD-induced de-regulated differentiation was explored. Interestingly, 
bafilomycin co-treatment and cathepsin D inhibition with pepstatin A or shRNA 
knockdown blocked the TCDD-induced reduction in filaggrin protein expression, 
although not significant.  Similarly, at mRNA level, TCDD-induced filaggrin, loricrin 
and CK10 expression was blocked by bafilomycin co-treatment. Although results 
were somewhat variable, data suggests lysosomal activity may be required for TCDD 
induced de-regulated differentiation.  
Although the role of lysosomes may not have been implicated in TCDD induced de-
regulated epidermal differentiation before, the literature does suggest lysosomal 
cathepsins have a role in epidermal differentiation.  For example, in rat keratinocytes, 
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expression of cathepsins B, H and L increased when keratinocytes were calcium 
differentiated (Tanabe et al., 1991). Similarly, cathepsin L activity has also been 
found to increase after 1-2 days then decrease again as differentiation progresses. 
Finally, in a clinical trial evaluating the efficacy and safety of the cathepsin K inhibitor 
balicatib for osteoporosis, one patient developed scleroderma with morphea lesions 9 
months after beginning the trial (Peroni et al., 2008) again suggesting cathepsin 
activity can influence epidermal differentiation and regulation. 
However, of interest to this project and data presented in this chapter, the aspartic 
protease cathepsin D in particular is known to have a role in epidermal differentiation. 
In corroboration with other cathepsin proteases, studies using primary human 
keratinocytes found cathepsin D expression to increase under calcium-induced 
differentiation (Horikoshi et al., 1998). Immunofluorescence staining for cathepsin D 
in whole skin biopsies found expression to be mainly in the stratum corneum and 
adjacent granular cells, with some staining present in the dermis. Data also 
suggested cathepsin D may be involved in the break down of pro filaggrin into 
filaggrin which had previously been found in rat skin (Kashima et al., 1988).  
These studies all demonstrate cathepsin D is expressed in epidermal models and 
induced upon differentiation, but the function of cathepsin D was not fully explored.  
Key work carried out by Egberts et al (2004) found that treatment with exogenous 
cathepsin D increased TGM-1 expression, whilst pepstatin A suppressed TGM-1 
activity. In cathepsin D deficient mouse models, reduced activity of TGM-1 caused a 
reduction in expression and activity of a variety of cornified envelope proteins 
including loricrin, filaggrin and involucrin. In cathepsin D knockout mice, the 
epidermis was also reported to have reduced thickness and a thickened stratum 
corneum. In keeping with results presented in this paper, data from the present study 
demonstrated pepstatin A treatment alone reduced filaggrin expression, presumably 
through inhibition of cathepsin D causing a decrease in TGM-1 expression and 
activity. In contrast to Egberts et al (2004) cathepsin D shRNA knockdown caused a 
distinct increase in filaggrin expression above vehicle control, regardless of 
treatment.  
Although surprising, differences between the present knockout model and published 
model are not entirely unexpected. The current study was carried out in human 
epidermal skin equivalents, whereas Egberts et al (2004) carried out 
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immunofluorescence on full thickness biopsies including dermis, from in vivo 
experiments in knockout mice. To confirm pepstatin A treatment is reducing filaggrin 
expression by TGM-1 downregulation, immunofluorescence or western blotting for 
TGM-1 protein expression would be valuable. It would also be interesting to 
investigate TGM-1 expression in shRNA knockdown epidermal equivalents, to help 
understand the increase in filaggrin expression above that of shNT vehicle control. It 
is also possible that by knocking down cathepsin D another type of cathepsin or an 
off target protein is upregulated or effected which could alter differentiation status, 
although this needs to be explored further.  
Altering lysosomal function in particular cathepsin D inhibition and knockdown clearly 
effected epidermal differentiation but further experiments are required to truly 
delineate the exact role in the chloracne phenotype. Repeating experiments in more 
donors to gain significance would initially be beneficial as well as exploring the effect 
of cathepsin D blockade on more differentiation markers at both the protein and 
mRNA level. 
In addition, to explore changes in proliferation status in the chloracne phenotype 
model further, and the potential role of lysosomal activity, Ki67 staining was 
performed. As presented previously (Chapter 3) TCDD treatment had no significant 
effect on Ki67 staining, but bafilomycin treatment appeared to increase Ki67 positive 
cells. As discussed, bafilomycin treatment reduced differentiation marker expression 
significantly. Epidermal differentiation is a complex balance between proliferation, 
differentiation and cell death. Perhaps by reducing rates of differentiation, cell 
proliferation was increased with bafilomycin treatment, through a feedback loop or 
some kind.  
 
5.3.3 Role of lysosomes in TCDD-induced apoptosis 
 
Lysosomes were previously thought to only have a role in necrosis or autophagic cell 
death, and lysosomal proteases such as cathepsin D only involved in general protein 
degradation (Benes et al., 2008). However, as previously discussed lysosome 
membrane permeabilisation and cathepsin activity are now thought to be involved in 
apoptosis. Many studies of apoptosis have demonstrated the contribution of 
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cathepsins and caspases. In a study by Appelqvis et al (2013) UVA irradiation of 
human keratinocytes resulted in nuclear fragmentation and a 9.5 fold increase in 
caspase-3 activity as well as increased caspase-8 activity. Interestingly, lysosomal 
exocytosis was also apparent, with lysosomes redistributing to the periphery of the 
cell and release of lysosomal contents including cathepsin D and the lysosomal 
enzyme acid sphingomyelinase. Similar to data presented in this chapter when using 
the inhibitor bafilomycin, prevention of lysosomal acidification with NH4Cl reduced 
exocytosis and caspase-8 activation. In addition, caspase-8 activity was also reduced 
by pepstatin A treatment and the cysteine cathepsin inhibitor E64D. By treating 
keratinocytes with cathepsin D antibodies before UVA irradiation Appelqvis et al 
(2013) also determined that caspase-8 activation was downstream of cathepsin D. Of 
interest to this study, it was suggested that treatment with NH4Cl, to increase the pH 
of the lysosome, may have attenuated caspase-8 activity by reducing the proteolytic 
action of cathepsins (Appelqvis et al., 2013).  
Histological staining of epidermal skin equivalents and quantification of viable cell 
layer thickness revealed inhibition of lysosomal function and more specifically 
chemical and genetic inhibition of cathepsin D, blocked the TCDD-induced reduction 
of viable cell layer. 
In keeping with the literature, one of the most interesting findings of this chapter was 
bafilomycin and pepstatin A treatment, as well as shRNA knockdown of cathepsin D 
all blocked TCDD-induced caspase-3 staining. Although TCDD was shown to induce 
caspase-3 expression in Chapter 3 (Fig. 3.8) and in siNT knockdown epidermal 
equivalents in Chapter 5, the present data further confirms TCDD-induced caspase-3 
is robust and reproducible. The induction of apoptosis by TCDD treatment has been 
acknowledged in a variety of models, but the role of lysosomal function in this TCDD 
induced keratinocyte apoptosis may be novel. 
As with most chemical inhibitors, pepstatin A is known to have off target effects 
including inhibition of cathepsin B and pepsin (Emert-Sedlak., et al 2005). Therefore, 
other methods, such as genetic interference of cathepsin D, are often pursued as 
they were in this study, to verify results and confirm involvement in apoptosis. In 
agreement with the present data, studies using siRNA constructs against cathepsin D 
in HeLa adherent cells and U937 suspension cells also found knockdown caused 
inhibition of cell death as well as delayed cytochrome c release and caspase-3 
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activity (Emert-Sedlak et al., 2005). Over expression studies in which cathepsin D 
was injected into the cytosol of fibroblasts (Roberg et al., 2002) and in vivo mouse 
models (Bewley et al., 2011) have also all implicated cathepsin D in apoptosis 
induction.  
Interestingly, as cathepsin D has been linked to the activation of a variety of 
caspases and subsequent apoptosis induction, it has been suggested that cathepsin 
D may be involved in a pro-apoptotic protease cascade (Heinrich et al., 2004). 
However, the mechanism by which cathepsin D activates caspases is still not entirely 
understood. It has previously been suggested cathepsin D causes the apoptosis 
regulator Bax to be activated and relocate to the mitochondria, inducing the release 
of apoptosis-inducing factor (AIF) (Benes et al., 2008, Bidere et al., 2003). In another 
study in which cathepsin D was added to the mitochondria in vitro (Zhao et al., 2003) 
results suggested the release of proteases caused mitochondrial dysfunction, 
increasing reactive oxygen species (ROS) production which in turn caused 
cytochrome c release (Benes et al., 2008). However, cathepsin D is usually 
enzymatically active in a low pH within the lysosome; therefore, its ability to degrade 
material required for apoptosis induction within the cytosol, has been questioned. 
Whilst investigating this, Appelvist et al (2012) discovered three cathepsin D specific 
cleavage sites on pro-apoptotic Bid through which cathepsin D activated apoptosis, 
by inducing Bax-mediated cytochrome c release. Interestingly, cleavage of Bid by 
cathepsin D was revealed to take place at neutral pH, in contrast to previous studies 
in which processing of Bid did not occur above pH 6.2 (Heinrich et al., 2004). 
However, Appelvist et al (2012) did suggest changes in the cytosol pH may influence 
the contribution of different proteases to Bid activation.  
Together these studies imply cathepsin D triggers apoptosis through multiple 
mechanisms, which are likely to be cell or model dependent, but probably involve 
mediators of apoptosis such as cytochrome c, caspases and bcl-2 family members 
(Benes et al., 2008). Therefore, the reduction in caspase-3 staining by cathepsin D 
knockdown and chemical inhibition through pepstatin A, or indeed treatment with 
bafilomycin is not surprising and is in agreement with the literature. The exact 
mechanism behind TCDD inducing cathepsin D mediated apoptosis will require 
further investigation.  
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As demonstrated in Chapter 4, genetic inhibition of autophagy also blocked TCDD 
induced caspase-3 staining. It is possible that by blocking lysosomal function or 
cathepsin D activity that this also attenuates the autophagy pathway/autophagic cell 
death, which may block the subsequent induction of apoptosis. Alternatively, TCDD 
induced apoptosis may be independent from autophagy. Since there is such complex 
cross talk between autophagy, lysosomal activity and apoptosis it is likely each 
process is contributing to the phenotype in some way. Due to this complexity, a 
proteomic study is currently being carried out in collaboration with AstraZeneca, with 
a particular interest in lysosomal proteins, and it is hoped this will help elucidate the 
contribution of these mechanisms involved in the chloracne phenotype. 
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5.4. Summary 
 
 TCDD treatment caused an increase in LAMP2 expression, indicating 
accumulation of lysosomes 
 
 Chemical inhibition of lysosomal function and cathepsin D through bafilomycin 
and pepstatin A respectively, altered TCDD-induced AhR degradation 
 
 Lysosomal function likely contributes to TCDD-induced de-regulated epidermal 
differentiation 
 
 The TCDD-induced reduced viable cell layer thickness was prevented with 
blockade of lysosomal function as well as chemical and genetic inhibition of 
cathepsin D 
 
 TCDD-induced caspase-3 staining was reduced with blockade of lysosomal 
function as well as chemical and genetic inhibition of cathepsin D 
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 Concluding Remarks Chapter 6
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6.1. Main Conclusions 
 
The principle aim of this project was to explore the mechanisms behind a previously 
developed TCDD-induced chloracne phenotype model (Forrester et al., 2014). 
Specific aims (as described in Chapter 1, section 1.9) included investigating further 
potential mechanisms contributing to the morphological features observed, including 
the balance between cell division and cell death and the role of autophagy, arising in 
part from data and hypotheses generated during previous work in our lab (Forrester 
Thesis). Another key aim of this project was to explore the role of lysosomal function, 
specifically cathepsin D in the chloracne phenotype. Cross talk between autophagy 
and lysosomal cell death is an emerging area and as such an additional aim was to 
determine the impact on TCDD-induced cell death. The overall findings of this 
project, focussing on work in epidermal equivalents, are presented in schematic 
diagrams (Figure 6.1 and Figure 6.2). 
The data generated provide increased insight into the physiological role of AhR in the 
skin and potentially highlight therapeutic targets for the treatment of chloracne. 
Furthermore, in the pharmaceutical industry potential drugs are often excluded if they 
activate AhR due to concerns of toxic side effects. Therefore, understanding the role 
of AhR further is potentially beneficial to the salvage of previously abandoned 
therapeutic compounds, as discussed by Van den Bogaard et al (2013) in which 
results demonstrated AhR activation is in fact required for epidermal barrier repair in 
eczema after coal tar treatment.  
Initially work reported in Chapter 3 was focused on optimising a TCDD treatment 
regime to produce a robust and reliable chloracne phenotype model, with reduced 
viable cell layer thickness and compacted stratum corneum, to use for delineating 
targets of TCDD induced AhR activation. Whilst TCDD has previously been shown to 
induce a chloracne phenotype (Forrester Thesis), data demonstrating the temporal 
regulation and development over 7 days was novel. Combined data from 8 
independent donors, found TCDD treatment significantly reduced viable cell layer 
thickness after 7 days, confirming the treatment regime and reproducibility of this 
model (p<0.0001, Chapter 3, Fig 3.3).  
Results (Chapter 3) demonstrated significant AhR protein degradation only occurred 
after treatment with TCDD for 7 days, indicating delayed or prolonged AhR protein 
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degradation compared to monolayer keratinocyte cultures (Chapter 4, Fig 4.1, Fig 
4.2, Fig 4.4A). Decreased AhR mRNA expression and induction of CYP1A1 mRNA 
expression were also evident after 7 days treatment, collectively indicative of TCDD 
interacting with AhR and subsequent degradation of the receptor. However, earlier 
time points were not explored in the context of mRNA expression and as such 
CYP1A1 mRNA induction and AhR mRNA degradation may be earlier events.  
However, this late or prolonged induction of CYP1A1 is indicative of the long half-life 
of TCDD and the sustained induction of the AhR pathway is also seen in vivo. Saurat 
et al (2009) found CYP1A1 mRNA expression to be increased significantly above 
control in chloracne skin lesions 5 months after TCDD poisoning. Furthermore, a 
delay in AhR degradation in the epidermal skin equivalent model has been seen 
previously (Forrester thesis, Forrester et al.,2014). Results from this study revealed 
AhR degradation occurred after only 2 days in monolayer primary human 
keratinocytes, whilst AhR degradation was evident only after 7 days in epidermal skin 
equivalents. 
Chloracne is a chronic skin disease; however, the onset of clinical symptoms is 
normally 2-4 weeks after exposure to chloracnegens (Ju et al., 2009). Therefore, a 
delay in AhR degradation and delay in phenotype development is likely more patho-
physiologically relevant than other cell models in which AhR degradation is detected 
much earlier.  This might also reflect the need for chronic stimulation of the system to 
induce the morphological changes observed. 
Another key difference noted in the present study was the differential effect of TCDD 
on cell viability between monolayer and epidermal equivalent models. Although 
TCDD was clearly activating AhR, as AhR protein expression was significantly 
reduced, TCDD caused no significant change to cell number in monolayer 
experiments. In contrast, one of the key early findings of the project was the 
significant induction of active caspase-3 expression after TCDD treatment, 
suggesting that apoptotic cell death may play a role in the development of the 
chloracne phenotype and specifically may account for the reduced viable cell layer. 
This increase in caspase-3 expression and likely apoptotic cell death is in keeping 
with the significant reduction in viable cell layer in the chloracne phenotype. 
Caspase-3 staining was detected in epidermal skin equivalents after 7 days of 
treatment with TCDD. This potential delayed induction of apoptosis or prolonged 
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apoptosis is in keeping with the delay in AhR degradation and induction of CYP1A1.   
Again this data supports the long half-life of TCDD and delayed clinical symptoms of 
chloracne in vivo. Furthermore, through KI67 staining, results suggested TCDD did 
not alter proliferative status of keratinocytes and as such it is unlikely the reduced 
viable cell layer is due to reduced proliferation, as no significant change in Ki67 
staining was detected.  
In epidermal equivalents, TCDD also clearly induced autophagic activity, with 
significantly increased LC3II protein expression and immunofluorescence staining 
revealed endogenous LC3 increased whilst P62 expression decreased, well-known 
markers of autophagic flux.  
These results then opened up the overarching question of how cross talk between 
these signalling pathways might contribute to the chloracne phenotype. The 
approach taken was to focus on autophagy, lysosomal activation and apoptosis and 
investigate how these pathways interact and thereby result in AhR degradation, 
deregulated epidermal differentiation and the morphological changes observed. 
The next chapter (Chapter 4) utilised a potential higher throughput monolayer 
chloracne model to study these pathways. However, results revealed differences in 
response to TCDD between monolayer and the epidermal equivalent model (as seen 
previously in these models) (Forrester thesis) and as such the monolayer model was 
not pursued in future chapters.  
One of the key differences in comparison to work in epidermal equivalents was 
TCDD caused no significant change to cell number after treatment in monolayer, 
even across time points and at different extracellular calcium concentrations (Chapter 
4, Fig 4.9 and Fig. 4.10). Another key difference was the lack of LC3II accumulation 
after TCDD treatment, in contrast to significant autophagy induction detected in 
epidermal skin equivalents. Although results generally revealed differential effects of 
TCDD treatment in monolayer cultures compared to epidermal equivalents, there was 
evidence of TCDD induced AhR degradation in monolayer and as such these 
differential results are likely not due to altered activation of AhR.  
Nevertheless, after optimising siRNA ATG7 knockdown in monolayer this was then 
taken into epidermal equivalents and revealed interesting results (as demonstrated 
by the orange arrows in Fig. 6.1). Knockdown of ATG7 not only blocked the TCDD-
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induced reduced viable cell layer but also blocked TCDD-induced caspase-3 
expression, suggesting autophagy is required at least in part for apoptotic cell death 
in this model. Furthermore, knockdown of ATG7 blocked TCDD-induced AhR 
degradation suggesting autophagy may play a role in AhR degradation. As discussed 
in the introduction (Chapter 1), AhR is thought to be principally degraded by the 26S 
proteasome pathway and crosstalk between this and autophagy, specifically 
chaperone-mediated autophagy has been reported. Therefore, to explore the 
potential crosstalk between these pathways in the chloracne phenotype model, the 
influence of lysosomal function which is required for chaperone mediated autophagy 
was explored in the final chapter.  
The lysosomal protease cathepsin D is of particular interest in this project after 
preliminary data (Forrester thesis) suggested TCDD treatment of epidermal skin 
equivalents and monolayer primary human keratinocytes de-regulated cathepsin D 
expression. In addition, studies have previously suggested a role for AhR in 
cathepsin D transcription (Wang et al., 1999) as well as a role for cathepsin D in 
epidermal differentiation, particularly in regulation and activation of TGM-1 (Egberts 
et al., 2004).  
Treatment with the lysosomal chemical inhibitor bafilomycin and cathepsin D inhibitor 
pepstatin A as well as cathepsin D shRNA knockdown in epidermal equivalents 
revealed important findings. Data suggested crosstalk between lysosomal activity 
and TCDD induced cell death as well as AhR degradation (as demonstrated by the 
green arrows in Fig. 6.1). Results in Chapter 5 revealed blockade of lysosomal 
function prevented the TCDD-induced reduction in viable cell layer thickness as well 
as reduction in TCDD-induced caspase-3 expression, suggesting lysosomes, 
perhaps through LMP, are likely involved in the induction of apoptotic cell death. 
Bafilomycin treatment also increased Ki67 staining above that of vehicle, although 
not significantly. As demonstrated in Chapter 5 (Fig. 5.5, Fig. 5.6) bafilomycin 
treatment altered epidermal differentiation marker expression at both protein and 
mRNA level. Epidermal differentiation is a complex balance between proliferation, 
differentiation and cell death and as such, it is not surprising bafilomycin also effects 
proliferation status of cells.  
TCDD-induced AhR degradation was also prevented with bafilomycin and pepstatin 
A co-treatment, although results with cathepsin D shRNA knockdown were variable. 
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Another novel result was the accentuated TCDD-induced CYP1A1 expression 
observed after co-treatment with bafilomycin.  
Although ATG7 knockdown in epidermal equivalents resulted in variable epidermal 
differentiation marker expression, bafilomycin, pepstatin A and cathepsin D 
knockdown all blocked TCDD-induced reduction in filaggrin protein expression. 
These results suggest a role for lysosomal function in TCDD de-regulated 
differentiation.  
Together, these novel data suggest apoptosis, autophagy and de-regulated 
differentiation all contribute to the development of a TCDD-induced chloracne 
phenotype. Results specifically demonstrated autophagy and lysosomal function are 
likely involved in this apoptotic activity. Furthermore, lysosomal activity and 
autophagy are required at least in part for the degradation of AhR after TCDD 
treatment, and we hypothesise this is through chaperone mediated autophagy. 
However, the intricate cross-talk between apoptosis, lysosomal activity and 
autophagy adds to the complexity of these findings.  
Although TCDD has previously been reported to induce apoptosis in other systems, 
and lysosomes are known to play a role in apoptosis through LMP (as discussed in 
Chapter 5, section 5.3.3), the involvement of lysosomes in TCDD-induced apoptosis 
in keratinocytes is a novel finding. Furthermore, only two studies reporting TCDD-
induced autophagy have been published, one of which in a bovine kidney cell line 
(Fiorito et al., 2011) and the other in the human neuroblastoma cell line SH-SY5Y 
(Zhao et al., 2015). In contrast to the present data, Zhao et al, (2015) suggest 
autophagy protects against TCDD induced apoptosis in cells and found blockade of 
autophagy through treatment with 3-MA led to increased apoptosis. However, 
crosstalk between apoptosis and autophagy is complex and studies have reported 
conflicting results as reviewed by Mukhopadhyay et al (2014). Indeed, as 
demonstrated above, autophagy can promote cell survival and block apoptosis in the 
same system but under alternative conditions.  Thus, autophagy can result in cell 
death through apoptosis or independently through non-apoptotic pathways 
(Mukhopadhyay et al., 2014). Therefore, the precise pathway and interaction 
between TCDD-induced apoptosis and induction of autophagy remains unclear and 
requires further delineation.  
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Conflicting data on TCDD induced de-regulated differentiation are also reported in 
the literature. Generally, results suggest TCDD treatment accelerates differentiation 
in corroboration with this, studies have shown TCDD treatment to increase 
differentiation marker expression in keratinocyte models (Loertscher et al., 2001b, 
Gaido and Maness, 1994, Sutter et al., 2009). However, in the present model, TCDD 
treatment induced downregulation of differentiation marker protein expression, whilst 
mRNA expression was increased. Interestingly, in agreement with results from the 
present study, Hu et al (2014) also demonstrated through proteomic analysis, 
treatment of keratinocytes with TCDD for two weeks induced downregulation of 
filaggrin, keratin 1 and keratin 10 protein expression. In addition, Geusau et al (2005) 
found TCDD treatment of organotypic models, revealed an increase in involucrin 
expression but decrease in keratin 1 and 10. The author suggests although 
hyperkeratosis is a known feature of chloracne, parakeratosis and loss of granular 
layer is also displayed and as such differentiation may be de-regulated rather than 
simply induced, in agreement with the present study. It has also been reported that 
induction of ROS, specifically TCDD-mediated production of hydrogen peroxide 
(H2O2) is essential for the TCDD-induced acceleration of differentiation (Kennedy et 
al., 2013). Therefore, differences in ROS generation likely contribute to differences in 
TCDD-induced de-regulated differentiation between studies. In addition, the technical 
and cellular differences between models, treatment regimens and culture conditions 
may all influence the effect of TCDD treatment.  
Collectively this study has demonstrated epidermal skin equivalents provide a 
physiologically relevant, reproducible tool to explore pathways and molecular targets 
of interest in disease models and environmental exposure. The data presented 
further delineates the pathophysiology of chloracne and has highlighted novel 
outcomes of TCDD-induced AhR pathway activation. As reviewed by Mulero-Navarro 
and Fernandez-Salguero (2016) the AhR is already implicated in significantly more 
cellular processes than initially thought and as evidenced by this project, likely to be 
involved in many more.  
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6.2. Future Work 
 
One of the key areas for future work would be to explore the role of chaperone 
mediated autophagy in AhR degradation. Although results strongly suggested 
lysosomal function and autophagy were required for AhR degradation in this model, 
delineating whether this is specifically chaperone mediated autophagy would require 
further experiments. 
There are a number of approaches to take when exploring chaperone mediated 
autophagy (Patel and Cuervo. 2015). To assess activity, post translational changes 
in key components of the pathway can be determined by immunoblotting or 
immunofluorescence. For example, staining for LAMP2A or lysosomal hsc-70, both of 
which known to be required for chaperone mediated autophagy activity (Agarraberes 
et al., 1997, Cuervo and Dice, 1996). Co-localisation of markers LAMP2A, hsc-70 or 
P62 in combination with AhR could also be valuable to determine whether this was 
specifically involved in AhR degradation. To determine whether a protein of interest, 
in this case AhR, is a chaperone mediated autophagy substrate there are also a 
number of readouts. Principally these are focused on determining the cellular 
localisation/levels of the protein or the effect of modulation of chaperone mediated 
autophagy on protein degradation. However, it should be noted that blocking 
chaperone mediated autophagy can alter other autophagy pathways and can 
increase protein degradation by alternative pathways (Kaushik and Cuervo 2009, 
Patel and Cuervo, 2015).  
Another area for future work would be determining if apoptosis was the primary 
mechanism responsible for the TCDD reduced viable cell layer. It would also be 
interesting to establish the relationship between autophagy and apoptosis in this 
model, as results suggested blocking autophagy blocked caspase-3 expression, but 
the precise order of events needs further investigation. Alternatively, epidermal 
equivalents could be treated with a pan-caspase inhibitor. However, it has been 
reported that at high concentrations, caspase inhibitors can also block cathepsins 
which can cause misinterpretations of data (Foghsgaard et al., 2001, Gomez-Sintes 
et al., 2016).  To specifically determine if LMP is occurring can be quite difficult as 
lysosomes are heterogeneous and have differential sensitivity to agents. 
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In addition, blocking lysosomal function prevented TCDD induced caspase-3 
expression; suggesting LMP is occurring and inducing apoptosis. However, blocking 
lysosomal function may simply be attenuating autophagy and as such confirmation of 
LMP and its time course (relative to caspase-3 activation) would be required to firmly 
establish the role of lysosomes in regulating apoptosis in this model. To explore the 
role of apoptosis further, knockdown of key regulatory genes involved in the intrinsic 
apoptosis pathway could be pursued, such as BAX or BAK. 
However, as well as cathepsin inhibitors used in this study, serpins (serine protease 
inhibitors) have also been found to inhibit caspases and cathepsins and block 
lysosomal cell death (Law et al., 2006). In addition, antioxidants can also be used to 
prevent ROS induced LMP inhibiting LMP and subsequent cell death (Zang et al., 
2001). It can be technically difficult to explore cellular activity in epidermal 
equivalents, however, if LysoTracker®, or indeed staining of cathepsin B or D to 
explore their release from lysosomes, could be optimised these would also be useful 
tools. The use of super-resolution microscopy or two photon microscopy would also 
enable us to explore localisation within the model further.  
Finally, proteomics analysis of TCDD-treated epidermal equivalents is on-going, with 
the specific aim of exploring lysosome-related proteins. Results from this will also 
help determine specific proteins of interest and confirm the involvement of 
lysosomes.   
Of note, although results demonstrated consistent trends in data there was often a 
lack of statistical significance. This is due to donor variability and relatively low 
sample number (in part because of the logistical/time considerations); although 
trends in donors were often exactly the same, values between donors varied, as such 
these trends were often deemed not significant. Therefore, repeating these 
experiments in more donors may be required to make firm conclusions.  
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 6.3. Potential molecular targets of interest 
 
A commentary paper of interest to this study has recently been published, focussing 
on the elucidation of dioxin-mediated chloracne and AhR (Bock, 2016). Although the 
paper focuses on sebaceous glands and TCDD activation of the AhR pathway in 
sebocytes it brings to light molecular targets which may be relevant to the present 
model.  
The proposed relationship between AhR and Blimp1 (B lymphocyte-induced 
maturation protein 1) is of particular importance. In murine sebaceous glands, AhR 
co-localised with Blimp1, known to regulate cell number, cell size and activity of 
sebaceous glands (Ikuta et al., 2010). Expression of Blimp1 mRNA was also induced 
in SZ95 sebocytes and HaCaT keratinocytes after treatment with AhR ligands and 
this was found to be dependent on AhR and ARNT (Ikuta et al., 2010). In a later 
study, TCDD treatment of ex vivo human skin samples and cultured SZ95 sebocytes 
was noted to induce irregular differentiation in the sebaceous gland cells (Ju et al., 
2011). Taken together, Ju et al (2011) hypothesise that TCDD causes hypoplasia of 
the sebaceous gland by induction of Blimp1 which represses c-Myc. Blimp1 is known 
to regulate the transcription factor c-Myc, which plays a role in the balance between 
pro-genitor cell self-renewal and differentiation (Bock, 2016, Wilson et al., 2004). 
Interestingly, Blimp1 has also been implicated in epidermal differentiation; with 
conditional knockout mice displaying enlarged granular layer cells and corneocytes, 
and a morphologically abnormal cornified layer (Magnúsdóttir et al., 2007).  However, 
key to the present study, c-Myc plays a pivotal role in in the apoptosis pathway as 
reviewed by Hoffman and Liberman (2008). A recent paper has also suggested 
AMBRA-1 facilitates the de-phosphorylation and degradation of c-Myc, 
demonstrating potential crosstalk between c-Myc and the autophagy signalling 
network (Cianfanelli et al., 2015). In addition, Mandavia (2015) hypothesises TCDD 
may directly, or indirectly (via AhR cross-talk) up regulate c-Myc via EGFR-ERK axis 
stimulation, increasing epidermal stem cell turnover in chloracne. Together this data 
suggests Blimp1 may be implicated in the TCDD induced de-regulated differentiation 
in the present model. In addition, the potential interaction with c-Myc and subsequent 
effect on the autophagic and/or apoptotic pathway, in the present model would be 
interesting to explore.  
 174 
 
Bock (2016) also comments on the involvement of AhR in modulation of cell cycle 
through p21/Cip1. Interestingly, a recent study has suggested p21 is key in the 
response of HaCat keratinocytes to UVB exposure (although HaCaTs are effectively 
p53 null) (Chen et al., 2015). UVB exposure downregulated p21 and was associated 
with significantly increased apoptosis, decreased proliferation, and increased G2 
phase arrest. Given the similarity between phenotypes, interaction between AhR and 
p21/Cip1 could possibly be involved in the current model. In corroboration with this, a 
microarray analysis of TCDD-treated multipotential C3H10T1/2 fibroblasts found 
altered expression of over 1000 genes, including a 1.8 fold reduction in the p21 gene 
(Hanlon et al., 2005).  
As discussed, there are a variety of potential molecular targets to further explore and 
as demonstrated by the present study, the robust and reproducible chloracne 
phenotype model represents an ideal environment to take these studies forward and 
understand their functional and pathophysiological relevance. 
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Appendix A. TCDD causes no significant induction of reduced keratinocyte viability at day 3, 5 or 7 
days in monolayer culture.  
 
Analysis of cell viability (SRB assay) in monolayer primary human keratinocytes following treatment with 
vehicle (DMSO) control (blue bars), TCDD (0.1, 1, 10 or 20nM) (red bars) every 48 hours for 3, 5 and 7 
days. Each bar is expressed relative to vehicle (DMSO) 1:100 control. n=3 independent donors, in 
triplicate (N=9) ± SEM. Statistics were acquired by one-way ANOVA with Dunnett’s multiple comparison 
test (NS) 
Appendices 
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Appendix B. TCDD causes no significant induction of reduced keratinocyte viability in monolayer 
culture even at different seeding densities.  
 
Analysis of cell viability (SRB assay) in monolayer primary human keratinocytes, seeded at 5,000, 10,000 
or 20,000 cells per well of a 48 well plate, following treatment with vehicle (DMSO) control (blue bars), 
TCDD (10nM) (red bars) bafilomycin (5nM) (dark green bars) or TCDD with bafilomycin (light green bars) 
every 48 hours for 5 days. Each bar is expressed relative to vehicle (DMSO) control. n=3 independent 
donors, in triplicate (N=9) ± SEM. Statistics were acquired by one-way ANOVA with Dunnett’s multiple 
comparison test ***p<0.001 ****p<0.0001 
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Appendix C. Optimisation of BECLIN-1 shRNA knockdown in monolayer primary 
human keratinocytes 
 
A) Representative western blot of BECLIN-1 (BEC-1) protein expression in monolayer 
primary human keratinocytes with either shNT or 3412, 3409, 3413, or 3414 BECLIN-1 
shRNA constructs. B) Densitometric analysis of BECLIN-1 expression in shNT and 
shBEC-1 knockdown monolayer primary human keratinocytes. Expression is  
normalised to GAPDH loading control expressed relative to shNT, n=1 independent 
donor and therefore no statistical analysis could be performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
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Appendix D. Treatment with vehicle (DMSO) causes no significant change in AhR or LC3II 
protein expression in monolayer primary keratinocyte cultures, over time.  
 
Densitometric analysis of A) AhR or B) LC3II protein expression in monolayer primary human 
keratinocytes vehicle (DMSO) treatment every 48 hours over 7 days. Each bar is normalised to 
GAPDH loading control expressed relative to vehicle (DMSO) control at day 2 n=3 independent 
donors, ± SEM. Statistics were acquired by one-way ANOVA with Dunnett’s multiple comparison 
test. A) (NS) B) (NS) 
A. 
B. 
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Appendix E. TCDD significantly reduced Hoechst positive cells in human epidermal 
equivalents.  
 
Mean fold change of Hoechst positive cells in epidermal equivalents treated with vehicle (DMSO) 
(blue bar) or TCDD (10nM) (red bar) every 48 hours for 7 days normalised relative to vehicle 
(DMSO) control. n=7 independent donors, ± SEM. Statistics were acquired by paired t-test 
**p=<0.01 
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Appendix F. Transduction efficiency of shRNA BECLIN-1 3409 construct.  
 
Representative photomicrographs of monolayer primary human keratinocytes 48 hours post 
transduction with shBECLIN-1 3409 depicting A) bright field or B) GFP fluorescence of the same field 
of view of cells. Scale bar= 250µm 
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Appendix G. Raw number of Caspase-3 and Hoechst positive cells after vehicle and TCDD 
treatment.  
 
Representative tiled photomicrographs taken at 10x magnification from one donor of epidermal skin 
equivalents treated with vehicle (DMSO) (A) or TCDD (10nM) (B) every 48 hours for 7 days depicting 
Hoechst nuclear staining (blue fluorescence) or caspase-3 expression (red fluorescence). Scale 
bar=5µm. C) Raw number of cells with Hoechst or caspase-3 expression in the epidermal skin 
equivalent photomicrographs presented, treated with vehicle (DMSO) or TCDD (10nM) every 48 
hours for 7 days. Data is from one representative donor so no statistical test was used. 
C. 
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Appendix H. Higher magnification images of Caspase-3 and Hoechst staining in epidermal skin 
equivalents after vehicle and TCDD treatment.  
 
Representative photomicrographs taken at 20x magnification from one donor of epidermal skin 
equivalents treated with vehicle (DMSO) (A) or TCDD (10nM) (B) every 48 hours for 7 days depicting 
Hoechst nuclear staining (blue fluorescence) or caspase-3 expression (red fluorescence). Scale 
bar=100µm. 
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Appendix I. Raw number of Caspase-3 and Hoechst positive cells in epidermal skin 
equivalents after chemical inhibition of cathepsin D 
 
Raw number of cells with Hoechst or caspase-3 expression in epidermal skin equivalents, treated with 
vehicle (DMSO), TCDD (10nM) Pepstatin A (10µg/ml) or TCDD with pepstatin A co-treatment every 
48 hours for 7 days, n=4 independent donors, ± SEM. Statistics were acquired by two-way ANOVA 
with Bonferroni’s multiple comparison test (NS) 
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Appendix J. Raw number of Caspase-3 and Hoechst positive cells in epidermal skin 
equivalents after blockade of lysosomal function 
 
Raw number of cells with Hoechst or caspase-3 expression in epidermal skin equivalents, treated with 
vehicle (DMSO), TCDD (10nM) bafilomycin (5nM) or TCDD with bafilomycin co-treatment every 48 
hours for 7 days, n=4 independent donors, ± SEM. Statistics were acquired by two-way ANOVA with 
Bonferroni’s multiple comparison test (NS) 
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Appendix K. Raw number of Caspase-3 and Hoechst positive cells in epidermal skin 
equivalents after siRNA ATG7 knockdown 
 
Raw number of cells with Hoechst or caspase-3 expression in siNT and siATG7 epidermal skin 
equivalents, treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days, n=3 
independent donors, ± SEM. Statistics were acquired by two-way ANOVA with Bonferroni’s multiple 
comparison test (NS) 
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Appendix L. Raw number of Caspase-3 and Hoechst positive cells in epidermal skin 
equivalents after shRNA cathepsin D knockdown 
 
Raw number of cells with Hoechst or caspase-3 expression in shNT and shCTSD epidermal skin 
equivalents, treated with vehicle (DMSO) or TCDD (10nM) every 48 hours for 7 days, n=3 
independent donors, ± SEM. Statistics were acquired by two-way ANOVA with Bonferroni’s multiple 
comparison test (NS) 
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